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Abstract 
Early-onset familial Alzheimer’s disease (EOfAD) is promoted by autosomal, 
dominant mutations, enabling the generation of EOfAD-like mutations in animal 
models for the study of its pathogenic mechanism. This thesis has succeeded in 
generating an EOfAD-like mutation and an Acne Inversa-like mutation in psen1 
using the CRISPR/Cas system. The EOfAD-like mutation can be used for 
investigation of EOfAD-specific transcriptome signatures, while the Acne Inversa-
like mutation (non-EOfAD-like) will be used in transcriptome comparisons with 
EOfAD-like mutations to refine (by exclusion) our definition of the AD-relevant 
aspects of EOfAD-like brain transcriptome profiles. On the other hand, the 
Alzheimer’s Disease Genetics Laboratory (ADGL) has generated two EOfAD-
relevant mutations in zebrafish, psen1K97fs and psen1Q96_K97del, and has performed 
brain transcriptome analyses on heterozygous 6-month-old and 24-month-old 
mutants compared to their wild type siblings to investigate gene expression changes 
induced by the mutations. Work by others in the ADGL had observed significant 
differences in gene expression due to the mutations at 6 months compared to 24 
months. In the work described in this thesis, further analyses were performed on 
these two mutations. I analysed transcript splicing associated with the psen1K97fs 
mutation and found that I could not detect equivalent alternative splice products 
associated with the human mutation upon which this mutation model is based. This 
indicated that the zebrafish psen1K97fs mutation is probably not a close model of the 
pathological action of human PSEN2K115fs. In addition, I performed transcriptome 
analysis of heterozygous psen1Q96_K97del mutant larvae to test their possible utility 
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in chemical library screening. I found that genes DE in the larvae were not 
consistent with those identified in 6-month-old heterozygous mutant brains, 
although similar cellular pathways were affected. Also, some larvae-specific effects 
were identified. However, these analyses encountered difficulties. I initially aimed 
to investigate the nature of this age-dependent transition in gene expression using 
quantitative PCR (qPCR). I intended to monitor the change in expression of these 
genes month by month. However, variability in the expression of the selected 
differentially expressed (DE) genes thwarted this analysis. Furthermore, I 
compared the behaviour of heterozygous psen1Q96_K97del mutant adult fish to their 
wild type siblings using the free-movement pattern (FMP) Y-maze test to assess 
impairments in short-term spatial working memory at 6, 12 and 24 months of age. 
However, no statistically significant differences in behaviour were identified.  
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Chapter 1. Literature review 
1.1 Introduction 
This project focuses on the analysis of two early onset familial Alzheimer’s disease 
(EOfAD)-like zebrafish models, psen1K97fs and psen1Q96_K97del, generated in the 
previous work of this laboratory, and attempts to generate another two mutations in 
the zebrafish psen1 gene to advance the investigation of Alzheimer’s disease (AD) 
pathological mechanisms. Therefore, this Introduction chapter first looks at 
Alzheimer’s disease and hypotheses of the pathological mechanisms that lead to it, 
followed by an examination of the genetics of this disease, animal models and the 
previous work of the Alzheimer’s Disease Genetics Laboratory.  
 
1.2 The definition of Alzheimer’s disease  
1.2.1 The classification of AD 
AD is a progressive neurodegenerative brain disorder that impairs cognitive 
functions and eventually develops to dementia. Without efficient treatments 
available, AD has become a major leading cause of death and shows an increasing 
disease incidence [1]. AD can be classified by its age of onset and whether or not it 
shows inheritance in families. Late onset, sporadic AD (sAD), occurs after 65 years 
of age and is responsible for most cases of AD (>95%) [2]. This form of AD has a 
very limited inheritance and a family history of affected close relatives is unusual 
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[2, 3], while it is affected by multiple factors including age, lifestyle, diet, genetic 
and environmental factors [4]. In contrast, EOfAD is autosomal and dominantly 
inherited. Most EOfAD-causative mutations have been identified in genes PSEN1, 
PSEN2 and APP [5]. The mean age of EOfAD onset is around 45 years of age [3, 
6]. Although EOfAD only contributes less than 5% of all AD cases [6], its dominant 
mode of inheritance enables genetic modeling in animals for AD studies. sAD and 
EOfAD share many common pathological features such as the accumulation of 
amyloid plaques and neurofibrillary tangles (Figure 1.1, described later), and there 
is no evidence showing that they have different pathological progressions. 
Therefore, in many AD pathology hypotheses, sAD and EOfAD are assumed to 
share a similar pathological process. Also, in most clinical respects, the rate of 
disease progression and biomarker profiles of these two forms are comparable [7]. 
However, as the results of genome-wide association studies (GWAS) for sAD did 
not identify the major EOfAD loci, APP and PSEN genes, as susceptibility loci [8], 
some argue that sAD and EOfAD should probably not be considered together but 
regarded as different diseases [9]. Nevertheless, analysis of EOfAD should 
probably provide insight into the genetic basis, etiology and pathology of both AD 
types, and treatments targeting the pathological development of EOfAD may also 
be effective in sAD. 
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Figure 1.1. The pathological features of AD revealed by the Bielschowsky silver 
stain (from [10]). Amyloid plaque is indicated by arrowheads while neurofibrillary 
tangles (NFTs) are indicated by arrows.  
 
1.2.2 The diagnosis of AD 
The pathology and diagnosis of AD remains controversial. Accumulation of 
amyloid plaques (amyloid- peptides) and neurofibrillary tangles (tau proteins) 
have been widely regarded as pathological features of AD for over one hundred 
years [11]. Currently the presence of deposits of these proteins in patients’ brains 
is still used to biologically define AD [12, 13]. However, the clinical diagnosis of 
AD is based on the observation of a progressive amnestic multidomain cognitive 
impairment culminating in dementia when other possible causes have been 
excluded [13]. These two definitions complicate the diagnostic criteria for AD. 
Most patients with biologically defined AD do not have these clinical symptoms, 
while some patients clinically diagnosed with AD, upon autopsy, have been shown 
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to lack these biological features [9, 13]. On the other hand, most current 
investigations of AD treatments attempt to the prevent or delay the formation of 
these biological features, but have met with challenges and failure [14]. A study by 
Jack et al., 2020 [13] suggested that patients with biologically defined AD are more 
prevalent than those with clinically diagnosed AD at any age, and raised concerns 
about the specific treatments that are used to prevent biological symptoms onset. 
Therefore, there is a great need to investigate the cause of AD. In future this will 
also require a more accurate definition of the disease to improve the reliability of 
diagnosis and facilitate investigation of treatments. 
 
1.2.3 Cognitive impairment  
The cognitive impairment caused by AD is a progressive process with three stages: 
the preclinical stage with no symptoms, a middle stage of mild cognitive 
impairment (MCI) and a final stage of dementia [15]. An early clinical feature of 
AD is often a prominent memory disturbance [16]. With disease progression, other 
cognitive issues, such as psychosis and depression [17], and behavioural 
disturbances [18] start to emerge. The clinical evolution of MCI due to AD involves 
impairments in one or more cognitive domains, typically including memory [19]. 
The impairment of short-term memory is normally one of the symptoms at the 
disease early stage. Short-term memory, also called primary or active memory, is a 
functional storage element that has the ability to hold pieces of information for a 
relatively short time [20]. Short-term memory is not equivalent to working memory 
but acts as a component of it, as working memory refers to the structures and 
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processes used for temporarily storing and manipulating information [20]. In 
contrast to short-term memory, long-term memory may hold an indefinite amount 
of information for many years [20]. As Alzheimer’s disease progresses, long-term 
memory trends to become fragmented, and eventually the capacity for memory may 
be entirely lost during the disease’s final stage.  
 
1.3 Hypotheses of Alzheimer’s disease 
1.3.1 The Amyloid Cascade Hypothesis 
The Amyloid Cascade Hypothesis is the most widely known hypothesis for the 
mechanism underlying AD. It posits that the major cause of AD is related to a 
pathological feature, the accumulation of a minor form of the amyloid- (A) 
peptide, A42. (The production of Aβ is discussed in section 1.4.2 below.) The 
proposed AD progression in this hypothesis is shown in Figure 1.2. A normally 
occurs in both 40 amino acid residue (A40) and 42 amino acid residue (A42) 
forms. Dominant missense mutations in EOfAD lead to increased production of the 
less abundant A42, while the failure of A clearance in sAD also results in the 
accumulation of A42. A42 accumulates in both sAD and EOfAD brains. An 
oligomeric form(s) of A42 aggregate is assumed to be toxic. The oligomers 
containing A42 aggregate and become plaques through gradual deposition, leading 
to a series of downstream reactions, such as inflammatory responses and the 
formation of tangles, finally resulting in dementia [21, 22]. 
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Figure 1.2. The amyloid hypothesis of Alzheimer’s disease as described by Herrup 
[21]. Different etiologies in EOfAD and sAD both lead to the production of an 
excess of A42. The A42 peptides are assumed to be toxic and the aggregation of 
A42 triggers a cascade of downstream events, resulting in a series of biological and 
neurological AD symptoms. 
The increased A seen in the brains of those with Down syndrome results in the 
development of pathological changes resembling AD by 35 years of age [23]. This 
is due to the extra copy of chromosome 21 in this syndrome. Chromosome 21 
contains the APP gene, leading to the increase of A production. Therefore, this 
early onset form of AD in Down syndrome supports that the accumulation of A 
may contribute to the pathology of AD.  
Some experimental data is inconsistent with the Amyloid Hypothesis. A recent 
study by Sun et al., 2017 [24] examined the ability of 138 reported EOfAD 
mutations in human PSEN1 to produce A40 and A42 in vitro, and found that the 
production of A40 and A42 was reduced for about 90% of these mutations and 
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10% of these mutations showed decreased ratios of A42/A40 (the A42/A40 ratio 
will be discussed further in section 1.4.2). The decreased A42 production and 
A42/A40 ratios are not consistent with the Amyloid Cascade Hypothesis. Also, the 
Amyloid Cascade Hypothesis fails to explain why there are cognitively normal 
people (without dementia) who have plaques and tangles in their brains [9]. The 
impacts of these plaques and tangles on cognitively normal people and AD patients 
remain unclear.  
 
1.3.2 Tau hypothesis 
Another major pathological feature, the accumulation of neurofibrillary tangles, is 
thought to cause AD in the tau hypothesis. Tau is a highly soluble microtubule-
associated protein (MAP) that can interact with tubulin to stabilize microtubule 
assembly [25]. There are six isoforms of tau transcripts expressed in adult human 
brains with or without Exons 2, 3 and 10. Inclusion or otherwise of exon 10 results 
in isoforms of Tau with either four or three microtubule binding domains, ie. 4-
repeat (4R) isoforms and 3-repeat (3R) isoforms (Figure 1.3, [26]).  
 
 
Figure 1.3. The alternative splicing of tau transcripts (from [26]). Six tau transcript 
isoforms are expressed in adult human brains with or without Exons 2, 3 and 10. 
There are four repeats of a microtubule binding domain, R1-4. Exon 10 contains 
the repeat R2.  
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The abnormal hyperphosphorylation of tau may affect isoform expression and 
promote the assembly of tau into paired helical filaments (PHFs) or straight 
filaments (SFs), which are the major components of the intracellular neurofibrillary 
tangles (NFTs) [25, 27] seen in AD brains. The insoluble structure of NFTs may 
accumulate and damage neuronal cells, eventually developing into dementia. The 
tau hypothesis has a similar limitation to the amyloid hypothesis in failing to 
explain the presence of neurofibrillary tangles in normal brains and their absence 
in some AD brains. Also, there are no clear explanations for how the genetic factors, 
such as the EOfAD-causative mutations, induce the tau pathology.  
 
1.3.3 MAM hypothesis 
The amyloid cascade hypothesis and the tau hypothesis focus on the major 
histopathological features of AD, amyloid plaques and neurofibrillary tangles 
respectively. However, they put little emphasis on other disease-related phenomena 
that occur years before the accumulation of plaques and tangles [28]. These 
phenomena include the altered metabolism of fatty acids and phospholipids [29, 
30], increased levels of circulating cholesterol [31], the deposition of lipid droplets 
in cells [32-34], aberrant calcium homeostasis [35], increased stress on the 
endoplasmic reticulum (ER) [36], and mitochondrial dysfunction [37, 38]. These 
phenomena are associated with the functions of a specialized subdomain of the ER 
known as the mitochondria-associated ER membranes (MAM) [28]. MAM, which 
has the features of a lipid raft, connects mitochondria and ER physically and is 
critical for the interactions between mitochondria and the ER, including 
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phospholipid biosynthesis, fatty acid metabolism, cholesterol esterification, 
calcium homeostasis, mitochondrial dynamics, and communication between the 
two organelles [39]. The MAM hypothesis focuses on these early features and 
proposes that they result from increased ER-mitochondrial apposition and 
perturbed MAM function, which are causative and early events in AD pathology. 
The accumulation of plaques and tangles is seen as a consequence rather than as a 
cause of these changes (reviewed in Area-Gomez and Schon, 2017 [28]). 
Furthermore, MAM is also related to A production [40, 41], and the active forms 
of PSENs, (in -secretase activity) and the -secretase cleavage of APP show 
localisation to the MAM in brains [42, 43]. Increases in MAM functionality are 
seen in fibroblasts both from sAD patients and when expression of the PSEN genes 
is reduced [44]. Therefore, a unified explanation for the pathology of both EOfAD 
and sAD is achieved in the MAM hypothesis.  
 
 
1.3.4 PSEN holoprotein multimer hypothesis 
EOfAD is autosomal and dominantly inherited, and PRESENILIN (PSEN) genes 
are major genetic loci of EOfAD [45]. The EOfAD-causative mutations share the 
common feature of following the “fAD reading frame preservation rule” [5]. These 
mutations do not change the open reading frame of the transcripts and retain the 
production of full-length proteins. Based on this feature, it is assumed in the PSEN 
holoprotein multimer hypothesis (illustrated in Figure 1.4) that the production of 
full-length proteins plays an essential role in disease pathology. In this hypothesis, 
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the normal PSEN holoprotein can form dimers/multimers that are critical for the 
maintenance of cellular homeostasis, while EOfAD-mutated PSEN holoprotein 
may multimerize with wild type holoprotein and inhibit the formation of normal 
PSEN holoprotein dimers/multimers, leading to the disruption of holoprotein 
functions and cellular homeostasis such as autophagy or secretion of A [5]. The 
hypothesis also proposes that, under hypoxia, hypoxia-inducible factor 1, alpha 
subunit (HIF1) might promote the endoproteolysis of PSEN holoprotein 
dimers/multimers to stimulate the formation of active -secretase [5]. As a result, 
EOfAD-mutated PSEN holoprotein would probably lead to increased production of 
A. Although this PSEN holoprotein multimer hypothesis has been advanced to 
interpret the action of EOfAD-causative mutations, it remains unknown how this 
hypothesis relates to sAD. This is a major limitation of this hypothesis and requires 
further exploration.  
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Figure 1.4. PSEN holoprotein multimer hypothesis (from [5]). PSEN holoproteins 
can form dimers/multimers the may be necessary for the endoproteolysis that 
activates -secretase activity, while mutated PSEN holoprotein may bind to wild 
type holoprotein and inhibit its activity, influencing cellular homeostasis. On the 
other hand, under hypoxia, HIF1 may be able to interact with holoprotein 
dimers/multimers to stimulate the formation of active -secretase. 
 
1.3.5 The vascular hypothesis 
In addition to genetic factors, age, as a major factor for both EOfAD and sAD, is 
taken into consideration in many hypotheses [21]. The features of brain 
degeneration during normal aging likely contribute to the occurrence of AD to some 
degree. The vascular hypothesis interprets AD progression from the viewpoint of 
the brain ageing and accumulated damage of vascular and neuronal cells. The 
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degeneration of vascular cells causes progressive reduction in cerebral blood flow 
(CBF), hypoperfusion and hypoxia [46]. Furthermore, the physical breakdown of 
the blood-brain barrier (BBB) caused by pericyte detachment leads to the leakage 
and accumulation of serum proteins and focal microhemorrhages and the 
extravasation of red blood cells (RBCs), subsequently resulting in hypoxia, 
hypoperfusion and the formation of toxic reactive oxygen species (ROS) (Figure 
1.5, [46]). Also, neurotoxic proteins are able to pass the defective BBB and 
accumulate in the brain. Therefore, the vascular hypothesis proposes that these 
factors causing neuronal injury become aggravated during ageing and eventually 
cause dementia.  
 
Figure 1.5. Neurodegeneration induced by the breakdown of BBB (from [46]). 
Pericyte detachment leads to leakage of serum proteins and focal 
microhaemorrhages, with extravasation of RBCs. Neural injury is aggravated by 
three proposed mechanisms: 1) Albumin promotes the formation of vascular 
oedema, which affects blood flow and subsequently induces hypoxia and 
hypoperfusion. 2) RBCs release haemoglobin, which provides iron to catalyse 
formation of toxic ROS. 3) The defective BBB allows vasculotoxic and neurotoxic 
proteins to enter the brain.  
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Under hypoxic conditions, upregulation of genes involved in A production has 
been observed, including APP, PSEN1 and BACE1 [47-49], probably resulting in 
increased production of A. In addition, due to the degeneration of pericytes and 
vascular smooth muscle cells, the clearance of A is probably reduced [50]. The 
accumulation of A is a major pathological feature of AD and may possibly cause 
other vascular diseases, such as cerebral amyloid angiopathy (CAA) [46], which, 
co-existing with AD, would significantly increase the risk of dementia [51]. Also, 
the reduced clearance flow in brains with vascular pathology probably contributes 
to the accumulation of secreted tau [52]. 
 
1.3.6 Change-of-state hypothesis  
Another age-dependent hypothesis, the change-of-state hypothesis, has been 
proposed by Herrup, 2010 (Figure 1.6 [21]). This hypothesis describes the 
pathological development of AD involving three key consecutive events: an 
initiating injury, a chronic inflammatory response and the change of brain cell 
states. Here, age acts as a risk factor for the initiating injury, which induces an 
inflammatory response to begin the pathogenic process. The correlation between 
the neuroinflammatory process and the neuropathology of AD has been 
demonstrated in several papers [53, 54]. Also, long-term use of nonsteroidal anti-
inflammatory drugs has been found associated with a reduced prevalence of AD 
[54-56]. The inflammatory response causes a chronic stress that drives brain cells 
from a normal state into a different, pathological state, affecting cell cycle events 
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and causing defects in autophagy and alterations of tau [21]. Furthermore, in this 
hypothesis, the amyloid hypothesis has not been subverted, but contributes as a 
cause of pathogenesis. Inflammatory responses stimulate the production of A, 
while the aggregation of A also stimulates inflammation, causing an amyloid 
deposition cycle. 
 
Figure 1.6. The expanded change-of-state hypothesis of AD of Herrup [21]. In this 
hypothesis, the three steps displayed in blue ovals and numbered are assumed to be 
key and necessary processes in disease pathology leading to AD. This expanded 
model also correlates relevant brain cell biology and biomedical processes with AD 
pathology, indicating the proposed role and involvement of related elements. A 
accumulation is both a key element and a symptom in AD and is involved in the 
amyloid deposition cycle. 
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1.3.7 Summary of AD hypotheses 
AD is a complicated neurodegenerative disease, and many AD hypotheses have 
been proposed focusing on different elements and features observed during disease 
progression. In the section 1.3, six AD hypotheses selected from among the most 
popular AD hypotheses have been discussed. Due to the complexity of human 
brains, most AD hypotheses have limitations in comprehensively explaining AD 
pathology, and AD treatments based on these hypotheses have faced difficulties 
[14, 57]. Moreover, AD pathology involves interactions between different 
pathways, making it even more difficult to investigate AD etiology. As a result, 
although there is quite a variety of AD hypotheses proposed, it is difficult to 
determine which hypothesis is most closely in alignment with the reality of AD 
pathology. Therefore, rather than focusing on AD hypotheses, the ADGL models 
EOfAD-relevant mutations in zebrafish models and pays attention to transcriptome 
changes induced by these mutations, to investigate transcriptional signatures of AD 
and to interpret AD pathology. 
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1.4 Genetics  
1.4.1 Genetic risk factors for sAD 
Although sAD shows only limited inheritance, genetic factors remain a strong 
contributor among the multiple risk factors. More than twenty genetic risk loci of 
sAD have been identified by large-scale GWAS and meta-analysis (Table 1.1, 
[58]). Among these loci, APOE is the major risk locus and is located on 
chromosome 19. The function of APOE is related to the normal catabolism of 
triglyceride-rich lipoproteins [7]. In the central nervous system (CNS), APOE is 
one of the major components of lipoprotein particles, which are responsible for 
transmitting cholesterol from astrocytes to neurons [59, 60]. A relationship between 
APOE and sAD has been identified through the observation of immunoreactivity 
to APOE at amyloid plaques and neurofibrillary tangles [61]. APOE protein has 
299 amino acids and has three isoforms in humans: APOE 2 (Cys112 and Cys158), 
APOE 3 (Cys112 and Arg158) and APOE 4 (Arg112 and Arg158) [7]. Based on 
population studies, the APOE 4 allele increases the risk of developing Alzheimer’s 
disease [62], while the APOE 2 allele significantly decreases the risk [63]. In a 
study by Deane et al., 2008 [64], the role of APOE was investigated in APOE 
knock-in mice and it was revealed that the clearance of A40 was inhibited in an 
allele-specific manner, showing the involvement of APOE in A clearance.  
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Table 1.1. Overview of sAD susceptibility loci from GWAS and meta-analysis 
summarized by Van Cauwenberghe et al. in 2016 (from [58]), with the description 
of the most significant SNP at each locus. The ranking of significant SNPs is based 
on their effect size. The population-attributable fraction (PAF) types are indicated 
with “a” for risk PAF and “b” for preventive PAF.  
OR, odds ratio; CI, confidence interval; CNV, copy-number variation. 
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1.4.2 EOfAD-causative mutation loci 
Autosomal dominant genetic mutations leading to EOfAD have been found in the 
genes encoding AMYLOID BETA A4 PRECURSOR PROTEIN (APP), 
PRESENILIN 1 (PSEN1) or PRESENILIN 2 (PSEN2) [5] and, possibly, SORTILIN-
RELATED RECEPTOR (SORL1) [65, 66]. APP is a type I transmembrane protein, 
encoded by the APP gene located on chromosome 21. APP contains cleavage sites 
for multiple enzymes (Figure 1.7, [5]), but A can only be produced through 
cleavage by -secretase and -secretase [67, 68]. Presenilin is the catalytic subunit 
of the -secretase enzyme that participates in APP cleavage. The neuronal function 
of APP remains ill defined, while A seems to be a normal product of APP 
metabolism and is generated at high levels in neurons [7].    
 
Figure 1.7. Cleavage of APP (from [5]). APP contains multiple cleavage sites, but 
A can only be produced through cleavage at both the -site and the -site.  
As APP, PSEN1 and PSEN2 are all involved in the production of A by -secretase 
cleavage of APP, this process is a major research focus in EOfAD. The -secretase 
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enzyme complex performs “endopeptidase” cleavages firstly to release APP’s 
cytosolic “intracellular domain” (AICD), and subsequently “carboxypeptidase” 
cleavages to shorten the remaining part of APP so that the hydrophobicity is 
reduced to release soluble A from the lipid bilayer [5]. A cell-free study by 
Chavez-Gutierrez et al., 2012 [69] further investigated the -secretase changes due 
to the EOfAD mutations in PSEN1 and APP gene, and found that these mutations 
have variable effects on the endopeptidase cleavage, indicating the impairment of 
the endopeptidase cleavage is not necessary for AD pathology. Another study 
introduced ten different EOfAD mutations into the PSEN1 gene to investigate their 
effects on -secretase activity using an in vitro cleavage assay [70]. The changes in 
-secretase activity were variable, but all these mutations led to increased ratios of 
A42/A40, suggesting that the regulation of -secretase activity possibly is not 
relevant to EOfAD pathology while a relatively increased production of A42 
(A42/A40 ratios) may contribute to disease progression. A similar result was 
observed in children carrying the mutation PSEN1 E280A who had increased 
plasma A42 levels and A42/A40 ratios compared to non-carriers [71]. However, 
an inconsistent result was achieved through examining the in vitro -secretase 
activity of 138 reported EOfAD mutations in human PSEN1, which found 
decreased production of both A40 and A42 for about 90% of these mutations and 
decreased A42/A40 ratios for 10% of the mutations [24]. Therefore, the role of -
secretase activity and A42/A40 ratios in AD pathology remains controversial and 
requires further investigation. Moreover, EOfAD-causative mutations follow a 
“fAD reading frame preservation rule” that the mutations do not destroy the open 
reading frame such that mutant transcript are always present encoding a “full-
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length” protein [5]. The human EOfAD mutation, PSEN2K115fs, which is a frame 
shift in PSEN2 leading to a premature termination codon, was previously thought 
to be an exception to this rule [72]. However, the identification of a new transcript 
splicing isoform from the PSEN2K115fs allele which restores the open reading frame 
and leads to production of full-length protein, indicated that the human PSEN2K115fs 
mutation also follows this rule [73]. Therefore, it has been argued that production 
of a full-length protein may be a necessary element in disease pathology, such as 
for the formation of PSEN1 holoprotein dimers/multimers in the PSEN holoprotein 
multimer hypothesis ([5], discussed in previous section 1.3.3).  
The gene SORTILIN-RELATED RECEPTOR (SORL1), also known as LR11, is 
another rare EOfAD mutation locus although this status is still subject to debate 
(reviewed in [66]). The identified EOfAD variants in SORL1 are illustrated in 
Figure 1.8. SORL1 encodes a transmembrane receptor with multiple functional 
domains, which participates in the endosomal sorting of proteins between the trans-
Golgi network (TGN), endosomes and the plasma membrane [65]. Unlike the 
PSEN genes for which hundreds of EOfAD variants have been defined, only a few 
EOfAD variants have been identified in SORL1 gene. These are disturbed over 
different protein domains (Figure 1.8). Also, genetic associations between SORL1 
and sAD have been identified in genome-wide association studies [74-76], 
indicating that SORL1 is involved in both sAD and EOfAD. SORL1 protein act in 
complex and essential roles in the trafficking and processing of APP within cells 
(reviewed in Barthelson et al., 2020 [65]). The overexpression of SORL1 leads to 
the accumulation of APP in the Golgi and failure to sort APP to late endosomal 
membranes where some A is produced, while deficiency of SORL1 results in an 
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increase in A levels [65, 77]. Therefore, the correlation between the expression of 
SORL1 and the production of A indicates potential roles for SORL1 in A-related 
pathologies in both sAD and EOfAD. 
 
 
Figure 1.8. A summary of the identified EOfAD variants in the gene SORL1 (from 
[65]). It encodes a protein with multiple domains: VPSP10, vacuolar protein sorting 
10; LDLR, low density lipoprotein receptor; EGF, epidermal growth factor; FN, 
fibronectin-type; TMD, transmembrane domain; ICD, intracellular domain. The 
position of known coding variants are indicated by arrows. Red arrows indicate 
variants published in Pottier et al., 2012 [78], and blue arrows indicate variants 
published in Thonberg et al., 2017 [79]. 
 
1.4.3 EOfAD-causative mutations in the gene PSEN1 
PSEN1 gene is the major EOfAD locus, and mutations in PSEN1 gene contribute 
to 70%-80% of EOfAD cases [45]. More than 205 different EOfAD-causative 
mutations in PSEN1 have been identified with a scattered distribution [80] (Figure 
1.9). These mutations all follow the “fAD reading frame preservation rule”, and 
missense mutations form a large proportion of these [5]. Interestingly, a known 
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frame shift mutation in human PSEN1, P242LfsX11, does not cause EOfAD but 
does cause another disease, the skin disease Acne Inversa (Hidradenitis 
Suppurativa) [43]. This mutation leads to a premature termination codon and may 
produce a truncated protein lacking -secretase activity. The existence and 
phenotypic effects of this mutation may support the PSEN holoprotein multimer 
hypothesis raised by Jayne et al., 2016 [5] that EOfAD-causative PSEN mutant 
holoproteins interact with wild type PSEN holoproteins to inhibit the formation of 
the normal holoprotein dimers/multimers, while the truncated PSEN proteins may 
be structurally unable to interact pathologically with wild type PSEN holoproteins. 
 
Figure 1.9. The structure of human PSEN1 protein (modified from [81]). The 
pathogenic EOfAD mutations are labelled in orange, while the non-pathogenic 
mutations are labelled in green. Mutations with unclear effects are labelled in blue. 
Two catalytic aspartate residues are critical for its -secretase activity. 
The major function of PSEN1 in AD pathology is currently thought to be the -
secretase cleavage of APP to form A. However, the role of -secretase in AD 
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pathology remains controversial (see above), as the increased A production or 
increased A42/A40 ratios proposed to be pathogenic are not observed for all 
EOfAD mutant forms of PSEN1 [24] while the truncating Acne Inversa mutation 
that should reduce -secretase activity does not cause EOfAD [43]. Therefore, 
further investigation of the role of -secretase in AD pathology is desirable, as the 
molecular changes caused by changes in -secretase activity can be excluded from 
consideration if the -secretase activity does not contribute to AD pathology. Also, 
other functions of PSEN1 and the pathways it is involved in have been investigated 
in animal models and require further exploration. It has been found that the PSEN1 
gene is essential for animal development, and Psen1 knock-out mice (Psen1-/-) are 
unable to survive during development [82] while the blockage of psen1 translation 
using morpholino antisense oligonucleotides in zebrafish embryos does not kill the 
zebrafish but leads to the formation of aberrant somites and defects in Notch 
signaling [83-85]. Furthermore, psen1 may act as a regulator of histaminergic 
neuronal development in the brains of psen1-/- zebrafish [86]. The brain 
histaminergic system is a major modulatory system regulating multiple functions 
including cognition and memory which are closely related to AD [87]. However, 
our understanding of PSEN1 functions is far from comprehensive, and further 
investigation is required to figure out what functional changes induced by EOfAD 
mutations directly contribute to AD pathology.  
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1.5 Animal models of AD 
1.5.1 AD in wild animals 
The accumulation of amyloid plaques, which is the major histological sign in AD, 
has been detected not only in human brains but also in the brains of other nonhuman 
primates [88]. Even dogs develop amyloid plaques as they age and have been used 
as a natural model of age-dependent cognitive dysfunction. The impacts of A in 
dogs’ brains on their cognition, such as their ability to learn, have been investigated 
in several studies [89-91]. However, it is an ongoing debate whether another 
essential feature of AD, the accumulation of NFTs, is present in these animals’ 
brains [92, 93]. In the study by Schmidt et al., 2015 [93], the presence of NFTs was 
detected in some extremely aged canines with cognitive dysfunction syndrome, 
indicating that canines might also develop NFTs but that a longer life span might 
be required. Also, the presence of both amyloid plaques and NFTs in brains has 
been found in dolphins, which have a relatively long life span like humans [88]. 
Therefore, it has been argued that the post-reproductive life span and longevity 
might contribute to the onset of AD rather than aging [88].  
 
1.5.2 Rodents models in AD studies 
Due to the inherited nature of EOfAD, modeling EOfAD in an animal model is an 
obvious pathway for investigating the molecular changes that occur in this disease 
in vivo. As mammals, rodents are the most common animal models used in AD 
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research. Compared to other mammals, rodent models are easy to manipulate 
genetically and have a relatively short life span. The formation of amyloid plaques 
has been successfully identified in several transgenic models of AD that 
overexpress the genes associated with EOfAD [94]. However, the majority of AD 
therapies that have succeeded in preclinical testing using rodent models have failed 
in clinical trials [94], suggesting that current transgenic EOfAD-like rodent models 
may not develop aspects of AD pathology and do not reflect closely the disease 
state of human patients. Hargis and Blalock, 2017 [95] compared brain 
transcriptional profiles in AD patients and five different transgenic mouse models 
of AD, and demonstrated that the transcriptional profiles of AD patients were 
consistent across studies while the transcriptional profiles of transgenic mouse 
models were not similar to one another or to the transcriptional profiles of AD 
patients. Also, none of the transgenic mice showed an essential, consistent 
transcriptional signature identified in AD patients, a downregulation of synaptic 
and mitochondrial genes. Therefore, due to their failure to reflect the transcriptional 
changes observed in postmortem human AD brains, the transgenic rodent models 
probably only reflect specific pathways involved to a limited degree, and are 
obviously deficient for the study of human AD pathology. Indeed, each animal 
model has its own advantages and disadvantages and there are no perfect animal 
models for human AD, while a combination of models might be used to study 
particular aspects of AD [96]. Therefore, the use of other relevant animal models 
in AD studies is highly desirable, and may inform us regarding potential molecular 
changes that are involved in human AD pathology but that do not occur in 
transgenic rodent models. 
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1.5.3 The zebrafish as a genetic model  
The zebrafish, Danio rerio, is a small tropical freshwater fish that is originally from 
the Ganges River and its tributaries in northern India [97]. The genome of the 
zebrafish has been fully sequenced and is well annotated [98]. Due to some obvious 
advantages over mammalian models, the zebrafish has become a popular vertebrate 
animal model that has been increasingly used in the study of human disease in 
recent decades. Although the divergence time between humans and zebrafish 
(teleosts) is approximately 450 million years [99], the zebrafish, as a vertebrate, 
shares more anatomical, physiological and biological properties with humans than 
invertebrate models such as Drosophila melanogaster and Caenorhabditis elegans 
[100]. The external and transparent embryos of the zebrafish are easily accessible 
for subtle and complex genetic manipulation and ideal for in vivo imaging, and the 
zebrafish has a short embryo development period and a relatively short generation 
time. Also, the zebrafish’s capacity to produce large families of siblings (100+ per 
spawning), which can then be raised in the same environment, is desirable for 
achieving high sample numbers for experimental analysis with limited 
environmental and genetic noise [101]. Moreover, multiple genes can be 
manipulated effectively simultaneously in the zebrafish, something which is 
currently relatively difficult to achieve within rodent models [101].  
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1.5.4 Zebrafish models of AD 
When used as an animal model in the study of AD, the zebrafish should show clear 
gene orthology to the relevant human genes involved in the disease. The zebrafish 
orthologs of the three human EOfAD genes PSEN1, PSEN2 and APP have been 
identified and are denoted as psen1 [102], psen2 [103], appa and appb [104] (the 
latter are duplicate “co-orthologues” of human APP). Also, orthologous genes in 
zebrafish involved with other elements of AD pathology in human include those 
encoding -secretase (bace1 [105] and bace2 [106]) and -secretase complex 
components (psenen [85, 107], ncstn [108] and aph1b [107]), the genes encoding 
tau (mapta and maptb co-orthologues in zebrafish [109]) as well as the apoea and 
apoeb co-orthologues of APOE [110] (reviewed in Newman et al., 2014 [101]). 
Furthermore, the normal functions of these genes in the zebrafish have been 
investigated respectively through the inhibition of protein translation, and several 
unique characteristics of these genes have been identified, which were not observed 
in knock-out rodent models (reviewed in Newman et al., 2014 [101]). Therefore, 
zebrafish EOfAD mutation models can reveal different aspects of the functions of 
these genes compared to rodent models, inducing specific effects on molecular 
interactions and cellular pathways. The combination of analyses from multiple 
animal models can contribute to a more thorough understanding of the pathology 
of human AD.  
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1.6 Introducing mutations into zebrafish models using genome 
editing technologies 
To use animal models for the study of human disease, mutations equivalent to those 
causing disease in humans can be introduced into an animal’s endogenous genes to 
generate animals with a genetic state resembling the human disease. Previously, the 
generation of equivalent mutations could only be achieved in rodent models based 
on homologous recombination through embryonic stem cell technologies, while in 
zebrafish models, the technologies available only enabled the temporary blockage 
of protein function through targeted knockdown approaches [111]. With the 
discovery of genome editing tools, the possibilities for generating desired mutations 
in animal models have dramatically improved. In particular, the clustered regularly 
interspaced short palindromic repeats (CRISPR) /CRISPR-associated gene (Cas) 
system has made genome editing feasible in almost any organism [112]. 
All genome editing tools contain two essential elements: a sequence-specific DNA 
targeting subunit and a double-strand DNA-cleaving nuclease. These two elements 
introduce double-strand breaks at a sequence of interest, and subsequently initiate 
innate DNA repair pathways, non-homologous end-joining (NHEJ) or homology-
directed repair (HDR) (Figure 1.10a, [111]). NHEJ repairs the broken double-
stranded DNA without a template, so that small insertions and deletions (indels) are 
frequently introduced into the breakpoint. Incorrect NHEJ repair of an open reading 
frame can lead to a frame shift and/or a premature stop codon, resulting in gene 
knock-out. In contrast, HDR requires a homologous DNA template, and enables the 
insertion of foreign DNA into a breakpoint to generate a desired mutation [113].  
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Three major genome editing tools, zinc finger nucleases (ZFNs), transcription 
activator-like effector nucleases (TALENs) and the type II prokaryotic 
CRISPR/Cas9 system, are frequently used in animal models including zebrafish. In 
both ZFNs and TALENs, DNA-binding proteins fused to the Fok1 endonuclease 
are used to target DNA and subsequently cause cleavage (Figure 1.10b and 1.10c), 
while the CRISPR/Cas9 system uses a guide RNA (gRNA) to guide the Cas9 
nuclease to the desired genomic locus (Figure 1.10d). ZFNs were the first genome 
editing tool used in zebrafish [114], but the complicated design of zinc finger 
motifs, time-consuming in vitro tests of binding affinity, and their high cost limited 
the use of this technology in the zebrafish [111]. In contrast to ZFNs, TALENs have 
a more predictable binding affinity and the design of a transcription activator-like 
effector (TALE) is technically easier [111]. Also, the high specificity of TALENs 
to the targeting sequence leads to rare off-targets effects [115, 116], which is 
preferable for genome editing. The CRISPR/Cas9 system identified from bacteria 
and archea is built on a different concept, having different technical features. The 
CRISPR/Cas9 system is the most cost-efficient and technically easiest to use, and 
the generation of mutations can be achieved easily in most laboratories [111]. Also, 
the influence of off-target mutations caused by the CRISPR/Cas9 system can be 
significantly reduced by outcrossing edited zebrafish to wild type fish [111]. 
Furthermore, the recent discovery of the class II type V CRISPR/Cas12a (Cpf1) 
system, which is similar to the CRISPR/Cas9 system but uses a different RNA 
guided endonuclease recognizing a different PAM site, typically 5’-TTTV-3’, 
provides an alternative selection of sequence target sites [117]. Therefore, the use 
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of CRISPR/Cas systems is an appropriate option for the generation of desired 
mutations in zebrafish. 
 
 
Figure 1.10. Mechanisms of genome 
editing technologies (from [111]). 
(a) Schematic representation of genome 
editing to generate a double-stranded 
DNA break and subsequently introduce 
mutations through DNA repair.  
(b) Schematic representation of ZFNs. 
Left and right ZFNs bind near each other 
to constitute an active Fok1 nuclease to 
induce a double-stranded break. Three to 
four zinc fingers are used on each side, 
and each zinc finger recognizes three 
nucleotides.   
(c) Schematic representation of TALENs. 
Left and right TALENs bind near each 
other to constitute an active Fok1 nuclease 
to induce a double-stranded break. 16 
TALE elements are used on each side, and 
each TALE recognizes one nucleotide. 
(d) Schematic representation of the 
CRISPR-/Cas9 system. The target site for 
cleavage is a three-nucleotide NGG motif 
adjacent to a 20-nucleotide sequence 
called the protospacer adjacent motif 
(PAM). A specific guide RNA (gRNA) 
with a 20-nucleotide sequence 
complementary to the target and a 
sequence that recruits the Cas9 nuclease is 
shown.  
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1.7 Methods for quantification of gene expression 
Assessment of a transcriptome involves description of a set of RNA transcripts and 
their quantity in a cell, tissue, or whole organism. Through transcriptome analysis, 
the global regulation genes in a sample can be assessed at a particular time point, 
and the changes in cellular function can be predicted. Therefore, transcriptome 
analysis is widely used for the investigation of disease-specific effects at genetic 
levels. DNA microarrays, a hybridization-based approach, was an early technique 
for transcriptome analysis. However, it has be limited by its reliance on existing 
knowledge about genome sequences, high background signals induced by cross-
hybridization of probes with similar rather than identical RNA sequences [118], 
and a limited range of detection due to background and the saturation of signals 
[119]. With the development of next-generation sequencing, DNA microarrays 
have been almost replaced by sequenced-based approaches, RNA-seq. A general 
workflow of RNA-seq is illustrated in Figure 1.11. A population of RNA is 
converted into a library of cDNA fragments through either RNA fragmentation 
followed by reverse transcription or reverse transcription followed by cDNA 
fragmentation. With adaptors attached to one or both ends, each fragment is then 
able to be sequenced from one end (single-end sequencing) or both ends (paired-
end sequencing) using high-throughput sequencing technology. The short reads 
achieved by sequencing can be aligned to a reference genome or to reference 
transcripts, or assembled de novo [119]. Gene quantification can be achieved 
through counting the reads aligned to each gene.  
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Figure 1.11. The workflow of a typical RNA-Seq experiment (from [119]). 
mRNAs are converted into a library of cDNA fragments through either RNA 
fragmentation followed by reverse trancription or reverse trancription followed by 
cDNA fragmentation. Each cDNA fragment is then attached to a sequencing 
adaptor (blue). A short sequence read is subsequently achieved from each cDNA 
through high-throughput sequencing technology.  
RNA-seq can provide a comprehensive overview of gene expression and regulation 
in a cell, tissue, or organism. The expression of genes of interest is subsequently 
normally assessed by reverse transcription quantitative PCR (RT-qPCR). The 
relative standard curve method of qPCR is based on the detection of fluorescence 
to monitor the production of amplification products during each cycle of a PCR 
monitored in real-time [120]. In this technique, an external standard curve for PCR 
of a particular gene is generated through performing a series of separate real-time 
PCRs on a serial dilution of a unknown sample. The standard curve produced can 
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then be used to estimate the quantity of that gene in unknown samples. The relative 
quantification of that gene from the standard curve can be normalized to that of a 
house-keeping gene in the same sample, and the normalized numbers enable the 
comparison of gene expression between samples.  
Digital qPCR (dqPCR) is an alternative technique for gene quantification (Figure 
1.12). DNA templates are firstly diluted and separated into individual reactions in 
cells (approximately 1 copy per two cells/reactions), and the presence of PCR 
products in each cell is detected by fluorescent probes [121]. The gene 
concentration can be estimated through statistical analysis, as positive signals 
should be distributed according to Poisson probabilities [122]. Compared to 
traditional standard curve qPCR, digital qPCR has the advantages of absolute 





Figure 1.12. Schematic of Digital PCR (from [121]). DNA templates are diluted 
and separated into individual reaction cells, and the presence of specific PCR 
products can be detected using corresponding fluorescence probes. Template 




1.8 Behavioural Analysis: Testing of short term working memory 
in animal models using Y-maze  
Cognitive impairment, including decline in memory and other executive functions, 
is the most significant clinical symptom of AD. Working memory involves 
temporary storage, which is known as short-term memory, and manipulation of 
information that is used for various cognitive activities [20, 123]. The most current 
multiple-component model of working memory consists of four subcomponents, 
the central executive, the phonological loop, the visuospatial sketch pad and the 
episodic buffer [123]. Spatial memory, which is related to the storage and retrieval 
of information for the identification and navigation of proximal or distal space [124], 
participates in the subcomponent visuospatial sketch pad. A study by Guariglia, 
2007 [125] used the Corsi block-trapping test to assess short-term spatial working 
memory in AD patients. Impairments in short-term spatial working memory were 
observed in AD patients with moderate dementia, while those with mild dementia 
did not show a significant decline. Therefore, short-term spatial working memory 
can be used for assessment of cognitive decline in EOfAD models. Although short-
term spatial memory in animals cannot be assessed as easily as in humans, the Free-
movement pattern (FMP) Y-maze is a rapid method that can be employed for this 
purpose. The original Y-maze was designed to detect changes in short-term spatial 
working memory through assessment of spontaneous alternative arm choice based 
on the idea that animals are driven by an innate curiosity to explore unvisited areas 
and thus trend to enter a less recently visited arm [126]. No training of the animals 
is required for this test. A high percentage of entries into consecutive arms is 
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regarded as indicating superior spatial working memory performance, as the tested 
animal can recall the arms it has already visited and enter another arm, resulting in 
a similar proportion of entries to each arm over time (Figure 1.13, [127]).  
 
Figure 1.13. Assessment of spontaneous alternative arm choice in the Y-maze. A 
high percentage of entries into consecutive arms is reflected as a similar proportion 
of entries into each of the arms (upper) indicating good spatial working memory, 
while a low percentage of entries into consecutive arms is reflected as a higher 
proportion of repeated entries into the same arm (lower) regarded as poor spatial 
working memory [127].  
However, the assessment of spontaneous alternative arm choice using the original 
Y-maze has limitations. Difficulties in interpreting results have been reported in 
several studies, especially when the tested models showed hypo- or 
hyperlocomotion, stereotyped behaviour, or anxiety-related novelty avoidance that 
could significantly affect the assessment of animals’ spontaneous alternative arm 
choice [128-132]. For example, in a behavioural study of the Tg2576 AD rodent 
model, these mice showed a perfectly stereotyped behaviour of always making right 
turns which results in equal entries into each arm during the test period, 
consequently giving a high percentage of entries into consecutive arms [129]. 
However, this performance was not due to superior spatial working memory but 
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was a result of the rodent model’s stereotyped behaviour. To overcome these 
limitations, the FMP Y-maze has been designed by Cleal et al., 2020 [132], which 
shifts the focus from novelty response to navigational search pattern by recording 
sequences of animals’ left and right turns apportioned into 16 possible tetragrams 
consisting of 4 turns in a 1-hour runtime of free exploration to identify strategic 
search patterns. This method is advanced in classifying movement patterns affected 
by other factors, such as stereotyped behaviour, into different search strategies, 
which do not overlap with normal search strategies. The search strategies used by 
vertebrates, including mice, zebrafish and humans, mainly consist of alternations 
(LRLR and RLRL tetragrams), and impairment of working memory would cause a 
reduction in these alternations, indicating the potential application of FMP Y-maze 
in the assessment of working memory [132]. 
There are several behavioural studies performed on zebrafish to assess cognition. 
A study by Aoki et al., 2015 [133] performed a 2-hour training session using a 
specific colour paired with electric shock on adult zebrafish. The zebrafish learned 
to choose the correct arm at an efficiency of 89%, demonstrating their memory and 
learning abilities. Another study by Cognato et al., 2012 [134] used a Y-maze 
memory task with a training session that blocks one arm as the novel arm to assess 
changes in zebrafish behaviour induced by either MK-801 or scopolamine 
dissolved in tank water. These drugs produced deficits in memory. Treatment of 
zebrafish pre-training with either MK-801 or scopolamine or post-training with 
MK-801 resulted in reduced exploration of the novel arm, highlighting the potential 
application of the zebrafish model to the study of cognition and memory. As 
impairment of short-term spatial working memory is one of the clinical symptoms 
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of AD and has been found in AD patients with moderate dementia [125], it will be 
a straightforward strategy to determine whether impaired short-term working 
memory can be observed in EOfAD-like zebrafish mutants through testing in a 
FMP Y-maze without training. In future, other cognitive abilities, such as learning 
ability and spatial reference memory, in EOfAD-like zebrafish mutants could be 
investigated further in Y-maze studies involving specific training treatments. 
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1.9 Previous work of the Alzheimer’s Disease Genetics laboratory 
on presenilin mutations 
1.9.1 The generation of two EOfAD-like mutations in the 
zebrafish gene psen1  
To investigate the changes in brain molecular state induced by EOfAD mutations, 
we have previously introduced two EOfAD-like mutations into the zebrafish psen1 
gene, psen1K97fs and psen1Q96_K97del. These mimic human EOfAD-causative 
mutations, and the location of the equivalent site on human PSEN1 protein for these 
mutations is highlighted in Figure 1.9.  
The psen1K97fs mutation is a 2 nucleotide deletion, leading to a reading frame shift 
and a premature termination codon. This mutation mimics the K115fs mutation of 
human PSEN2, which is a frameshift mutation leading to an early termination 
codon and was previously thought to represent the only known exception to the 
“fAD reading frame preservation rule” of EOfAD mutations in presenilin genes 
[72]. (However, the human mutation was subsequently shown to obey this rule, see 
below). The human PSEN2 mutation results in transcripts encoding a truncated 
PSEN2 protein similar to that produced by a naturally occurring alternative 
transcript of the PSEN2 gene, PS2V. In PS2V transcripts, exon 5 of PSEN2 is 
excluded leading to a frameshift and a premature termination codon [135]. The 
alternative splicing event that generates PS2V is induced by hypoxia and is 
observed at higher levels in sAD brains [136]. PS2V-like isoforms have been 
observed in the brains of guinea pigs and are predicted to occur in most other 
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mammals [137], but alternative PS2V-like splicing has been identified for the 
zebrafish psen2 gene under hypoxia [138]. Instead, the Alzheimer’s Disease 
Genetics Laboratory (ADGL) found that, in zebrafish, a PS2V-like isoform is 
produced from the paralogous psen1 gene, and has been named PS1IV [136]. 
Although human PS2V and zebrafish PS1IV share little structural similarity, they 
both stimulate -secretase activity and suppress the unfolded protein response under 
hypoxia [136]. Therefore, in attempting to model the human PSEN2K115fs mutation 
in zebrafish, equivalent mutation was introduced into the psen1 gene (rather than 
psen2) and is designated psen1K97fs. In 2019, a new transcript splicing isoform from 
the human PSEN2K115fs allele was identified that restores the open reading frame 
[73], which means that this mutation also follows the “fAD mutation reading frame 
preservation rule” [5] like all other EOfAD-causative mutations in the presenilin 
genes. In this thesis I demonstrate that no such isoform can be identified for 
transcripts of the psen1K97fs allele, indicating that the psen1K97fs mutation is not a 
good model of PSEN2K115fs as it does not follow the reading frame preservation rule 
of EOfAD mutations.  
Another mutation of psen1 that is EOfAD-like, psen1Q96_K97del, has a deletion of 6 
nucleotides in psen1 gene, but maintains the open reading frame, leading to 
structural and hydrophilicity changes in the first lumenal loop of the translated 
protein (Figure 1.9). This mutation is not an exact equivalent of any currently 
known human EOfAD mutation, but is similar to numerous EOfAD mutations that 
distort the first luminal loop of human PSEN1, such as PSEN1L113_I114insT [139] and 
PSEN1P117L [140]. Like all the various and widely distributed human EOfAD 
mutations in the PRESENILIN genes, this mutation follows the “fAD mutation 
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reading frame preservation rule” [5]. Most of the analyses conducted in this thesis 
use the psen1Q96_K97del mutation in the heterozygous state as a model of EOfAD-
like mutation. 
 
1.9.2 Brain transcriptome analysis of two heterozygous EOfAD-like 
mutants 
To investigate the molecular changes induced by the psen1K97fs and psen1Q96_K97del 
mutations, brain transcriptome analyses have been performed on young adult 
zebrafish (6 months of age, recently sexually mature) and aged adult zebrafish (24 
months of age) [141, 142]. Numerous differentially expressed (DE) genes have 
been identified in each mutant strain at both ages. There is a set of common DE 
genes identified in both young adult and aged adult zebrafish brains heterozygous 
for the psen1K97fs mutation, but showing transcriptional “inversion” (the regulation 
of these genes was in opposite directions at the two ages; Figure 2.2, discussed in 
following sections 2.1 and 2.2.1) [141]. A similar transcriptional inversion has also 
been seen in humans in a postmortem transcriptome comparison of mild cognitive 
impairment (MCI), Alzheimer’s disease and age-matched normal brains [143]. This 
found that the expression of particular genes related to synaptic function, energy 
metabolism and protein homeostasis were predominantly upregulated in patients 
with mild cognitive impairment but downregulated in AD brains. As the process 
driving disease progression remains unknown, we have proposed two possible 
models by which this change in gene expression could occur. The expression of the 
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genes undergoing “inversion” could 1) change smoothly during disease progression 
or 2) it could change rapidly at a certain stage in the progression. Further 
experiments are required to clarify this issue.  
The cellular functions and pathways involved in disease progression in the 
heterozygous psen1K97fs zebrafish brains have been predicted through gene 
ontology analysis (GO) and gene set enrichment analysis (GSEA). These analyses 
predict accelerated brain aging and increased glucocorticoid signaling in young 
adult heterozygous psen1K97fs mutant brains, while the inversion of gene expression 
in aged adult heterozygous psen1K97fs mutant brains may reflect glucocorticoid 
resistance [141]. The GO analysis of young adult heterozygous psen1Q96_K97del 
mutant brain transcriptomes indicates impairment of mitochondrial function, 
particularly energy production (ATP synthesis), and lysosomal dysfunction [142]. 
 
1.10 Project aims 
In our previous work, transcriptome analyses have only been perform on the young 
adult and aged adult zebrafish brains of two heterozygous EOfAD-like mutations, 
psen1K97fs and psen1Q96_K97del. The exploration of these two EOfAD-like models is 
far from comprehensive. Therefore, this thesis focuses mainly on further analyses 
of these two mutations and attempts to address the following questions: 
1) whether the gene expression changes during aging (e.g. the inversion of DE 
gene expression seen in psen1K97fs) occur smoothly or show rapid change at 
a particular age; 
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2) whether the psen1K97fs mutation promotes alternative splicing of transcripts 
as seen for human PSEN2K115fs; 
3) whether heterozygous psen1Q96_K97del zebrafish larvae show similar bulk 
transcriptome signatures to those identified in heterozygous 6-month-old 
zebrafish adult psen1Q96_K97del brains; 
4) whether (and, if so, at what age) impairments of short-term spatial working 
memory can be detected in heterozygous mutant adult zebrafish by the 
assessment of FMP Y-maze tests. 
In addition, two additional psen1 mutations were generated to investigate the 
similarities and differences in their effects on the brain transcriptome from 
psen1K97fs and psen1Q96_K97del heterozygous mutants. One is an Acne Inversa-like 
frame shift mutation, which truncates PSEN1 protein but does not cause EOfAD in 
humans. This Acne Inversa-like mutation will help exclude irrelevant molecular 
changes caused by impaired protein functions from the transcriptome “signature” 
of EOfAD mutations that we are attempting to define. The second mutation will be 
a missense mutation to alter one of the catalytic aspartate residues in the Psen1 
protein. This should cause production of a full-length Psen1 protein lacking -
secretase activity, which can be used to investigate the involvement of -secretase 
activity in the EOfAD brain transcriptome signature.  
 48 
1.11 References 
1. Gaugler, J., et al., 2019 Alzheimer's disease facts and figures. Alzheimers 
& Dementia, 2019. 15(3): p. 321-387. 
2. Kepp, K.P., Ten Challenges of the Amyloid Hypothesis of Alzheimer's 
Disease. J Alzheimers Dis, 2017. 55(2): p. 447-457. 
3. Masters, C.L., et al., Alzheimer's disease. Nature Reviews Disease Primers, 
2015. 1. 
4. Beydoun, M.A., et al., Epidemiologic studies of modifiable factors 
associated with cognition and dementia: systematic review and meta-
analysis. BMC Public Health, 2014. 14: p. 643. 
5. Jayne, T., et al., Evidence For and Against a Pathogenic Role of Reduced 
gamma-Secretase Activity in Familial Alzheimer's Disease. J Alzheimers 
Dis, 2016. 52(3): p. 781-99. 
6. Barber, R.C., The genetics of Alzheimer's disease. Scientifica (Cairo), 2012. 
2012: p. 246210. 
7. Masters, C.L., et al., Alzheimer's disease. Nat Rev Dis Primers, 2015. 1: p. 
15056. 
8. Tosto, G. and C. Reitz, Genome-wide association studies in Alzheimer's 
disease: a review. Curr Neurol Neurosci Rep, 2013. 13(10): p. 381. 
9. Whitehouse, P., Is There Alzheimer’s Disease? 2015: Journal of 
Alzheimer’s Disease. 
10. Nixon, R.A., Autophagy, amyloidogenesis and Alzheimer disease. J Cell 
Sci, 2007. 120(Pt 23): p. 4081-91. 
11. Alzheimer, A., Über eine eigenartige Erkrankung der Hirnrinde. 
Allgemeine Zeitschrift fur Psychiatrie und Psychisch-gerichtliche Medizin, 
1907. 64: p. 146-148. 
12. DeTure, M.A. and D.W. Dickson, The neuropathological diagnosis of 
Alzheimer's disease. Mol Neurodegener, 2019. 14(1): p. 32. 
13. Jack, C.R., Jr., et al., Prevalence of Biologically vs Clinically Defined 
Alzheimer Spectrum Entities Using the National Institute on Aging-
Alzheimer's Association Research Framework. JAMA Neurol, 2019. 
 49 
14. Goedert, M. and M.G. Spillantini, A century of Alzheimer's disease. 
Science, 2006. 314(5800): p. 777-81. 
15. Sperling, R.A., et al., Toward defining the preclinical stages of Alzheimer's 
disease: recommendations from the National Institute on Aging-Alzheimer's 
Association workgroups on diagnostic guidelines for Alzheimer's disease. 
Alzheimers Dement, 2011. 7(3): p. 280-92. 
16. Kelley, B.J. and R.C. Petersen, Alzheimer's disease and mild cognitive 
impairment. Neurol Clin, 2007. 25(3): p. 577-609, v. 
17. Rosen, J. and G.S. Zubenko, Emergence of psychosis and depression in the 
longitudinal evaluation of Alzheimer's disease. Biol Psychiatry, 1991. 
29(3): p. 224-32. 
18. Teri, L., E.B. Larson, and B.V. Reifler, Behavioral disturbance in dementia 
of the Alzheimer's type. J Am Geriatr Soc, 1988. 36(1): p. 1-6. 
19. Albert, M.S., et al., The diagnosis of mild cognitive impairment due to 
Alzheimer's disease: recommendations from the National Institute on 
Aging-Alzheimer's Association workgroups on diagnostic guidelines for 
Alzheimer's disease. Alzheimers Dement, 2011. 7(3): p. 270-9. 
20. Cascella, M. and Y. Al Khalili, Short Term Memory Impairment, in 
StatPearls. 2020: Treasure Island (FL). 
21. Herrup, K., Reimagining Alzheimer's disease--an age-based hypothesis. J 
Neurosci, 2010. 30(50): p. 16755-62. 
22. Hardy, J. and D.J. Selkoe, The amyloid hypothesis of Alzheimer's disease: 
progress and problems on the road to therapeutics. Science, 2002. 
297(5580): p. 353-6. 
23. Wisniewski, K.E., et al., Alzheimer's disease in Down's syndrome: 
clinicopathologic studies. Neurology, 1985. 35(7): p. 957-61. 
24. Sun, L., et al., Analysis of 138 pathogenic mutations in presenilin-1 on the 
in vitro production of Abeta42 and Abeta40 peptides by gamma-secretase. 
Proc Natl Acad Sci U S A, 2017. 114(4): p. E476-E485. 
25. Mohandas, E., V. Rajmohan, and B. Raghunath, Neurobiology of 
Alzheimer's disease. Indian J Psychiatry, 2009. 51(1): p. 55-61. 
 50 
26. Kametani, F. and M. Hasegawa, Reconsideration of Amyloid Hypothesis 
and Tau Hypothesis in Alzheimer's Disease. Front Neurosci, 2018. 12: p. 
25. 
27. Iqbal, K. and I. Grundke-Iqbal, Alzheimer neurofibrillary degeneration: 
significance, etiopathogenesis, therapeutics and prevention. J Cell Mol 
Med, 2008. 12(1): p. 38-55. 
28. Area-Gomez, E. and E.A. Schon, On the Pathogenesis of Alzheimer's 
Disease: The MAM Hypothesis. FASEB J, 2017. 31(3): p. 864-867. 
29. Fraser, T., H. Tayler, and S. Love, Fatty acid composition of frontal, 
temporal and parietal neocortex in the normal human brain and in 
Alzheimer's disease. Neurochem Res, 2010. 35(3): p. 503-13. 
30. Pettegrew, J.W., et al., Brain membrane phospholipid alterations in 
Alzheimer's disease. Neurochem Res, 2001. 26(7): p. 771-82. 
31. Stefani, M. and G. Liguri, Cholesterol in Alzheimer's disease: unresolved 
questions. Curr Alzheimer Res, 2009. 6(1): p. 15-29. 
32. Pani, A., et al., Altered cholesterol ester cycle in skin fibroblasts from 
patients with Alzheimer's disease. J Alzheimers Dis, 2009. 18(4): p. 829-41. 
33. Pani, A., et al., Accumulation of neutral lipids in peripheral blood 
mononuclear cells as a distinctive trait of Alzheimer patients and 
asymptomatic subjects at risk of disease. BMC Med, 2009. 7: p. 66. 
34. Gomez-Ramos, P. and M. Asuncion Moran, Ultrastructural localization of 
intraneuronal Abeta-peptide in Alzheimer disease brains. J Alzheimers Dis, 
2007. 11(1): p. 53-9. 
35. Bezprozvanny, I. and M.P. Mattson, Neuronal calcium mishandling and the 
pathogenesis of Alzheimer's disease. Trends Neurosci, 2008. 31(9): p. 454-
63. 
36. Lindholm, D., H. Wootz, and L. Korhonen, ER stress and 
neurodegenerative diseases. Cell Death Differ, 2006. 13(3): p. 385-92. 
37. Gillardon, F., et al., Proteomic and functional alterations in brain 
mitochondria from Tg2576 mice occur before amyloid plaque deposition. 
Proteomics, 2007. 7(4): p. 605-616. 
 51 
38. Wang, X., et al., The role of abnormal mitochondrial dynamics in the 
pathogenesis of Alzheimer's disease. J Neurochem, 2009. 109 Suppl 1: p. 
153-9. 
39. Hayashi, T., et al., MAM: more than just a housekeeper. Trends Cell Biol, 
2009. 19(2): p. 81-8. 
40. Puglielli, L., et al., Role of acyl-coenzyme a: cholesterol acyltransferase 
activity in the processing of the amyloid precursor protein. J Mol Neurosci, 
2004. 24(1): p. 93-6. 
41. Puglielli, L., et al., Acyl-coenzyme A: cholesterol acyltransferase modulates 
the generation of the amyloid beta-peptide. Nat Cell Biol, 2001. 3(10): p. 
905-12. 
42. Area-Gomez, E., et al., Presenilins are enriched in endoplasmic reticulum 
membranes associated with mitochondria. Am J Pathol, 2009. 175(5): p. 
1810-6. 
43. Newman, M., et al., Differential, dominant activation and inhibition of 
Notch signalling and APP cleavage by truncations of PSEN1 in human 
disease. Hum Mol Genet, 2014. 23(3): p. 602-17. 
44. Area-Gomez, E., et al., Upregulated function of mitochondria-associated 
ER membranes in Alzheimer disease. EMBO J, 2012. 31(21): p. 4106-23. 
45. Dai, M.H., et al., The genes associated with early-onset Alzheimer's disease. 
Oncotarget, 2018. 9(19): p. 15132-15143. 
46. Zlokovic, B.V., Neurovascular pathways to neurodegeneration in 
Alzheimer's disease and other disorders. Nat Rev Neurosci, 2011. 12(12): 
p. 723-38. 
47. Tamagno, E., et al., Oxidative stress activates a positive feedback between 
the gamma- and beta-secretase cleavages of the beta-amyloid precursor 
protein. J Neurochem, 2008. 104(3): p. 683-95. 
48. Sun, X., et al., Hypoxia facilitates Alzheimer's disease pathogenesis by up-
regulating BACE1 gene expression. Proc Natl Acad Sci U S A, 2006. 
103(49): p. 18727-32. 
 52 
49. Guglielmotto, M., et al., The up-regulation of BACE1 mediated by hypoxia 
and ischemic injury: role of oxidative stress and HIF1alpha. J Neurochem, 
2009. 108(4): p. 1045-56. 
50. Winkler, E.A., A.P. Sagare, and B.V. Zlokovic, The pericyte: a forgotten 
cell type with important implications for Alzheimer's disease? Brain Pathol, 
2014. 24(4): p. 371-86. 
51. Attems, J. and K.A. Jellinger, The overlap between vascular disease and 
Alzheimer's disease--lessons from pathology. BMC Med, 2014. 12: p. 206. 
52. Iliff, J.J., et al., Impairment of glymphatic pathway function promotes tau 
pathology after traumatic brain injury. J Neurosci, 2014. 34(49): p. 16180-
93. 
53. Glass, C.K., et al., Mechanisms underlying inflammation in 
neurodegeneration. Cell, 2010. 140(6): p. 918-34. 
54. McGeer, P.L., M. Schulzer, and E.G. McGeer, Arthritis and anti-
inflammatory agents as possible protective factors for Alzheimer's disease: 
a review of 17 epidemiologic studies. Neurology, 1996. 47(2): p. 425-32. 
55. Stewart, W.F., et al., Risk of Alzheimer's disease and duration of NSAID 
use. Neurology, 1997. 48(3): p. 626-32. 
56. Vlad, S.C., et al., Protective effects of NSAIDs on the development of 
Alzheimer disease. Neurology, 2008. 70(19): p. 1672-7. 
57. Du, X., X. Wang, and M. Geng, Alzheimer's disease hypothesis and related 
therapies. Transl Neurodegener, 2018. 7: p. 2. 
58. Van Cauwenberghe, C., C. Van Broeckhoven, and K. Sleegers, The genetic 
landscape of Alzheimer disease: clinical implications and perspectives. 
Genet Med, 2016. 18(5): p. 421-30. 
59. Liu, C.C., et al., Apolipoprotein E and Alzheimer disease: risk, mechanisms 
and therapy. Nature Reviews Neurology, 2013. 9(2): p. 106-118. 
60. Vance, J.E., Dysregulation of cholesterol balance in the brain: contribution 
to neurodegenerative diseases. Disease Models & Mechanisms, 2012. 5(6): 
p. 746-755. 
 53 
61. Namba, Y., et al., Apolipoprotein E immunoreactivity in cerebral amyloid 
deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque 
amyloid in Creutzfeldt-Jakob disease. Brain Res, 1991. 541(1): p. 163-6. 
62. Farrer, L.A., et al., Effects of age, sex, and ethnicity on the association 
between apolipoprotein E genotype and Alzheimer disease. A meta-
analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA, 
1997. 278(16): p. 1349-56. 
63. Corder, E.H., et al., Gene dose of apolipoprotein E type 4 allele and the risk 
of Alzheimer's disease in late onset families. Science, 1993. 261(5123): p. 
921-3. 
64. Deane, R., et al., apoE isoform-specific disruption of amyloid beta peptide 
clearance from mouse brain. J Clin Invest, 2008. 118(12): p. 4002-13. 
65. Barthelson, K., M. Newman, and M. Lardelli, Sorting Out the Role of the 
Sortilin-Related Receptor 1 in Alzheimer's Disease. J Alzheimers Dis Rep, 
2020. 4(1): p. 123-140. 
66. Campion, D., C. Charbonnier, and G. Nicolas, SORL1 genetic variants and 
Alzheimer disease risk: a literature review and meta-analysis of sequencing 
data. Acta Neuropathol, 2019. 138(2): p. 173-186. 
67. Serneels, L., et al., Differential contribution of the three Aph1 genes to 
gamma-secretase activity in vivo. Proc Natl Acad Sci U S A, 2005. 102(5): 
p. 1719-24. 
68. Vassar, R., et al., Beta-secretase cleavage of Alzheimer's amyloid precursor 
protein by the transmembrane aspartic protease BACE. Science, 1999. 
286(5440): p. 735-41. 
69. Chavez-Gutierrez, L., et al., The mechanism of gamma-Secretase 
dysfunction in familial Alzheimer disease. EMBO J, 2012. 31(10): p. 2261-
74. 
70. Bai, X.C., et al., An atomic structure of human gamma-secretase. Nature, 
2015. 525(7568): p. 212-7. 
71. Quiroz, Y.T., et al., Brain Imaging and Blood Biomarker Abnormalities in 
Children With Autosomal Dominant Alzheimer Disease: A Cross-Sectional 
Study. JAMA Neurol, 2015. 72(8): p. 912-9. 
 54 
72. Jayadev, S., et al., Alzheimer's disease phenotypes and genotypes associated 
with mutations in presenilin 2. Brain, 2010. 133(Pt 4): p. 1143-54. 
73. Braggin, J.E., et al., Alternative splicing in a presenilin 2 variant associated 
with Alzheimer disease. Ann Clin Transl Neurol, 2019. 6(4): p. 762-777. 
74. Miyashita, A., et al., SORL1 is genetically associated with late-onset 
Alzheimer's disease in Japanese, Koreans and Caucasians. PLoS One, 
2013. 8(4): p. e58618. 
75. Wen, Y., et al., SORL1 is genetically associated with neuropathologically 
characterized late-onset Alzheimer's disease. J Alzheimers Dis, 2013. 
35(2): p. 387-94. 
76. Meng, Y., et al., Association between SORL1 and Alzheimer's disease in a 
genome-wide study. Neuroreport, 2007. 18(17): p. 1761-4. 
77. Yin, R.H., J.T. Yu, and L. Tan, The Role of SORL1 in Alzheimer's Disease. 
Mol Neurobiol, 2015. 51(3): p. 909-18. 
78. Pottier, C., et al., High frequency of potentially pathogenic SORL1 
mutations in autosomal dominant early-onset Alzheimer disease. Mol 
Psychiatry, 2012. 17(9): p. 875-9. 
79. Thonberg, H., et al., Identification and description of three families with 
familial Alzheimer disease that segregate variants in the SORL1 gene. Acta 
Neuropathol Commun, 2017. 5(1): p. 43. 
80. Cruts, M., J. Theuns, and C. Van Broeckhoven, Locus-specific mutation 
databases for neurodegenerative brain diseases. Hum Mutat, 2012. 33(9): 
p. 1340-4. 
81. MUTATIONS PSEN-1. n.d.  [cited 2020 1 July]; Available from: 
https://www.alzforum.org/mutations/psen-1. 
82. Shen, J., et al., Skeletal and CNS defects in Presenilin-1-deficient mice. Cell, 
1997. 89(4): p. 629-39. 
83. Nornes, S., et al., Developmental control of Presenilin1 expression, 
endoproteolysis, and interaction in zebrafish embryos. Exp Cell Res, 2003. 
289(1): p. 124-32. 
 55 
84. Nornes, S., et al., Interference with splicing of Presenilin transcripts has 
potent dominant negative effects on Presenilin activity. Human Molecular 
Genetics, 2008. 17(3): p. 402-412. 
85. Campbell, W.A., et al., Zebrafish lacking Alzheimer presenilin enhancer 2 
(Pen-2) demonstrate excessive p53-dependent apoptosis and neuronal loss. 
J Neurochem, 2006. 96(5): p. 1423-40. 
86. Sundvik, M., Y.C. Chen, and P. Panula, Presenilin1 regulates histamine 
neuron development and behavior in zebrafish, danio rerio. J Neurosci, 
2013. 33(4): p. 1589-97. 
87. Kohler, C.A., et al., Histaminergic mechanisms for modulation of memory 
systems. Neural Plast, 2011. 2011: p. 328602. 
88. Gunn-Moore, D., et al., Alzheimer's disease in humans and other animals: 
A consequence of postreproductive life span and longevity rather than 
aging. Alzheimers & Dementia, 2018. 14(2): p. 195-204. 
89. Borghys, H., et al., Young to Middle-Aged Dogs with High Amyloid-beta 
Levels in Cerebrospinal Fluid are Impaired on Learning in Standard 
Cognition tests. J Alzheimers Dis, 2017. 56(2): p. 763-774. 
90. Cotman, C.W. and E. Head, The Canine (Dog) Model of Human Aging and 
Disease: Dietary, Environmental and Immunotherapy Approaches. Journal 
of Alzheimers Disease, 2008. 15(4): p. 685-707. 
91. Studzinski, C.M., J.A. Araujo, and N.W. Milgram, The canine model of 
human cognitive aging and dementia: Pharmacological validity of the 
model for assessment of human cognitive-enhancing drugs. Progress in 
Neuro-Psychopharmacology & Biological Psychiatry, 2005. 29(3): p. 489-
498. 
92. Youssef, S.A., et al., Pathology of the Aging Brain in Domestic and 
Laboratory Animals, and Animal Models of Human Neurodegenerative 
Diseases. Vet Pathol, 2016. 53(2): p. 327-48. 
93. Schmidt, F., et al., Detection and Quantification of beta-Amyloid, 
Pyroglutamyl Abeta, and Tau in Aged Canines. J Neuropathol Exp Neurol, 
2015. 74(9): p. 912-23. 
 56 
94. Drummond, E. and T. Wisniewski, Alzheimer's disease: experimental 
models and reality. Acta Neuropathol, 2017. 133(2): p. 155-175. 
95. Hargis, K.E. and E.M. Blalock, Transcriptional signatures of brain aging 
and Alzheimer's disease: What are our rodent models telling us? Behav 
Brain Res, 2017. 322(Pt B): p. 311-328. 
96. Neff, E.P., Animal models of Alzheimer's disease embrace diversity. Lab 
Anim (NY), 2019. 48(9): p. 255-259. 
97. Teame, T., et al., The use of zebrafish (Danio rerio) as biomedical models. 
Anim Front, 2019. 9(3): p. 68-77. 
98. Howe, K., et al., The zebrafish reference genome sequence and its 
relationship to the human genome. Nature, 2013. 496(7446): p. 498-503. 
99. Kumar, S. and S.B. Hedges, A molecular timescale for vertebrate evolution. 
Nature, 1998. 392(6679): p. 917-20. 
100. Lieschke, G.J. and P.D. Currie, Animal models of human disease: zebrafish 
swim into view. Nat Rev Genet, 2007. 8(5): p. 353-67. 
101. Newman, M., E. Ebrahimie, and M. Lardelli, Using the zebrafish model for 
Alzheimer's disease research. Front Genet, 2014. 5: p. 189. 
102. Leimer, U., et al., Zebrafish (Danio rerio) presenilin promotes aberrant 
amyloid beta-peptide production and requires a critical aspartate residue 
for its function in amyloidogenesis. Biochemistry, 1999. 38(41): p. 13602-
9. 
103. Groth, C., et al., Identification of a second presenilin gene in zebrafish with 
similarity to the human Alzheimer's disease gene presenilin2. Dev Genes 
Evol, 2002. 212(10): p. 486-90. 
104. Musa, A., H. Lehrach, and V.A. Russo, Distinct expression patterns of two 
zebrafish homologues of the human APP gene during embryonic 
development. Dev Genes Evol, 2001. 211(11): p. 563-7. 
105. Moussavi Nik, S.H., et al., The BACE1-PSEN-AbetaPP regulatory axis has 
an ancient role in response to low oxygen/oxidative stress. J Alzheimers 
Dis, 2012. 28(3): p. 515-30. 
 57 
106. van Bebber, F., et al., Loss of Bace2 in zebrafish affects melanocyte 
migration and is distinct from Bace1 knock out phenotypes. J Neurochem, 
2013. 127(4): p. 471-81. 
107. Francis, R., et al., aph-1 and pen-2 are required for Notch pathway 
signaling, gamma-secretase cleavage of betaAPP, and presenilin protein 
accumulation. Dev Cell, 2002. 3(1): p. 85-97. 
108. Strausberg, R.L., et al., Generation and initial analysis of more than 15,000 
full-length human and mouse cDNA sequences. Proc Natl Acad Sci U S A, 
2002. 99(26): p. 16899-903. 
109. Chen, M., R.N. Martins, and M. Lardelli, Complex splicing and neural 
expression of duplicated tau genes in zebrafish embryos. J Alzheimers Dis, 
2009. 18(2): p. 305-17. 
110. Woods, I.G., et al., The zebrafish gene map defines ancestral vertebrate 
chromosomes. Genome Res, 2005. 15(9): p. 1307-14. 
111. Schmid, B. and C. Haass, Genomic editing opens new avenues for zebrafish 
as a model for neurodegeneration. J Neurochem, 2013. 127(4): p. 461-70. 
112. Gaj, T., C.A. Gersbach, and C.F. Barbas, 3rd, ZFN, TALEN, and 
CRISPR/Cas-based methods for genome engineering. Trends Biotechnol, 
2013. 31(7): p. 397-405. 
113. Zu, Y., et al., TALEN-mediated precise genome modification by 
homologous recombination in zebrafish. Nat Methods, 2013. 10(4): p. 329-
31. 
114. Doyon, Y., et al., Heritable targeted gene disruption in zebrafish using 
designed zinc-finger nucleases. Nat Biotechnol, 2008. 26(6): p. 702-8. 
115. Kim, Y., et al., A library of TAL effector nucleases spanning the human 
genome. Nat Biotechnol, 2013. 31(3): p. 251-8. 
116. Ding, Q., et al., A TALEN genome-editing system for generating human stem 
cell-based disease models. Cell Stem Cell, 2013. 12(2): p. 238-51. 
117. Paul, B. and G. Montoya, CRISPR-Cas12a: Functional overview and 
applications. Biomed J, 2020. 43(1): p. 8-17. 
 58 
118. Okoniewski, M.J. and C.J. Miller, Hybridization interactions between 
probesets in short oligo microarrays lead to spurious correlations. BMC 
Bioinformatics, 2006. 7: p. 276. 
119. Wang, Z., M. Gerstein, and M. Snyder, RNA-Seq: a revolutionary tool for 
transcriptomics. Nat Rev Genet, 2009. 10(1): p. 57-63. 
120. Bustin, S.A. and R. Mueller, Real-time reverse transcription PCR (qRT-
PCR) and its potential use in clinical diagnosis. Clin Sci (Lond), 2005. 
109(4): p. 365-79. 
121. Vogelstein, B. and K.W. Kinzler, Digital PCR. Proc Natl Acad Sci U S A, 
1999. 96(16): p. 9236-41. 
122. Fazekas de St, G., The evaluation of limiting dilution assays. J Immunol 
Methods, 1982. 49(2): p. R11-23. 
123. Baddeley, A., Working memory and language: an overview. J Commun 
Disord, 2003. 36(3): p. 189-208. 
124. Mehta, M.A., Spatial Memory in Humans, in Encyclopedia of 
Psychopharmacology, I.P. Stolerman, Editor. 2010, Springer Berlin 
Heidelberg: Berlin, Heidelberg. p. 1262-1266. 
125. Guariglia, C.C., Spatial working memory in Alzheimer's disease: A study 
using the Corsi block-tapping test. Dement Neuropsychol, 2007. 1(4): p. 
392-395. 
126. Lalonde, R., The neurobiological basis of spontaneous alternation. 
Neurosci Biobehav Rev, 2002. 26(1): p. 91-104. 
127. Kraeuter, A.K., P.C. Guest, and Z. Sarnyai, The Y-Maze for Assessment of 
Spatial Working and Reference Memory in Mice. Methods Mol Biol, 2019. 
1916: p. 105-111. 
128. Heredia-Lopez, F.J., et al., An automated Y-maze based on a reduced 
instruction set computer (RISC) microcontroller for the assessment of 
continuous spontaneous alternation in rats. Behav Res Methods, 2016. 
48(4): p. 1631-1643. 
129. Stewart, S., F. Cacucci, and C. Lever, Which Memory Task for My Mouse? 
A Systematic Review of Spatial Memory Performance in the Tg2576 
 59 
Alzheimer's Mouse Model. Journal of Alzheimers Disease, 2011. 26(1): p. 
105-126. 
130. Hughes, R.N., The value of spontaneous alternation behavior (SAB) as a 
test of retention in pharmacological investigations of memory. 
Neuroscience and Biobehavioral Reviews, 2004. 28(5): p. 497-505. 
131. King, D.L. and G.W. Arendash, Behavioral characterization of the Tg2576 
transgenic model of Alzheimer's disease through 19 months. Physiology & 
Behavior, 2002. 75(5): p. 627-642. 
132. Cleal, M., et al., The Free-movement pattern Y-maze: A cross-species 
measure of working memory and executive function. Behav Res Methods, 
2020. 
133. Aoki, R., T. Tsuboi, and H. Okamoto, Y-maze avoidance: an automated and 
rapid associative learning paradigm in zebrafish. Neurosci Res, 2015. 91: 
p. 69-72. 
134. Cognato Gde, P., et al., Y-Maze memory task in zebrafish (Danio rerio): the 
role of glutamatergic and cholinergic systems on the acquisition and 
consolidation periods. Neurobiol Learn Mem, 2012. 98(4): p. 321-8. 
135. Sato, N., et al., A novel presenilin-2 splice variant in human Alzheimer's 
disease brain tissue. J Neurochem, 1999. 72(6): p. 2498-505. 
136. Moussavi Nik, S.H., et al., Alzheimer's disease-related peptide PS2V plays 
ancient, conserved roles in suppression of the unfolded protein response 
under hypoxia and stimulation of gamma-secretase activity. Hum Mol 
Genet, 2015. 24(13): p. 3662-78. 
137. Sharman, M.J., et al., The Guinea Pig as a Model for Sporadic Alzheimer's 
Disease (AD): The Impact of Cholesterol Intake on Expression of AD-
Related Genes. PLoS One, 2013. 8(6): p. e66235. 
138. Moussavi Nik, S.H., M. Newman, and M. Lardelli, The response of HMGA1 
to changes in oxygen availability is evolutionarily conserved. Exp Cell Res, 
2011. 317(11): p. 1503-12. 
139. De Jonghe, C., et al., Aberrant splicing in the presenilin-1 intron 4 mutation 
causes presenile Alzheimer's disease by increased Abeta42 secretion. Hum 
Mol Genet, 1999. 8(8): p. 1529-40. 
 60 
140. Wisniewski, T., et al., A novel Polish presenilin-1 mutation (P117L) is 
associated with familial Alzheimer's disease and leads to death as early as 
the age of 28 years. Neuroreport, 1998. 9(2): p. 217-21. 
141. Hin, N., et al., Accelerated brain aging towards transcriptional inversion in 
a zebrafish model of the K115fs mutation of human PSEN2. PLoS One, 
2020. 15(1): p. e0227258. 
142. Newman, M., et al., Brain transcriptome analysis of a familial Alzheimer's 
disease-like mutation in the zebrafish presenilin 1 gene implies effects on 
energy production. Mol Brain, 2019. 12(1): p. 43. 
143. Berchtold, N.C., et al., Brain gene expression patterns differentiate mild 
cognitive impairment from normal aged and Alzheimer's disease. Neurobiol 
Aging, 2014. 35(9): p. 1961-72. 
 61 
Chapter 2: Investigating changes in transcriptome state 
during disease progression in heterozygous psen1K97fs and 
psen1Q96_K97del mutant brains 
2.1 Introduction 
AD is thought to take decades to develop before disease onset [1]. The process of 
disease progression in AD is a controversial research issue. There are two broad 
possibilities for describing this process (Figure 2.1): Either brain cellular damage 
accumulates during ageing and eventually degrades brain function sufficiently to 
cause AD cognitive change, or increasing stress and other factors in ageing brains 
cause cells to shift into an alternative, “stable” pathological state where cognition 
progressively worsens. Importantly, if the onset of AD is caused by a state shift of 
the brain cells, it may be possible to find drugs that can revert the pathological state 





Figure 2.1. Two proposed processes of gene expression change from a normal state 
to a pathological state. With increasing age, the state of the brain transcriptome 
during progression to AD may reflect accumulated damage until it irreversibly 
passes a pathological threshold (left), or a change in state at a certain disease stage 
and shift into an alternative stable state (right) which may possibly be reversed. 
In previous work in the ADGL, bulk transcriptome analyses were performed on the 
entire brains of young adult zebrafish (6 months of age, recently sexually mature) 
and aged adult zebrafish (24 months of age) for two heterozygous EOfAD-like 
mutations, psen1K97fs [3] and psen1Q96_K97del [4] (discussed in previous section 1.9.1 
and section 1.9.2). In heterozygous psen1K97fs mutant brains, a group of DE genes 
was identified showing an obvious expression inversion between young adult and 
aged adult zebrafish ([3], Figure 2.2). A similar transcriptional inversion has been 
seen in humans in a postmortem transcriptome comparison of mild cognitive 
impairment (MCI), Alzheimer’s disease and age-matched normal brains, which 
found the expression of particular genes was predominantly upregulated in patients 
with MCI but downregulated in AD brains [5]. However, we do not know whether 
the expression inversion represents a gradual change with age consistent with 
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steady, incremental accumulation of damage as in Figure 2.1, or a more rapid shift 
to an alternative pathological state as also illustrated in that figure. Therefore, we 
designed a month-by-month study monitoring transcriptional state during aging 
from 6 months to 24 months. Through this month-by-month study, we expected to 
determine both the rate of gene expression change during aging and whether all DE 
genes invert their expression simultaneously or whether this occurs separately for 
different genes at different ages. This work could further inform us on the process 
of AD progression and the likelihood that interventions could reverse this 
pathological process. 
Initially, I aimed to select a set of highly DE genes identified from among those 
identified in the transcriptome analyses of heterozygous psen1K97fs and 
psen1Q96_K97del brains as potential biomarkers to represent brain genetic states. The 
expression of these DE genes could then be assessed by qPCR. The brains of 
heterozygous psen1K97fs and psen1Q96_K97del mutant zebrafish with their wild type 
siblings were collected every month from 6 months to 24 months. Through tracking 
these highly DE genes month by month, I expected to clarify the rapidity of the 
expression change leading to the inversion of expression between 6 months and 24 
months of age.  
Digital quantitative PCR (dqPCR) can be employed to measure the expression of 
representative genes in zebrafish brains collected each month. Before conducting 
this month-by-month study, I first needed to be validate the changes in gene 
expression measured by dqPCR corresponded to the changes that had been detected 
in the brain transcriptome analyses. Therefore, I performed dqPCRs on selected 
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highly DE genes to validate the brain transcriptome analyses of both the 
heterozygous psen1K97fs and psen1Q96_K97del mutants. The results of these dqPCRs 
are showed in this chapter and were inconsistent with the transcriptome analyses, 
even when using cDNA synthesized from the same RNA as was used in a 
transcriptome analysis. The reason for this inconsistency remains unclear but 
reflects variability in gene expression seen between the brains of different 
individuals. (Also, this contrasts with the consistency of our dqPCR and 
transcriptome analysis results when analyzing pools of individuals in Chapter 4.) 
Since the dqPCR results were in apparent conflict with the transcriptome results, 
the bulk of the month-by-month study was, ultimately, abandoned.  
 
2.2 Results 
2.2.1 dqPCR assessment of supposedly DE genes in heterozygous 
psen1K97fs mutant brains 
The DE genes identified in the transcriptome analysis of 6-month-old and 24-
month-old heterozygous psen1K97fs mutant brains are displayed in Figure 2.2. 
Figure 2.2A displays the DE genes identified at 6 months and Figure 2.2B displays 
the DE genes identified at 24 months. Interestingly, there was a set of common DE 
genes identified in both 6-month-old and 24-month-old mutant brains, but the 
regulation of these genes was in opposite directions (i.e. their differential 
expression was “inverted”). These genes were upregulated at 6 months of age but 
showed downregulation at 24 months. Among these genes, five genes, nfkbiab, plk3, 
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pik3r3a and fkbp5, which showed more significant fold changes in gene expression, 
were selected to represent this group and were subjected to dqPCR to validate the 
changes seen in the RNA-seq analyses. Also, two DE genes, tenm4 and nr3c2, 
showing upregulation in only one age group, were also assessed by dqPCRs.  
 
 
(The duplication of pik3r3a gene in Figure 2.2a is due to the genome reference 
used in mapping, which contains multiple visions of a gene.) 
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Figure 2.2. DE genes in 
heterozygous psen1K97fs mutant 
zebrafish brains compared to 
their wild type siblings at 6 
months and 24 months of age 
(the heatmap was produced by 
Nhi Hin prior to the publication 
of [3] in PLoS ONE, therefore it 
is slightly different from the final 
published figure). Figure 1a and 
1b presents the relative 
expression of DE genes 
identified in 6-month and 24-
month brains respectively (in 
black boxes), which have FDR-
adjusted p-values < 0.05 and 
log2fold change > 0.5. The p-
value bar shows the FDR-
adjusted p-value of the genes in 
24-month brains. The individual 
zebrafish are numbered below. 
The genes tested by dqPCR are 
highlighted in red boxes.  
dqPCRs for the gene indicated in Figure 2.2 were first performed on cDNA 
generated from the brains of individual 6-month-old and 24-month-old 
heterozygous psen1K97fs mutants. The results are displayed in Figure 2.3. Gene 
expression levels were normalized using the “house-keeping” gene eef1a1l1. Beta-
actin was another house-keeping gene used as a control. In Figure 2.3, the 
normalized expression of beta-actin was at the same level between mutant brains 
and their wild type siblings, supporting that the expression level of this house-
keeping gene was stable among samples.  
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The normalized expression of the genes measured by dqPCR was inconsistent with 
their differential expression detected by transcriptome analysis. The expression of 
the genes nfkbiab, nr3c2 and fkbp5 genes was downregulated in 6-month-old 
mutant brains (Figure 2.3A), which was opposite to the results observed in the 
transcriptome analysis (Figure 2.2A). There were no significant differences in 
normalized gene expression in 24-month-old mutant brains (Figure 2.3B). Notably, 
the expression of some genes differed greatly between individuals, such as the 
expression of fkbp5 gene in 24-month-old brains, indicating that individual 





Figure 2.3. Assessing the expression of the DE genes by dqPCR in 6-month-old 
and 24-month-old heterozygous psen1K97fs mutant brains. The gene expression 
levels were normalized to the expression level of house-keeping gene eef1a1l1. The 
p-values where genes were differentially expressed between genotypes are 
indicated if less than 0.05. 
One possibility for the discrepancy between the results from the dqPCRs and the 
transcriptome analysis was that different tanks/families of the same zebrafish 
genotype might be aging at different rates. Therefore, dqPCRs were performed on 
older heterozygous psen1K97fs mutant and wild type sibling brains at 7, 8 and 15 
months of age (Figure. 2.4a-c). However, none of the dqPCR results showed 
significant gene expression differences between the mutant brains and their wild 
type siblings. 
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As dqPCRs failed to support the differences in gene expression identified in the 
transcriptome analysis, we could not use these genes as biomarkers to represent 
brain genetic states in the intended month-by-month study.  
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Figure 2.4. Assessing the expression of the DE genes by dqPCRs in 7-month-old, 
8-month-old and 15-month-old heterozygous psen1K97fs mutant brains. Instead of 
plk3, the gene tenm4 was assayed in 8-month-old brains. No genes showed 
statistically significantly differential expression between genotypes (i.e. p-value 
was always greater than 0.05). 
 
Interestingly, there is large variation in the expression of the gene fkbp5 between 
samples of the same genotype, whether wild type or mutant, in the various qdPCR 
tests. The gene fkbp5 encodes FK506 binding protein 5 (FKBP5), which acts as a 
negative-feedback regulator of glucocorticoid receptor (GR) [6, 7]. Glucocorticoids 
are the major stress hormones, and overexpression of FKBP5 interacts with GRs 
and promotes resistance to glucocorticoid [8]. The large spreads of fkbp5 expression 
shown here probably reflect environmental impacts on these tested zebrafish. 
However, these zebrafish were treated similarly during euthanasia and brain 
excision. The zebrafish were collected together and euthanised for brain removal 
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around 11:00 a.m. after feeding. Therefore, the differences in fkbp5 expression were 
not likely due to circadian influences, which regulate the release of glucocorticoid 
[9]. Neither were there notable external environmental stresses on the fish. Probably 
zebrafish individuals responded differently to environmental changes, resulting in 
the variability in fkbp5 expression.  
 
2.2.2 dqPCR assessment of supposedly DE genes in heterozygous 
psen1Q96_K97del mutant brains 
Transcriptome analysis (by RNA-Seq) had also been performed on 6-month-old 
and 24-month-old heterozygous psen1Q96_K97del mutant brains to investigate the 
genetic changes induced by this EOfAD-like mutation [4]. While numerous DE 
genes were identified in this study, a difference compared to the psen1K97fs brain 
analysis was that no genes were found to be DE at both 6 months and 24 months 
(and so “inverted” patterns of gene expression were not observed, see section 2.2.1). 
The transcriptome DE genes analysed by dqPCR are shown in Figure 2.5. In 6-
month-old psen1Q96_K97del mutant brain transcriptomes, the expression of gene 
abcd3a, pid1 and kalrnb was upregulated and the expression of gene clcn3 was 
downregulated; in 24-month-old psen1Q96_K97del mutant brains, gene spsb1 was 
upregulated and genes BX469889.4 and mtor genes were downregulated.  
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Figure 2.5. DE genes in heterozygous psen1Q96_K97del mutant brains compared to 
their wild type siblings at 6 months and 24 months of age (data generated by Nhi 
Hin). As the DE gene list is too long, only the genes used in our dqPCR analyses 
are shown here.  
dqPCRs were performed on the cDNA generated from 6-month-old heterozygous 
psen1Q96_K97del mutant brain samples to assess the expression of the 7 DE genes 
selected from transcriptome analysis. The dqPCR results are shown in Figure 2.6. 
Gene expression levels were normalized to that of house-keeping gene eef1a1l1. 
Similar to the results seen from psen1K97fs mutant brains, the normalized expression 
levels of these DE genes were similar between heterozygous psen1Q96_K97del mutant 
 73 
brains and the wild type siblings. No statistically significant differences in gene 
expression were detected.  
 
Figure 2.6. Assessing the expression of the DE genes by dqPCR in 6-month-old 
heterozygous psen1Q96_K97del mutant brains. No genes showed statistically 
significantly differential expression between genotypes. 
Due to the failure to detect the above genes as DE using dqPCR, they could not be 
used as biomarkers to monitor the brain genetic state in the month-by-month 
analysis. As the expression level of some of the genes assayed varied considerably 
between individuals of the same genotype, this represented one possible 
explanation for the failure to detect them as DE. To counter the problem of sample 
variability between those brains used to generate mRNA for RNA-Seq in the 
transcriptome analysis, and those brains used for dqPCR, I then performed dqPCR 
on cDNAs synthesized from the same RNAs that were used for the transcriptome 
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analysis (Figure 2.7A). dqPCRs performed on genes clcn3, abcd3a and kalrnb still 
did not detected differences in expression, indicating that between-sample 
variability did not seem to be the cause of the inconsistency. Another possibility for 
the inconsistency between the transcriptome and dqPCR results was that the dqPCR 
technique itself was somehow invalid. To support that dqPCR produces reliable 
results, I compared data produced by this technique to that produced by another 
quantitative PCR technique, relative standard curve qPCR. Relative standard curve 
qPCR analyses were also performed on cDNA synthesized from the RNAs used in 
the transcriptome analysis. The results are shown in Figure 2.7B. Although still 
inconsistent with the results of the transcriptome analyses, the expression of clcn3 
and kalrnb measured by relative standard curve qPCRs was similar to their 
expression measured in dqPCRs, indicating that both quantitative PCR techniques 





Figure 2.7. Gene expression in 6-month-old heterozygous psen1Q96_K97del mutant 
brains achieved by a) digital qPCR and b) relative standard curve qPCR. Each data 
point is labeled with a sample number, which corresponds with an individual fish 
in the transcriptome analysis. No genes showed statistically significantly 
differential expression between genotypes. (The cDNA of Sample 1’ of 
heterozygous psen1Q96_K97del mutant was too degraded in dqPCRs, so Sample 1’ was 
not shown in Figure 2.7A) 
The analyses do not support that sample variability or the quantitative PCR 
technique used contribute to the inconsistency between the results of transcriptome 
(RNA-Seq) analysis and the dqPCRs. As for the month-by-month study of the 
psen1K97fs heterozygous mutant brains, the month-by-month study of the 




The brain transcriptome analyses of heterozygous psen1K97fs and psen1Q96_K97del 
mutants should provide insight into the molecular changes induced by EOfAD-like 
mutations. However, the differential expression of the DE genes identified in these 
analyses could not be validated by the qPCRs performed. Some attempts were made 
to test possible reasons for this inconsistency. The possibility of different rates of 
aging rates between separate tanks/families was tested through assessing the DE 
genes identified from 6-month-old heterozygous psen1K97fs mutant brains in the 
brains of fish at older ages (7 months, 8 months and 15 months of age). However, 
none of these genes showed similar differences in gene expression between 
heterozygous mutant and wild type sibling fish as those seen in the transcriptome 
analysis. Furthermore, the influences of variability between samples and the 
reliability of the dqPCR technique were also assessed through preforming two 
quantitative RT-PCR techniques in parallel, dqPCR and relative standard curve 
qPCR, on cDNA synthesized from the actual RNA used in the transcriptome 
analysis. The two qPCR techniques detected similar patterns of differential gene 
expression (i.e. no differential expression) which were still inconsistent with the 
transcriptome analysis, supporting that both qPCR techniques appeared to work 
appropriately and that variability between samples was not responsible for the 
inconsistency with the transcriptome data. Some other possibilities were then 
considered, such as that the observations of differential expression of some genes 
in the transcriptome analysis were an artefact of the RNA-Seq technique or the 
bioinformatics analysis that followed it, the bias induced in RNA-seq process or the 
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following bioinformatic analysis. However, RNA-Seq analyses are expensive and, 
therefore, difficult to replicate. Nevertheless, two facts are noteworthy:  
1) The ADGL did attempt to replicate the RNA-seq analysis of 6-month-old 
heterozygous psen1Q96_K97del mutant brains compared to wild type siblings using a 
less expensive non-domestic service. However, the RNA-seq data produced was of 
lower quality, possibly because of the additional treatment of the RNA required for 
it to survive export from Australia. Ultimately, little consistency was found between 
the two sets of RNA-seq data (Lachlan Baer, Honours thesis 2019).   
2) In Chapter 4 I describe how relative standard curve qPCR was used successfully 
to validate the expression patterns of the DE genes identified in transcriptome 
analysis of heterozygous psen1Q96_K97del mutant larvae (see section 4.3, 
Supplementary data 2 for detailed explanation). In those experiments, 40 sibling 
larvae were pooled for each sample (which would “average out” differences 
between individuals) and the qPCRs were conducted on the same RNA samples as 
were used in the RNA-seq analysis. Nevertheless, the large differences observed 
between samples in the differential expression of the various genes tested is 
remarkable.  
During the early era of transcriptome studies using mainly microarrays, it was a 
common requirement to validate findings of differential expression by qPCR tests. 
Indeed, qPCR often found larger differences in expression of a gene between 
samples than were indicated by microarray hybridisation signals [10, 11]. The same 
tests are not commonly applied to RNA-seq-based studies today.   
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As gene expression can be diverse between samples, a limited sample size used in 
a RNA-Seq analysis might misidentify genes as DE, or fail to identify DE genes, 
both leading to unreliable conclusions. In contrast, using an excessive number of 
samples can waste time and resources. Thus, a suitable samples size is critical for 
RNA-seq analysis to achieve confident results with high efficiency. Since the 
psen1K97fs and psen1Q96_K97del analyses were performed, power calculations have 
been performed using the strategy from Zhao et al., 2018 [12], and have showed 
that n=6 provides a power of ~70% for detection of fold-change > 2 at a false 
discovery rate (FDR) of 0.05 across the vast majority of expressed transcripts in 
zebrafish brain transcriptomes (Stephen Pederson, unpublished results). However, 
n=3 and n=4 were used in psen1K97fs and psen1Q96_K97del analyses respectively, 
which were relatively low sample sizes for identification of DE genes. Due to the 
genetic diversity between siblings, the low sample sizes may have led to 
misidentification of some genes as DE, which is a major limitation of our 
transcriptome analyses. Therefore, the sample numbers used in the above brain 
transcriptome analyses was suboptimal. It is for the reason that a sample size of 6 
was used in the transcriptome analysis described in Chapter 4.  
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2.4 Methods 
Excision of zebrafish brains 
The psen1K97fs and psen1Q96_K97del families used for month-by-month transcriptome 
monitoring were initially generated through mating an individual heterozygous 
mutant zebrafish with a wild type individual to produce a family of ~50% 
heterozygous and ~50% wild type siblings. Three wild type and three heterozygous 
mutant zebrafish brains were extracted each month from 6 months to 24 months 
after the family was spawned. Zebrafish were euthanised in a loose icy slurry before 
brain removal. The extracted brains were placed into 400 μl RNAlaterTM 
(Invitrogen, Camarillo, California, USA) overnight at 4°C for RNA stabilization. 
RNAlaterTM solution was then removed and brain samples were stored at -80°C. 
 
RNA purification and cDNA synthesis  
Total brain RNA was extracted using the QIAGEN RNeasy mini Kit (QIAGEN, 
Hilden, Germany). DNase treatment was performed on RNA to remove remaining 
genomic DNA using the DNA-freeTM Kit (Ambion, Life Technologies, Thermo 
Fisher Scientific, Waltham, MA, USA). Purified RNA (1000 ng) was then used to 
synthesise 20 μL of first-strand cDNA by reverse transcription (SuperScript III kit, 




QuantStudio 3D Digital PCR 
Digital quantitative PCR was performed on a QuantStudio™ 3D Digital PCR 
System (Life Technologies, Thermo Fisher Scientific, Waltham, MA, USA). Each 
reaction mix contained 1X QuantStudio™3D digital PCR Master Mix, SYBR® 
green dye, 0.2 μM of specific primers and a specific amount of cDNA for each gene 
(primer sequences and cDNA amount used in each dqPCR reactions are shown in 
2.5 Appendix), to give a final product concentration in the reactions within a range 
of 200 to 2000 copy numbers per microliter. The reaction mixture (14.5 μl) was 
loaded onto a QuantStudio™3D digital PCR 20 K chip using an automatic chip 
loader following the manufacturer’s instructions. Loaded chips underwent thermo-
cycling on the Gene Amp 9700 thermo-cycling system under the following 
conditions: 96°C for 10 min, 39 cycles of 60°C for 2 min and 98°C for 30 sec, 
followed by a final extension step at 60°C for 2 min. The chips were imaged on a 
QuantStudio™ 3D instrument, which assesses raw data and calculates the estimated 
concentration of the nucleic acid sequence targeted by the SYBR® green dye by 
Poisson distribution [13]. The concentration of tested genes was normalized to the 
concentration of house-keeping gene eef1a1l1 to correct for sample to sample 
variations in RT-PCR efficiency and errors in sample quantification. 
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Relative standard curve qPCR  
Relative standard curve qPCR was used to repeat the quantification on two DE 
genes to ensure the reliability and reproducibility of dqPCR. Each 25 μL qPCR 
reaction contained 20 ng cDNA, 0.2 μM of each PCR primers and Power SYBR 
green master mix PCR solution (Applied Biosystems, Thermo Fisher Scientific Inc., 
Waltham, MA, USA). The standard curve was generated by a serial dilution, having 
50 ng, 25 ng, 12.5 ng and 6.25 ng of wild type cDNA per reaction. The qPCR was 
performed on an ABI 7000 Sequence Detection System (Applied Biosystems) using 
a 96-well plate. The amplification consisted of a holding stage and a cycling stage. 
The holding stage performed 50°C for 2 mins and 95°C for 10mins, and the cycling 
stage had 40 cycles of 95°C for 15 s and 60°C for 1 min. Three technical PCR 
replicates were performed on each cDNA sample and their mean was used to 
represent the quantity. The quantities of the selected genes were calculated relative 
to the quantities of house-keeping gene eef1a1l1, which were then compared using 
an unpaired t-test. 
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2.6 Appendix: Primer information  
















































































Chapter 3: Do zebrafish with the psen1K97fs mutation show 
the alternative splicing seen in human PSEN2K115fs 
carriers? 
3.1 Introduction  
EOfAD is autosomal and dominantly inherited, and hundreds of EOfAD-causative 
mutations are located in the three major genetic loci PSEN1, PSEN2 and APP [1]. 
Interestingly, these mutations have a common feature of following a “fAD reading 
frame preservation rule” specifying that these EOfAD mutations must not change 
the reading frame and so must allow translation of “full-length” proteins [2]. 
PSEN2K115fs, a frame shift EOfAD-causative mutation in human PSEN2 gene, was 
previously thought to be a unique exception to this rule [3]. As, supposedly, the 
only frame shift mutation of the PREESENLIN genes causing EOfAD, the 
PSEN2K115fs mutation had been studied to investigate the differences between this 
mutation and other frame shift mutations and how this mutation could induce AD 
pathology. It has been proposed that decreased PSEN function may contribute to 
AD pathogenesis [3], or that the truncated PSEN2 protein encoded by the mutated 
coding sequence may function like the hypoxia-induced truncated PSEN2 isoform 
PS2V, which shows increased expression under hypoxia and in sAD brains and can 
stimulate -secretase activity and suppress the unfolded protein response [4]. 
However, a recent study in 2019 identified an alternative transcript splicing isoform 
from the PSEN2K115fs allele in humans that includes 77-nucleotides of intronic 
sequence leading to the restoration of the open reading frame [5]. This means that, 
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in fact, the PSEN2K115fs mutation also follows the “fAD mutation reading frame 
preservation rule” like all other EOfAD-causative mutations in the presenilin genes 
and is not an exception to this rule. 
Previously, we modeled the human PSEN2K115fs mutation in zebrafish by 
introducing an equivalent 2 nucleotide deletion into the coding sequence of the 
psen1 gene, psen1K97fs (This mutation was introduced into psen1, rather than psen2 
because, in contrast to humans, a PS2V-related isoform is produced in zebrafish 
from its psen1 gene rather than from psen2, details in section 1.9.1). However, the 
recent identification of a low-abundance, alternatively spliced isoform from the 
human PSEN2 gene that restores the open reading frame in PSEN2K115fs mutants 
raised the question of whether the psen1K97fs mutation was influenced by an 
equivalent isoform and so still a suitable model of the human PSEN2K115fs mutation. 
Therefore, we sought to determine whether such an isoform occurs in zebrafish. 
This chapter describes an effort to detect alternative splicing in heterozygous 
psen1K97fs mutant brains by using RT-PCR to amplify a region of cDNA spanning 
the exon containing the mutation and multiple neighbouring exons. However, no 
alternatively spliced transcript isoforms were identified, indicating that the 




A low-abundance, alternative splicing isoform of human PSEN2 restores the open 
reading frame in PSEN2K115fs mutants through insertion of 77-nucleotides of 
intronic sequence upstream of the exon in which the PSEN2K115fs mutation residues 
[5]. The psen1K97fs mutation is located in zebrafish psen1 exon 3. As psen1K97fs is a 
model of human PSEN2K115fs, we needed to detect whether there is a similar 
alternatively spliced isoform from the psen1K97fs allele that inserts intronic sequence 
near exon 3 and restores open reading frame. Therefore, two primer pairs for RT-
PCR covering the mutation region were designed for the detection of aberrant 
splicing. Their binding sites are showed in Figure 3.1.  
 
 
Figure 3.1. The design of RT-PCR “splicing” primer pairs for detection of 
alternative splicing in psen1K97fs/+ mutants. These primer pairs should amplify 
cDNA derived from the normal psen1 transcript (Upper) and the PS1IV isoform 
(Lower) which results from hypoxia-induced exclusion of exon 3 [4]. Under 
normoxia, the expression of PS1IV is at a low level and can be difficult to detect. 
 
 88 
Note that the exons shown above have the following ID codes in the Ensembl 













PCRs were performed on cDNA generated from 24-month-old heterozygous 
psen1K97fs mutant brains, and the results are shown in Figure 3.2. In the tests of 
both primer pairs, all wild-type and mutant samples showed a single clear band at 
the expected product size of normal psen1 transcripts. No products of a size 
indicating the presence of PS1IV transcripts were seen, probably because the 
expression of PS1IV transcripts was at a very low level under normoxia. No 
aberrant splicing products were identified. Therefore, this result informed us that 
our zebrafish psen1K97fs mutation probably is not a very informative model of the 
human PSEN2K115fs mutation, as it does not appear to produce an alternative 
transcript that restores the open reading frame. 
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Figure 3.2. PCR tests for detection of alternative splicing on cDNA generated from 
24-month-old heterozygous psen1K97fs mutant brains. “Splicing primer pair 1” is 
Splicing_Primer_F1 with Splicing_Primer_R1, and “Splicing primer pair 2” is 
Splicing_Primer_F2 with Splicing_Primer_R2, corresponding to the primer 
binding sites illustrated in Figure 3.1. 
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3.3 Discussion  
The identification of an alternatively spliced isoform in human PSEN2, which 
restores the open reading frame in the PSEN2K115fs mutant allele, indicates that the 
pathological mechanism through which this mutation drives EOfAD likely does not 
need to involve mimicry of the naturally truncated isoform PS2V. Instead, like other 
EOfAD-causative mutations, translation of a “full-length” protein still appears to 
be an essential element in the pathogenesis of EOfAD. As no alternatively spliced 
isoform from the psen1K97fs allele has been identified that restores this gene’s open 
reading frame, the zebrafish psen1K97fs mutation is probably not a close model of 
the pathological action of human PSEN2K115fs. Consequently, the DE genes and 
predicted pathways identified in transcriptome analysis of zebrafish heterozygous 
psen1K97fs mutant brains may not reflect the molecular genetic state of EOfAD 
brains. Therefore, based on our current understanding, psen1K97fs mutants were not 
regarded as an EOfAD-like model in my following experiments but analysis of 
them may help to exclude irrelevant effects induced by reduced PSEN2 expression. 




RNA purification and cDNA synthesis 
Three heterozygous psen1K97fs mutant zebrafish and three their wild type siblings at 
24 months of age were euthanised in a loose icy slurry before brain extraction. Total 
RNA was then extracted from each zebrafish brain using the QIAGEN RNeasy mini 
Kit (QIAGEN, Hilden, Germany). 250 ng of total RNA from each brain was then 
used to synthesise 20 μL of first-strand cDNA by reverse transcription (SuperScript 
III kit, Invitrogen, Camarillo, California, USA).  
 
RT-PCR for alternative splicing products 
One unit of Phusion high-fidelity DNA polymerase (New England Biolabs, Ipswich, 
Massachusetts) was used in each 25 μL PCR reaction containing 10 ng of a cDNA 
sample, 0.2 mM of each deoxyribonucleotide triphosphate (dNTP, each at a final 
concentration of 0.2 mM), and 0.4 μM of each PCR primer. PCR cycling was 
performed with 35 cycles of a denaturation temperature of 95°C for 30 s, then an 
annealing temperature of 60°C for 30 s and then an extension temperature of 72°C 
for 2 minutes. PCR products were electrophoresed through a 1.5% agarose gel in 
1×TAE buffer for separation and identification. 
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3.5 Appendix: Primer information  
Primers for detection of alternative splicing 
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Chapter 4: Transcriptome analyses of 7-day-old 
heterozygous psen1Q96_K97del zebrafish larvae  
4.1 Summary 
Zebrafish larvae can be used for screening of chemical libraries in drug discovery. 
A 2015 paper by Wagner et al. [1] showed that the most effective drugs in an animal 
model (of dyslipidemia) were those able to revert disease transcriptome signatures 
back to normal. In accordance with this philosophy, we investigated whether we 
could use our EOfAD-like heterozygous psen1Q96_K97del mutant larvae for the 
discovery of drugs that can reverse their presumably pathological transcriptome 
state to normal. Although the previous brain transcriptome analysis of 6-month-old 
heterozygous psen1Q96_K97del mutants indicated defects in mitochondrial function 
and lysosomal acidification, similar transcriptome effects would need to be seen in 
7 day post fertilization (dpf) mutant larvae if we were use them in a drug screen 
based on restoring normality to the transcriptome. Therefore, we performed 
transcriptome analysis on clutches of 7 dpf wild type and heterozygous 
psen1Q96_K97del larvae using a specific paired-mating strategy. We performed 
transcriptome analysis on whole larvae rather than on larval brains, although the 
magnitude of some transcriptome changes only occurring in nervous tissues might 
be diluted or masked by the inclusion of transcriptomes from other cells of whole 
larvae. The major reason is that larval brains are so tiny that large numbers of larval 
brains would be required to generate sufficient RNA for RNA-seq. Physically 
isolating this tissue from larvae would also be difficult technically. Also, any high-
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throughput drug screen would be designed to use whole larvae, as it would be 
extremely technically challenging to generate sufficient RNA from individual 
larval brains for assessment of brain transcriptome changes. In larval transcriptome 
analysis, 228 differentially expressed (DE) genes were identified, and gene set 
enrichment analysis (GSEA) and Goseq analysis were used to predict the effects of 
the mutation on cellular functions. Due to the lack of correspondence between DE 
genes identified in heterozygous psen1Q96_K97del mutant 7 dpf larvae and in 
heterozygous mutant 6-month-old brains as well as the variability of gene 
expression level between larvae clutches of the same genotype, psen1Q96_K97del 
larvae appear to be unsuitable for the discovery of drugs to suppress the 
transcriptome changes seen in psen1Q96_K97del mutant brains. However, we still 
observed similar affected cellular pathways between the larvae and the brains, 
including oxidative phosphorylation, mitochondrial function, lysosomal 
acidification, and iron ion transport although the larvae lacked detectable 
enrichment of the prevalence of transcripts containing iron responsive elements 
(IREs) in their 3’UTRs. Also, some apparently larva-specific effects of the mutation 
were identified, including effects on extracellular matrix (ECM) and 
minichromosome maintenance protein complex (mcm) function.  
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4.2 Transcriptome analyses of 7-day-old zebrafish larvae 
possessing a familial Alzheimer’s disease-like mutation in psen1 
indicate effects on oxidative phosphorylation, ECM and mcm 
functions, and iron homeostasis 
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Abstract 
Background: Early-onset familial Alzheimer’s disease (EOfAD) is promoted by 
dominant mutations, enabling the study of Alzheimer’s disease (AD) pathogenic 
mechanisms through generation of EOfAD-like mutations in animal models. In a 
previous study, we generated an EOfAD-like mutation, psen1Q96_K97del, in zebrafish and 
performed transcriptome analysis comparing entire brains from 6-month-old wild type 
and heterozygous mutant fish. We identified predicted effects on mitochondrial function 
and endolysosomal acidification. Here we aimed to determine whether similar effects 
occur in 7 day post fertilization (dpf) zebrafish larvae that might be exploited in 
screening of chemical libraries to find ameliorative drugs. 
Results: We generated clutches of wild type and heterozygous psen1Q96_K97del 7 dpf 
larvae using a paired-mating strategy to reduce extraneous genetic variation before 
performing a comparative transcriptome analysis. We identified 228 differentially 
expressed genes and performed Goseq analysis and gene set enrichment analysis (GSEA) 
to predict cellular functions.  
Conclusions: Our analyses predicted a significant effect on oxidative phosphorylation, 
consistent with our earlier observations of predicted effects on ATP synthesis in adult 
heterozygous psen1Q96_K97del brains. The dysregulation of minichromosome maintenance 
protein complex (MCM) genes strongly contributed to predicted effects on DNA 
replication and the cell cycle and may explain earlier observations of genome instability 
due to PSEN1 mutation. The upregulation of crystallin gene expression may be a 
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response to defective activity of mutant Psen1 protein in endolysosomal acidification. 
Genes related to extracellular matrix (ECM) were downregulated, consistent with 
previous studies of EOfAD mutant iPSC neurons and postmortem late onset AD brains. 
Also, changes in expression of genes controlling iron ion transport were observed 
without identifiable changes in the prevalence of transcripts containing iron responsive 
elements (IREs) in their 3’ untranslated regions (UTRs). These changes may, therefore, 
predispose to the apparent iron dyshomeostasis previously observed in 6-month-old 




Alzheimer’s disease (AD) is a progressive neurodegenerative brain disorder that 
eventually develops into dementia. AD is a serious worldwide health issue and shows a 
trend of increasing disease incidence [1]. AD may be classified in numerous ways. Late 
onset, sporadic AD, occurs after 65 years of age and is the most common form, 
contributing to more than 95% of AD cases [2]. This form of AD is affected by multiple 
factors, including age, diet, life style, genetic and environmental factors [3]. Therefore, 
it has been difficult to model in animals. An early onset, familial form of AD (EOfAD) 
shows autosomal, dominant inheritance and contributes less than 5% of all AD cases [4]. 
As both AD forms share similar pathologies [2], many researchers model EOfAD 
through genetic manipulation of animals to study AD ontology and pathology in general. 
 
Rodent models are the most commonly used in AD research. However, current 
transgenic rodent models used in EOfAD studies do not reflect closely the disease state 
of human patients. In 2017, Hargis and Blalock [5] summarized brain transcriptional 
profiles in human AD, and compared five transgenic mouse models of AD to human AD 
profiles. All of these mouse models failed to model the most consistent transcriptional 
signature of human AD, a downregulation of neuronal and mitochondrial genes. Also, 
the focus of most AD studies is on the pathologies of the advanced disease, such as the 
accumulation of amyloid-β peptide and tau protein, and on identification of new 
biomarkers for early diagnosis. Our laboratory seeks deeper insight into the early 
molecular states of AD brains to explore disease etiology and molecular mechanisms. 
We have modeled EOfAD-like mutations in another popular vertebrate animal model, 
the zebrafish. The zebrafish has a fully sequenced and well annotated genome [6], and 
has the advantages of rapid development with a relatively short generation time. It is 
easily manipulated genetically and has the capacity to produce large families of siblings 
which can then be raised together in the same environment to limit the effects of 
environmental and genetic noise in molecular analyses [7]. Moreover, zebrafish possess 
orthologs of the human genes mutated in EOfAD. Most recognized EOfAD-causative 
mutations have been found in the genes PSEN1, PSEN2 and APP [8]. (The majority of 
these mutations, ~63%, occur in the gene PSEN1 [9].) The zebrafish orthologs of these 
genes have been identified as psen1 [10], psen2 [11], appa and appb [12]. Therefore, 
zebrafish have the potential to model EOfAD mutations for the study of the molecular 
pathological processes of AD. The zebrafish is also a versatile model for drug screening 
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as its tiny larvae can be obtained in large numbers and arrayed into microtitre plates for 
molecular, developmental, or behavioural analyses [13].  
 
One EOfAD-like mutation we have generated is psen1Q96_K97del, a deletion of 6 
nucleotides in the zebrafish psen1 gene. This mutation deletes 2 codons but maintains 
the open reading frame, leading to structural and hydrophilicity changes in the first 
lumenal loop of the translated protein. Although this mutation is not the exact equivalent 
of any currently known human EOfAD mutation, there are numerous similar EOfAD 
mutations that distort the first luminal loop of human PSEN1 (e.g. PSEN1L113_I114insT [14], 
PSEN1P117L [15]) and, like all the many various and widely distributed EOfAD mutations 
in the PRESENILIN genes, it follows the “fAD mutation reading frame preservation rule” 
[8]. 
 
Like human EOfAD mutations, psen1Q96_K97del has dominant effects when heterozygous. 
We have observed that the brains of 6-month-old (young, recently sexually mature adult) 
zebrafish heterozygous for psen1Q96_K97del show transcriptome alterations consistent with 
disturbances in energy production (ATP synthesis) and lysosomal dysfunction [16]. 
These may represent the initial stresses that, after decades in humans, lead to AD. 
 
Could our heterozygous mutant zebrafish be used to identify drugs that suppress these 
molecular defects and so prevent the pathological progression to AD? A 2015 paper by 
Wagner et al. [17] showed that the most effective drugs in an animal model (of 
dyslipidemia) were those that best caused reversion of the transcriptome disease 
signature to normal. In accordance with this philosophy, zebrafish mutants could be used 
to screen for AD-preventative drugs based on the drugs’ ability to revert transcriptome 
signatures of ATP synthesis disruption and lysosomal dysfunction back to wild type. 
Therefore, as a first step in assessing the viability of this idea, we were interested to 
observe whether the transcriptome signatures evident in 6-month-old zebrafish 
psen1Q96_K97del heterozygous adult mutant brains were discernable in whole zebrafish 
larvae. 
 
Our previous analysis of psen1Q96_K97del heterozygous adult mutant brain transcriptomes 
was facilitated by the ability to perform bulk RNA-seq on the entire ~7 mg brains of 
individual mutant zebrafish and their wild type siblings. While an individual zebrafish 
larva at 7 days post fertilization (dpf, when feeding would normally begin) is too small 
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to provide sufficient RNA for bulk RNA-seq analysis without some form of 
amplification, we can produce clutches of uniformly heterozygous larvae by crossing a 
homozygous mutant parent fish with a wild type parent. Analysis of pooled RNA from 
multiple individuals also reduces between-genotype variability due to “averaging” of the 
mRNA expression levels contributed by each larva in the pool. Also, using a single male 
fish to produce both a heterozygous mutant clutch and a wild type clutch of larvae 
(through mating with a single homozygous mutant or wild type female fish respectively) 
further reduces genetic variability in the analysis (see Figure 3).   
 
In this paper we describe a transcriptome analysis on clutches of 7 dpf heterozygous 
mutant and wild type larvae structured as described above to minimize genetic variation. 
This identified 228 potentially differentially expressed (DE) genes. Bioinformatic 
predictive analysis identified probable significant changes in DNA replication and cell 
cycle processes, to which changes in the regulation of genes related to the 
minichromosome maintenance protein complex (MCM) were the main contributors. In 
addition, effects on iron ion transport were identified, suggesting a potential early 
disruption of iron homeostasis components that might lead, ultimately, to mitochondrial 





Our previous study examined the effects of heterozygosity for the psen1Q96_K97del 
mutation on the transcriptome of 6-month-old zebrafish brains. The changes in gene 
expression observed were predicted to affect ATP synthesis and lysosomal acidification 
[16]. Here we sought to identify the changes present in entire, heterozygous 7 dpf larvae 
to assess whether these larvae might be a suitable system in which to screen drug 
libraries for compounds ameliorating the young adult brain ATP synthesis and lysosomal 
acidification effects. The mating scheme described in Figure 3 was employed to generate 
n=6 pairs of heterozygous mutant and wild type clutches of larvae. (Power calculations 
performed since our first publication indicated that n=6 provides a power of 
approximately 70% for detection of fold-change > 2 at a false discovery rate (FDR) of 
0.05 across the vast majority of expressed transcripts in zebrafish brain transcriptomes 
[18], data not shown.) RNA-seq was performed on RNA purified from these clutches 
followed by a comparative transcriptome analysis to identify differentially expressed 
genes and explore potential functional effects caused by the mutation. 
 
Differentially expressed genes (DE genes) 
Gene expression differences between wild type and heterozygous psen1Q96_K97del/+ 
clutches were calculated through a design matrix considering each pair of clutches as a 
factor and genotypes as the common difference.  
 
228 significantly DE genes were identified (Supplementary data 1), although most of 
these genes showed only minor fold-change differences in expression. Comparison of 
the significantly DE genes identified from heterozygous mutant 7 dpf larvae with those 
seen in heterozygous mutant 6-month brains [16], revealed only one gene, lgals8b, as 
common between the two datasets. It is upregulated in both.   
 
To support the accuracy and reliability of the RNA-seq data, relative standard curve 
quantitative PCRs (qPCRs) were performed for four of the most statistically significantly 
DE genes that showed relatively large fold-changes in expression. The qPCRs were 
performed using cDNA synthesized from the same preparations of RNA that were used 
in the RNA-seq analysis. Three of the four genes were seen to be differentially expressed 
(p < 0.05, Supplementary data 2).  
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GOseq analysis of pathways and GO terms 
To predict the cellular functions affected by heterozygosity for the psen1Q96_K97del 
mutation, we analysed the DE genes using the Hallmark, KEGG, and Wiki pathway 
databases and the Gene Ontology database. Different pathway databases may contain 
different representations of similar biological pathways. Hallmark gene sets summarize 
well-defined biological states or processes built on the overlapping of several gene set 
collections, and so are useful to achieve an overall view [19]. The KEGG and Wiki gene 
sets are two popular pathway databases allowing examination of high-level functions. 
Different pathway databases might show low between-database consistency due to the 
incomprehensive gene sets and gene interactions in each category [20]. Therefore, to 
generate a more comprehensive result, we used both KEGG and Wiki pathway databases 
for pathway analysis. 
 
Pathway and GO analysis were performed using Goseq, which weighted DE genes and 
calculated each category’s significance amongst DE genes to identify significantly 
changed pathways or GO terms. Goseq analysis only focuses on the proportions of DE 
genes in each category but does not consider gene expression fold change and pathway 
regulation direction. Table 1 shows the Goseq results with a FDR cutoff of 0.05 in the 
analysis of Hallmark, KEGG and Wiki pathways (Table 1) and of GO terms (Figure 1). 
In the Hallmark pathway (Table 1), G2M_CHECKPOINT contains genes critical for cell 
division cycle progression, and E2F_TARGETS includes numerous genes that play 
essential rolls in the cell cycle and DNA replication [21]. Therefore, the Goseq results 
of the Hallmark, KEGG and Wiki pathway analyses (Table 1) show significant changes 
in DNA replication and cell cycle control. Among the DE genes in these two categories, 
most are members of the minichromosome maintenance (MCM) protein family. 
Downregulation of the genes mcm2, mcm3, mcm4, mcm5, mcm6 and mcmbp and 
upregulation of the gene mcm7 were observed in the heterozygous mutant larvae. 
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Table 1. Significantly-changed pathways in the Goseq analysis of Hallmark, KEGG and 
Wiki pathways filtered by a FDR cutoff of 0.05.  
 
In GO analysis, one DE gene can contribute to several related GO terms. The network 
shown in Figure 1 illustrates how the DE genes are shared between GO terms. Similar 
to the pathway analyses, most of the GO terms showing significant enrichment for DE 
genes are related to the cell cycle and DNA replication. In the network, these GOs cluster 
around the MINICHROMOSOME MAINTENANCE (mcm) genes. The network also 
illustrates how numerous genes can form a functionally related cluster contributing to 
only one or a few GOs. This is seen for the significantly upregulated CRYSTALLIN genes 
that contribute to eye lens structure (GO: Structural constituent of eye lens) but also 
function in lysosomal acidification (not revealed here, see Discussion). In contrast, the 
four genes included in the GO Iron ion transport show significantly changed regulation. 
This includes downregulation of the genes tfa and tfr1b that act to import iron via the 
endolysosomal pathway [22]. The ferritin heavy chain like genes fthl30 and fthl31 are 
upregulated and downregulated respectively, presumably influencing the storage of 
ferric iron within cells.  
 
We recently published an analysis using a novel method of transcriptome analysis to 
detect differences in ferrous iron (Fe2+) status in cells [23]. Using this technique, we 
detected for the first time, that young (6-month-old) adult brains from psen1Q96_K97del/+ 
zebrafish are likely deficient for ferrous iron. Therefore, we were very interested to see 
evidence of iron ion transport gene expression changes in the 7 dpf psen1Q96_K97del/+ 
larvae. To confirm these changes in gene expression we performed qPCRs for the genes 
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tfa, tfr1b, and fthl31 on cDNA made from the same mRNA samples that were subjected 
to RNA-seq (see Supplementary data 2, fthl31 was not examined because its expression 
level is particularly low). The qPCRs for these three genes were consistent with the 
RNA-seq results. 
 
When ferrous iron is deficient in cells, Iron Regulatory Proteins bind to Iron-Responsive 
elements in the 3’ untranslated regions (3’UTRs) of mRNAs encoding proteins that 
function to increase ferrous iron levels (such as human TFR1 [24] or zebrafish Tfr1b 
[25]). To detect ferrous iron dyshomeostasis in transcriptome data, we looked for 
enrichment of a large set of gene mRNAs that include putative IREs in their 3’ UTRs. 
We did not see enrichment of this gene set in the 7 dpf psen1Q96_K97del/+ zebrafish larvae, 
likely indicating that the apparent ferrous iron deficiency of young adult psen1Q96_K97del/+ 














Gene set enrichment analysis (GSEA) 
Goseq analysis only focuses on significantly DE genes and predicts affected pathways 
based on DE gene numbers in each GO. In contrast, GSEA ranks all genes based on fold 
change and P-value, and then estimates their contributions to each pathway. Therefore, 
GSEA can show pathway regulation direction, and provides a complementary view of 
gene sets.  
 
Table 2. Significantly-changed pathways in the GSEA analysis of Hallmark, KEGG and 
Wiki pathways filtered by a Bonferroni correction P-value of 0.05. ES and NES indicate 
enrichment score and normalized enrichment score respectively. NES is generated 
through normalizing enrichment score to mean enrichment score of random samples. 











We applied GSEA using the Hallmark, KEGG and Wiki pathway databases. Several 
significantly-changed pathways were identified in each analysis (Table 2), including 
pathways previously identified in the Goseq pathway analysis. Four of the significantly-
changed KEGG pathways are illustrated in Figure 2. DNA replication (Figure 2a) and 
cell cycle (Figure 2b) were the most significantly affected pathways identified in the 
Goseq pathway analysis and the GO analysis. Regulation of the MCM complex plays 
essential roles in both pathways. The MCM complex forms a DNA helicase, which 
cooperates with replication protein A (RPA) to unwind duplex parental DNA before 
DNA synthesis (Figure 2a, [27]). Dysregulation of the MCM complex would influence 
the DNA replication and might cause replication stress leading to genomic instability 
[28]. The pathways ECM receptor interaction (Figure 2c) and oxidative phosphorylation 
(OXPHOS, Figure 2d) were also significantly changed in 7 dpf psen1Q96_K97del/+ 
zebrafish larvae. ECM receptor interaction was the most significantly changed pathway 
in KEGG pathway analysis (the lowest P-value), and most genes involved were 
downregulated (Figure 2c), including the COLLAGEN gene group identified in the 
previous GO analysis. The KEGG pathway ECM receptor interaction plays important 
roles in control of cellular activities, including functioning to provide cell structural 
support and to regulate cell-cell and cell matrix interactions [29]. In developing brains, 
ECM receptor interaction participates in cell migration and the guidance of growing 
axons, having crucial effects on neural cells. This has implicated ECM receptor 
interaction in processes underlying many central nervous system diseases such as AD, 
schizophrenia and Parkinson’s disease [30]. OXPHOS (Figure 2d), as well as fatty acid 
metabolism (shown in Table 2), contribute to the fundamentally important function of 
energy production. In our previous GO analysis of 6-month-old psen1Q96_K97del/+ 
zebrafish brains, we saw very significant apparent effects on ATP synthesis [16]. The 
analysis here suggests that that energy production capacity is downregulated in the 
mutant larvae and this is expected to include ATP synthesis. Furthermore, Beta-alanine 
metabolism, glutathione metabolism, pyrimidine metabolism, butanoate metabolism and 
focal adhesion are also identified as significantly-changed pathways (Table 2). The 
interpretation of these pathway changes requires further investigation. KEGG diagrams 
for the statistically significantly affected pathways not shown in Figure 2 are given in 





No suitable transcriptome biomarkers identified for drug screening 
Zebrafish larvae represent a powerful system for screening of chemical libraries in drug 
discovery [13]. However, the lack of consistency in transcriptome changes seen between 
heterozygous mutant psen1Q96_K97del 7 dpf larvae compared to heterozygous mutant 6-
month-old brains would appear to preclude the use of these mutant larvae to find drugs 
to suppress the transcriptome changes seen in the brains. Also, although the RNAs used 
for transcriptome analyses were extracted from clutches of larvae rather than individuals, 
the expression levels of the DE genes were, nevertheless, quite variable between clutches 
of the same genotype, either wild type or mutant (Supplementary data 2). We were able 
to identify significantly changed cellular pathways in common between the larvae and 
the brains. These related to oxidative phosphorylation, mitochondrial function and 
lysosomal acidification, indicating that similar stresses/biological effects caused by the 
presence of the psen1Q96_K97del mutation likely exist during the entirety of zebrafish 
development from larvae to young adult. However, analysis of transcriptomes at this 
level would be unsuitable for the massively parallel screening of chemical libraries. 
Therefore, use of the psen1Q96_K97del EOfAD-like mutation for discovery of AD-
preventative drugs remains infeasible until a suitable biomarker can be identified.  
 
 
MCM complex dysregulation may drive DNA replication stress 
Comparison of the transcriptomes of pools of 7 dpf heterozygous psen1Q96_K97del mutant 
larvae to their wild type siblings revealed highly significant regulatory effects on genes 
involved with DNA replication and the cell cycle. These were identified by both Goseq 
analysis and GSEA. The majority of DE genes contributing to these two terms are related 
to the minichromosome maintenance (MCM) protein family. The eukaryotic MCM 
complex functions as a DNA helicase essential for DNA replication and cell division. 
The complex is comprised of the protein products of six genes, MCM2-7 (Figure2a, 
[31]). We observed a downregulation of zebrafish genes mcm2, mcm3, mcm4, mcm5, 
mcm6 and mcmbp and an upregulation of mcm7. If this gene dysregulation phenomenon 
affects other vertebrates, including mammals, it may clarify a hitherto unexplained 
mutagenic effect of EOfAD mutations in, specifically, PSEN1. In 2002, Chan et al. [32] 
showed that forced expression of EOfAD mutant PSEN1, but not wild type PSEN1, 
increased the sensitivity of Rat pheochromocytoma (PC12) cells to DNA damage by 
etoposide. Responses included greater than normal increases in p53 protein levels and 
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phosphorylation. In 2010, Michelsen et al. [33], studied the effects in mouse brains of 
transgenes expressing EOfAD mutant forms of the genes APP, or PSEN1, or both 
simultaneously. They observed an increase in the number of single-strand DNA breaks 
occurring in hippocampal granule cells of the dentate gyrus and hippocampal pyramidal 
cells in areas CA1/2 when brains expressed only the PSEN1 mutant transgene. 
Interestingly, simultaneous expression of EOfAD mutant forms of both APP and PSEN1 
reduced the single stand break rate so that it was similar to that seen for only APP mutant 
transgene expression alone. In mice, reduced function of the Mcm4 gene led to 
susceptibility to chromosome breaks induced by a DNA replication inhibitor, aphidicolin 
[34]. Notably, in 2011, Yurov et al. [28] suggested a DNA replication stress hypothesis 
of AD which proposes that replication stress caused by incomplete DNA replication 
leads to DNA damage or improper repair, subsequently resulting in the accumulation of 
genomic instabilities in AD brains. Genomic instabilities are associated with 
neurodegeneration in other aging-related diseases [35, 36]. Our observations, those of 
others (above), and Yurov et al.’s ideas suggest that associations between PSEN1 
functions and DNA integrity are an interesting area for further exploration and may give 
us greater insight into cellular stresses driving AD pathologies.   
 
Are crystallin genes upregulated due to disturbance of lysosomal 
acidification? 
The discovery that DE genes were enriched under the GO term structural constituent of 
eye lens, focused our attention on the crystallin genes crygm2d9, crygm2d17, cryba1l2, 
and cryaa. Crystallin genes have not previously been linked with AD or PSEN functions. 
However, a paper by Valapala et al., 2013 [37] reported that the loss of the βA3/A1-
crystallin gene in rat (Cryba1) reduces endolysosomal acidification, leading to reduced 
γ-secretase-mediated release of Notch intracellular domain (NICD) and impaired 
lysosomal-mediated degradation of Notch. Overexpression of Cryba1 in a Cryba1-/- 
knockout mouse apparently was able to rescue the deficient function of the vacuolar 
ATPase (v-ATPase) responsible for endolysosomal acidification. EOfAD mutations of 
human PSEN1 are thought to reduce lysosomal acidification due to a requirement for the 
PSEN1 holoprotein for correct N-glycosylation of the v-ATPase subunit, V0a1 [38]. Our 
transcriptome analysis of the effect of heterozygosity for the psen1Q96_K97del mutation on 
6-month-old zebrafish brains also implied effects on lysosomal acidification [16]. While 
lysosomal acidification was not revealed as an affected GO in our analysis of 7 dpf 
 114 
heterozygous psen1Q96_K97del larvae, we speculate that the upregulation of crystallin genes 
observed may be a homeostatic response to cope with disturbed lysosomal acidification. 
 
Interestingly, Notch signaling has been seen to control expression of the protein products 
of the human mcm gene orthologues, MCM2 and MCM6 in cells where Notch signaling 
suppresses proliferation [39]. However, since Notch signaling was seen to downregulate 
these proteins, loss of Notch signaling due to increased lysosomal pH would not appear 
to explain the downregulation of mcm2 and mcm6 gene expression we observed in the 
heterozygous mutant zebrafish larvae. 
 
 
Does downregulation of ECM related genes increase the risk of AD? 
The most significant KEGG pathway identified in GSEA was ECM (extracellular matrix) 
receptor interaction. Most genes in this pathway, including those encoding collagen, 
laminin, tenascin and thrombospondin, were significantly downregulated (Figure 2c). 
ECM receptor interaction is not currently a focus in AD studies, although altered 
regulation of these genes has previously been observed in some AD relevant research. 
In 2019, Kwart et al. [40] identified 1,515 overlapping DE genes from three human iPSC 
lines carrying EOfAD mutations in APP and PSEN1. These DE genes were used to 
perform a enrichment analysis, and ECM receptor interaction was the second most 
statistically significant KEGG pathway identified. However, the relationships between 
EOfAD mutations and ECM receptor interaction have not been further explored. 
Another study by Conejero-Goldberg et al., 2014 [41] analysed human postmortem 
cortex and identified upregulation of ECM-related gene transcripts in carriers of the AD-
protective 2 allele of the gene APOE (i.e. APOE2). Based on this observation, they 
assumed increased ECM expression would reduce amyloid-β secretion or excitotoxicity. 
Thus, it appears that increased ECM gene expression is associated with decreased AD 
risk while EOfAD mutation-associated decrease of ECM gene expression promotes AD 
pathology. This may indicate the potential for ECM gene expression to act as an AD risk 




Mitochondrial dysfunction is an early effect of the psen1Q96_K97del mutation 
In addition to the pathways mentioned above, fatty acid metabolism, oxidative 
phosphorylation (OX PHOS) and cholesterol biosynthesis were identified in the GSEAs 
of KEGG and Wiki pathways. These pathways represent linked systems that control 
ATP production to meet cellular energy demand and in response to oxygen availability. 
Acetyl-CoA, as the starting point of cholesterol biosynthesis, is produced by oxidation 
reactions including oxidative decarboxylation of pyruvate and β-oxidation of fatty acids 
[42], and is a substrate in the tricarboxylic acid cycle (TCA cycle) to drive oxidative 
phosphorylation [43]. The AD brain is hypometabolic [44] and mitochondrial 
dysfunction is associated with oxidative stress in AD neuropathology through reduced 
ATP production [45]. Reductions in oxidative phosphorylation enzyme activities and 
functions have been identified in AD and other neurodegenerative processes [46]. A 
study by Manczak et al. [47] examined the expression of oxidative phosphorylation 
genes in AD patients and found downregulation of mitochondrial genes coding for 
electron transport chain (ETC) complex I, which is consistent with the gene expression 
in our mutant larvae (Figure 2d). However, Manczak et al. saw increased mRNA 
expression for components of complexes III and VI in contrast to our observations in 
mutant larvae. A more recent analysis by Mastroeni et al. [48] saw downregulation of 
nuclear-encoded ETC genes in AD but increased expression of these relative to age-
matched controls in mild cognitive impairment (MCI). The downregulation of fatty acid 
metabolism, oxidative phosphorylation (OX PHOS) and cholesterol biosynthesis genes 
observed in mutant larvae indicates that the implied impairment of energy production by 
the EOfAD-like psen1Q96_K97del mutation occurs early in life. 
 
Iron homeostasis  
We have previously proposed that cellular iron dyshomeostasis may represent a unifying 
effect-in-common of the EOfAD mutations in APP, PSEN1 and PSEN2 [22] since APP 
was thought to stabilize the iron export protein FERROPORTIN [49], while 
endolysosomal acidification (affected by EOfAD mutations in PSEN1 [38]) is important 
for import of iron into cells [50]. Recently, the role of APP in stabilization of 
FERROPORTIN has been challenged [51, 52]. However, it has been revealed that 
EOfAD mutations in APP, (like those in PSEN1), also affect acidification of the 
endolysosomal pathway [53] and so would be expected to affect cellular iron 
homeostasis. Our identification that the GO iron ion transport is affected in 7 dpf 
psen1Q96_K97del/+ larvae, particularly with downregulation of the tfa and tfr1b genes 
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required for importation of iron, supports that EOfAD mutations in PSEN1 disturb 
ferrous iron homeostasis. The fact that we have seen transcriptome evidence for such 
dyshomeostasis in 6-month-old psen1Q96_K97del/+ brains [16] but were unable to detect 
stabilization of mRNAs containing IREs in their 3’UTRs in 7 dpf larvae, suggests that 
any disruption of ferrous iron homeostasis begins subtly. Therefore, we propose that 
gene dysregulation promoting ferrous iron dyshomeostasis occurs by 7 dpf, but that the 
iron dyshomeostasis requires time to develop before it becomes apparent as ferrous iron 






The research described in this paper was carried out under permit S-2017-073 
issued to members of the Alzheimer’s Disease Genetics Laboratory by the 
Animal Ethics Committee of the University of Adelaide. 
 
Zebrafish pair-mating breeding strategy  
The zebrafish genetic lines used in this study were bred as stocks within the zebrafish 
facility of the Alzheimer’s Disease Genetics Laboratory of the University of Adelaide. 
Adult fish were returned to their families after mating. A female zebrafish homozygous 
for the psen1Q96_K97del allele was crossed to a male wild-type fish to generate a clutch of 
heterozygous psen1Q96_K97del/+ larvae. The same male wild-type fish was then crossed to 
a female wild-type fish to generate a group of wild-type embryos (Figure 3). The use of 
the male fish as the common parent in this mating scheme avoids the possibility that 
maternal effects might obscure transcriptome differences between the larval genotypes 
[54]. These two clutches of larvae from an individual male wild-type fish were labeled 
a “pair” (Figure 3). From previous work analysing the transcriptomes of psen1Q96_K97del/+ 
whole zebrafish brains compared to the brains of wild type siblings [16], we found that 
n = 6 would provide a power of ~70% for detection of fold-change > 2 at a false 
discovery rate (FDR) of 0.05, across the vast majority of expressed transcripts [18]. 
Therefore, for this analysis involving pooled larvae, we analysed n=6 pairs of larval 
clutches. Note that no individual adult fish contributed to more than one larval clutch 
pair.  
 
Figure 3. Mating scheme to generate pairs of 7 dpf zebrafish larval clutches.  
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Sample preparation and RNA purification  
Six pairs of larval clutches were generated as described above (12 clutches in total). The 
parents of 4 pairs of clutches were approximately 5 months old, while the parents of the 
other two pairs of clutches were approximately 12 months old. The larvae were raised 
in E3 medium for 7 days, allowing complete larval yolk absorption but not food intake. 
This was done to minimize the influence of environmental factors on gene expression. 
As individual larvae are too small to generate sufficient RNA for bulk RNA-seq analysis, 
40 larvae were pooled from each clutch (i.e. a total of 480 larvae were consumed in this 
experiment). Larvae were cooled on ice for anaesthesia before their aqueous medium 
was replaced with 400 L of Invitrogen RNAlaterTM Stabilization Solution (Thermo 
Fisher Scientific, Waltham, MA, USA) and then kept at 4°C for 24 hours before storage 
at -80°C until lysis for total RNA extraction (below). 
 
Total RNA was extracted from pooled larvae using the mirVanaTM miRNA isolation 
Kit (Ambion, Life Technologies, Thermo Fisher Scientific, Waltham, MA, USA). 
DNase treatment was performed on RNA to remove remaining genomic DNA using the 
DNA-freeTM Kit (Ambion, Life Technologies, Thermo Fisher Scientific, Waltham, MA, 
USA). Purified total RNA was then delivered to the Genomics Facility at the South 
Australian Health and Medical Research Institute (SAHMRI, Adelaide, Australia) for 
RNA sequencing. Demultiplexed libraries were provided by the sequencing centre at 
SAHMRI as 75 bp single-end reads, after using polyA amplification. All libraries were 
sequenced to a minimum depth of 30 million reads, across two NextSeq lanes which 
were subsequently merged. The data has been deposited in NCBI Gene Expression 
Omnibus (GEO) database [55] and are accessible through GEO accession number 
GSE148631. 
 
Transcriptome data treatment and DE gene identification 
Reads from each sample were trimmed using AdapterRemoval [56] setting a minimum 
quality of 30 and a minimum length of 35. Trimmed reads were aligned to the Danio 
rerio genome Ensembl Release 96 (GRCz11) using STAR v2.5.3a [57], and the aligned 
reads were assigned to each gene using featureCount [58], specifying that only unique 
alignments which strictly overlapped exonic regions were counted. The 19,396 genes 
that received more than 1 count per million reads (CPM) in at least 6 samples, were 
retained for further analysis. The remaining 12,661 genes were discarded as undetectable 
genes, giving library sizes ranging between 44,498,373 and 52,779,608 reads. A design 
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matrix was specified with an intercept for each pair and with genotype as the common 
difference. An initial Differential Gene Expression (DE) analysis was then performed 
using the glmLRT method as implemented in edgeR [59, 60]. The 5000 lowest ranked 
genes from this analysis (i.e. with the highest p-value) were selected as unchanged 
negative control genes and passed to RUVg [61], setting k = 1. After RUV treatment, 
the same design matrix with the addition of the offset term from RUV was used to 
perform a new DE analysis. A FDR cutoff of 0.01 was then used to identify a gene as 
differentially expressed (DE). 
  
 
Goseq analysis and Gene set enrichment analysis (GSEA) 
The mappings linking zebrafish genes to Hallmark/KEGG pathways, Wiki pathways and 
GO terms were achieved by msigdbr [19], rWikipathways [62] and org.Dr.eg [63] 
respectively. To look for enrichment of gene-sets within our defined set of DE genes, a 
Probability Weighting Function (PWF) was calculated based on the set DE genes using 
gene lengths as the bias data. Then goseq analysis [64] was performed using this PWF 
and gene-sets were considered as significantly enriched in the set of DE genes using a 
FDR threshold of 0.05.  
 
In order to look at the more complete list of all expressed genes, we then used Gene Set 
Enrichment Analysis (GSEA, [65]) as implemented in the fgsea [66] package. A ranked 
list was formed using sign(log2FC) * (-log10PValue) as the ranking statistic and the same 
gene-sets as for goseq were tested, using n = 105 iterations. A Bonferroni corrected p-
value < 0.05 was used to identify significantly-altered pathways. Pathway Diagrams for 
detected KEGG pathways were plotted by pathview [26] using log2FC . 
 
Iron responsive elements (IRE) enrichment analysis 
Genes containing iron responsive elements (IRE) in either their 5’ or 3’ UTRs were 
identified using searching for IREs (SIREs) [67]. Both goseq [64] and GSEA were 
performed to detect the enrichments of the genes containing IREs in their 5’UTR or 
3’UTR respectively. A FDR and a Bonferroni corrected p-value < 0.05 were used to 




CPM: Count per million reads 
DE: Differentially expressed 
Dpf: Day post fertilization 
ECM: Extracellular matrix 
EOfAD: Early-onset familial Alzheimer’s disease 
ETC: Electron transport chain 
FDR: False discovery rate 
GO: Gene Ontology 
GSEA: Gene set enrichment analysis 
IRE: Iron responsive elements 
MCI: Mild cognitive impairment 
MCM: Minichromosome maintenance protein complex 
NICD: Notch intracellular domain 
OX PHOS: Oxidative phosphorylation 
PWF: Probability Weighting Function 
qPCRs: Quantitative PCRs 
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4.3 Supplementary data 
4.3.1 Supplementary data 1: DE gene list 
Ensembl Gene ID Gene Name log2FC log2CPM P-Value FDR Rank statistics 
ENSDARG00000039682 si:ch211-121a2.2 -3.195357333 1.235549038 1.02E-19 1.97E-15 -18.99272019 
ENSDARG00000093024 si:ch211-213a13.2 1.024518193 2.754478867 4.23E-17 4.11E-13 16.37330497 
ENSDARG00000040781 sult3st4 2.138069863 0.454818767 8.44E-16 5.46E-12 15.07353918 
ENSDARG00000077068 si:ch211-11p18.6 -0.864354589 3.602471014 1.20E-15 5.80E-12 -14.92244699 
ENSDARG00000099511 CABZ01034698.2 1.543570078 1.421034013 2.11E-15 8.19E-12 14.67552448 
ENSDARG00000079589 si:dkeyp-73d8.6 1.443060699 1.352980164 2.62E-15 8.48E-12 14.58124549 
ENSDARG00000070011 si:ch211-167j6.4 -1.908088181 0.767768566 1.91E-14 5.29E-11 -13.7187776 
ENSDARG00000078995 tex11 1.597973265 0.050168575 2.32E-13 5.63E-10 12.63444414 
ENSDARG00000091150 mki67 -0.808754804 4.228953545 3.96E-13 8.53E-10 -12.40271393 
ENSDARG00000103849 mdh1ab -0.997592103 4.619204283 7.00E-13 1.36E-09 -12.15487997 
ENSDARG00000057128 hadhaa -0.75378883 4.163723502 1.32E-12 2.32E-09 -11.88042279 
ENSDARG00000090600 si:ch211-213a13.1 -0.976482451 3.064074262 4.45E-12 7.20E-09 -11.35129904 
ENSDARG00000055618 acta1b -1.006861962 8.137870503 6.27E-12 9.35E-09 -11.20292308 
ENSDARG00000097973 si:ch1073-190k2.1 -3.505690905 0.796352288 7.11E-12 9.85E-09 -11.14811482 
ENSDARG00000002991 cep135 1.421043604 3.223492835 1.05E-11 1.35E-08 10.97994542 
ENSDARG00000101331 tekt1 1.777045206 1.441434581 2.59E-11 3.13E-08 10.58742462 
ENSDARG00000039266 rbm25a 0.791212475 4.697857144 8.63E-11 9.84E-08 10.06407143 
ENSDARG00000057911 zgc:86709 -0.829827607 3.052393611 2.11E-10 2.28E-07 -9.675355646 
ENSDARG00000052905 zgc:165423 -0.871362117 5.364876864 2.26E-10 2.31E-07 -9.64516326 
ENSDARG00000100584 ccdc40 0.936664349 2.876472155 2.54E-10 2.36E-07 9.594642588 
ENSDARG00000055644 prss60.2 -0.993640356 2.054457212 2.67E-10 2.36E-07 -9.573680566 
ENSDARG00000099470 muc5.3 -0.836508789 5.136950151 2.67E-10 2.36E-07 -9.572796952 
ENSDARG00000053558 rtkn2a 1.631287552 1.380797037 4.56E-10 3.84E-07 9.341240402 
ENSDARG00000087046 si:ch211-222k6.2 -0.99726875 1.384573132 1.14E-09 9.23E-07 -8.942485719 
ENSDARG00000098754 si:ch211-156p11.1 1.190011799 0.592942087 1.23E-09 9.47E-07 8.910371332 
ENSDARG00000044976 krt93 -0.70878209 2.99783341 1.27E-09 9.47E-07 -8.896342655 
ENSDARG00000115545 clec19a -1.084395275 1.641603661 2.09E-09 1.50E-06 -8.679414234 
ENSDARG00000103019 gstp2 -1.270901121 2.320425211 2.44E-09 1.69E-06 -8.612332837 
ENSDARG00000023861 dnase1l1l 0.718054558 3.960688269 2.84E-09 1.90E-06 8.547159082 
ENSDARG00000045089 si:ch211-270n8.1 -1.4986985 0.57880414 3.88E-09 2.51E-06 -8.411536327 
ENSDARG00000074531 spag9a 0.556940205 5.063666392 6.00E-09 3.76E-06 8.221646887 
ENSDARG00000060622 si:ch73-14h1.2 -0.800851248 4.222779945 7.60E-09 4.60E-06 -8.119394682 
ENSDARG00000026726 anxa1a -0.911330132 6.883579699 1.62E-08 9.50E-06 -7.791620686 
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ENSDARG00000104899 CR931813.2 0.797276959 2.222911283 2.28E-08 1.30E-05 7.64203466 
ENSDARG00000093699 si:ch73-27e22.4 -1.11597696 0.776462666 2.83E-08 1.57E-05 -7.547667417 
ENSDARG00000042708 tuba8l -0.595215461 6.540256941 3.46E-08 1.86E-05 -7.461509512 
ENSDARG00000054753 col10a1a -0.86519819 5.992846267 4.17E-08 2.19E-05 -7.379646882 
ENSDARG00000002192 aspn -0.796058659 3.202490712 4.47E-08 2.28E-05 -7.350010695 
ENSDARG00000111240 dhrs13a.2 -0.69005071 3.063465613 5.08E-08 2.53E-05 -7.293895761 
ENSDARG00000095082 ITLN1 (1 of many) 1.221736969 2.517845631 6.37E-08 3.09E-05 7.19584603 
ENSDARG00000090946 si:zfos-364h11.2 -1.064785007 2.008884056 1.25E-07 5.92E-05 -6.902753457 
ENSDARG00000061196 emilin2a -0.773607167 4.174377486 1.65E-07 7.63E-05 -6.782149367 
ENSDARG00000077620 cdca7a -1.020105533 1.69086497 1.75E-07 7.91E-05 -6.755867887 
ENSDARG00000074844 CABZ01061495.1 -0.58476051 3.508221205 1.93E-07 8.35E-05 -6.715442107 
ENSDARG00000002403 nusap1 -0.795198538 2.050108206 1.94E-07 8.35E-05 -6.713068228 
ENSDARG00000007377 odc1 -0.672830165 2.791019939 2.18E-07 9.16E-05 -6.662173734 
ENSDARG00000095643 si:dkey-253d23.3 -1.044948874 2.061783969 2.22E-07 9.16E-05 -6.653924496 
ENSDARG00000016771 tfa -0.671676383 8.554705029 2.47E-07 0.000100008 -6.606437353 
ENSDARG00000097080 si:ch73-181m17.1 -1.65835602 2.097257516 2.63E-07 0.000104035 -6.580335285 
ENSDARG00000040004 si:ch211-244a23.1 -0.692229586 2.752512157 2.86E-07 0.000111123 -6.542939515 
ENSDARG00000053315 tmprss3a -1.070024307 1.929990633 3.35E-07 0.000127454 -6.474789887 
ENSDARG00000040944 ntd5 -0.468030637 4.548711917 4.30E-07 0.000159063 -6.366749628 
ENSDARG00000054292 si:ch211-14a17.11 -0.807462069 2.276822992 4.48E-07 0.000159063 -6.34827596 
ENSDARG00000115701 crygm2d9 0.599624682 6.269020854 4.49E-07 0.000159063 6.348077012 
ENSDARG00000114577 si:dkey-159n16.2 0.633189257 4.05784447 4.51E-07 0.000159063 6.34577921 
ENSDARG00000014803 cryba1l2 0.519039708 5.570475475 5.55E-07 0.000191717 6.256040925 
ENSDARG00000019995 bmp4 0.524759243 3.440304714 5.63E-07 0.000191717 6.249176993 
ENSDARG00000042018 fhl2a -0.46009233 4.931139513 6.33E-07 0.000211738 -6.198485901 
ENSDARG00000035700 zgc:101664 -0.78608191 1.547410463 7.22E-07 0.000237207 -6.141733201 
ENSDARG00000040192 nenf -0.983845052 1.784594465 7.50E-07 0.000242531 -6.124794204 
ENSDARG00000069817 crygm2d17 0.802494829 7.428088002 8.22E-07 0.000260853 6.08488259 
ENSDARG00000052122 rag1 -0.812963532 2.882403277 8.42E-07 0.000260853 -6.074611713 
ENSDARG00000062152 chaf1a -0.589901411 3.40881466 8.47E-07 0.000260853 -6.071975734 
ENSDARG00000104600 CABZ01070527.1 0.75093988 4.101177283 9.34E-07 0.000283074 6.029632389 
ENSDARG00000071347 aftphb 0.566251958 3.348876842 9.64E-07 0.000287552 6.016082274 
ENSDARG00000092243 BX005065.1 3.110361261 0.767626336 9.82E-07 0.000288531 6.007975389 
ENSDARG00000100311 si:dkey-165e24.1 -1.115812313 1.185592335 1.06E-06 0.000307334 -5.974026734 
ENSDARG00000094210 fthl31 0.721720727 4.52370205 1.21E-06 0.000340598 5.917673361 
ENSDARG00000071604 si:ch211-156p11.1 -0.750495506 1.643388314 1.21E-06 0.000340598 -5.916620921 
ENSDARG00000039422 fuom -0.923275979 0.393504689 1.43E-06 0.000397583 -5.843186044 
ENSDARG00000056386 TMC1 -1.284697882 0.500523184 1.49E-06 0.000405801 -5.82814103 
ENSDARG00000104403 oscp1a 1.09236325 0.393697183 1.56E-06 0.00042042 5.806695993 
ENSDARG00000067520 zgc:158482 -0.621573732 2.832616145 1.74E-06 0.000457334 -5.758632634 
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ENSDARG00000052779 zgc:153932 -1.039601293 3.871096157 1.74E-06 0.000457334 -5.758247353 
ENSDARG00000092890 si:ch73-44m9.5 3.475227963 1.38806443 1.81E-06 0.000467173 5.743173218 
ENSDARG00000093997 si:dkey-9i23.15 -0.640748862 2.046458609 1.91E-06 0.00048633 -5.719967404 
ENSDARG00000024488 top2a -0.689341995 3.45397341 2.01E-06 0.000506099 -5.696986266 
ENSDARG00000038668 gbp1 -0.915790111 1.995418233 2.15E-06 0.000528743 -5.667701139 
ENSDARG00000039051 hhatla -0.504417271 6.919728817 2.18E-06 0.000528743 -5.661969186 
ENSDARG00000071543 si:dkey-42i9.7 1.307596316 0.755250411 2.18E-06 0.000528743 5.661377194 
ENSDARG00000086917 crygm2d2 0.533488034 8.871350006 2.34E-06 0.000559655 5.631306798 
ENSDARG00000024278 adh8b -0.699520736 5.923896572 2.41E-06 0.000571005 -5.617258462 
ENSDARG00000105183 CT009487.2 0.891864324 2.831933755 2.46E-06 0.000575673 5.608458016 
ENSDARG00000062618 kcnj12b -0.577582883 3.408560592 2.61E-06 0.00060271 -5.583324669 
ENSDARG00000090847 si:ch211-209l18.4 -0.905488007 2.617969336 2.64E-06 0.000603548 -5.577581568 
ENSDARG00000024847 col5a2b -0.823672363 2.875421324 2.72E-06 0.000613074 -5.565700708 
ENSDARG00000093628 s100a11 -0.735886765 2.519790467 2.84E-06 0.000630335 -5.547264023 
ENSDARG00000117693 CR318673.1 0.630086321 3.096319409 2.86E-06 0.000630335 5.543657852 
ENSDARG00000015998 wdhd1 -0.780646227 1.011028119 3.01E-06 0.000655056 -5.52204392 
ENSDARG00000053323 zgc:112285 0.552984827 6.528180422 3.16E-06 0.000680667 5.500535173 
ENSDARG00000014805 fhl5 -0.966360641 1.129981443 3.47E-06 0.000732596 -5.460239767 
ENSDARG00000069846 zgc:162944 -0.576344774 4.013066855 3.47E-06 0.000732596 -5.459059645 
ENSDARG00000055270 
si:ch1073-
358c10.1 -0.849574258 1.415830401 3.52E-06 0.000733341 -5.453922973 
ENSDARG00000096905 si:ch73-23l24.1 -0.78693341 1.628948068 4.29E-06 0.00088487 -5.367704884 
ENSDARG00000058285 cpt1b -0.798461743 3.016533095 4.36E-06 0.00089104 -5.360091607 
ENSDARG00000036139 lctla 0.472389158 5.821464535 4.49E-06 0.000906347 5.348146365 
ENSDARG00000030215 matn1 -0.562516104 5.954454526 4.88E-06 0.000975883 -5.311542474 
ENSDARG00000074546 si:ch211-213a13.2 -0.720514193 1.68968825 4.93E-06 0.000976143 -5.306972728 
ENSDARG00000009844 dusp23a -0.475972548 4.253820595 5.19E-06 0.001008038 -5.28512206 
ENSDARG00000078419 filip1a -1.006270345 0.606602049 5.20E-06 0.001008038 -5.284235076 
ENSDARG00000069559 muc13a -0.541359769 4.559822655 5.29E-06 0.001015369 -5.276766854 
ENSDARG00000033757 ncaph2 -0.94369771 0.565800288 5.74E-06 0.0010921 -5.240849629 
ENSDARG00000052734 hmgcra -0.87452332 3.414099804 5.95E-06 0.001120243 -5.225562618 
ENSDARG00000095615 si:dkeyp-86h10.3 -0.479758572 3.248050203 6.54E-06 0.001217807 -5.18417276 
ENSDARG00000038716 casq1a -0.779606314 5.862824768 6.59E-06 0.001217807 -5.180944441 
ENSDARG00000040306 otomp -0.443774273 4.184549758 6.86E-06 0.001254837 -5.163818994 
ENSDARG00000104823 znf648 -0.827036777 3.962059604 7.06E-06 0.001279242 -5.151375846 
ENSDARG00000094466 si:ch73-199e17.1 -0.573899315 2.547311741 8.02E-06 0.00143975 -5.096001466 
ENSDARG00000101495 ugt5b2 -1.220029149 1.350745811 8.35E-06 0.00148559 -5.078386838 
ENSDARG00000058966 zgc:112332 0.837936727 3.402575014 8.65E-06 0.001524377 5.063227097 
ENSDARG00000037613 lgals8b 0.679196419 1.279105177 9.32E-06 0.001628137 5.030698219 
ENSDARG00000101180 mcm7 0.484027692 6.247258419 9.81E-06 0.001689977 5.008208849 
ENSDARG00000105443 si:ch211-63p21.8 0.718399505 3.432737805 9.85E-06 0.001689977 5.006752922 
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ENSDARG00000077372 tfr1b -0.531823196 4.874578002 1.01E-05 0.001726522 -4.993635259 
ENSDARG00000070140 RETSAT 0.838124313 0.363779272 1.06E-05 0.001774807 4.976540887 
ENSDARG00000028664 ahsa1a -0.653234178 1.87197908 1.06E-05 0.001774807 -4.974102965 
ENSDARG00000074749 abca12 -0.454219232 6.486104629 1.09E-05 0.001804261 -4.963227038 
ENSDARG00000052039 caspb -0.589137419 2.783999382 1.11E-05 0.001824512 -4.954683508 
ENSDARG00000077360 fthl30 -0.845820443 1.35832497 1.15E-05 0.001871454 -4.939985991 
ENSDARG00000003311 pank2 0.43819455 6.752264535 1.19E-05 0.001925239 4.924046313 
ENSDARG00000086103 slc37a1 -0.579442767 2.395649313 1.30E-05 0.002082787 -4.886282032 
ENSDARG00000024204 mcm3 -0.782118733 2.849975251 1.34E-05 0.002129828 -4.873007717 
ENSDARG00000052000 cav2 0.433401574 4.060659341 1.36E-05 0.002139985 4.867396287 
ENSDARG00000073720 si:dkey-250l23.4 0.609534896 2.736974186 1.37E-05 0.002149592 4.861934549 
ENSDARG00000019507 mcm5 -0.925367859 2.847134848 1.50E-05 0.00232581 -4.824227839 
ENSDARG00000052113 hexa 0.463508612 4.461687782 1.53E-05 0.002355283 4.81529856 
ENSDARG00000019752 rom1a 0.434083015 4.635254278 1.55E-05 0.002369383 4.809273258 
ENSDARG00000079145 CABZ01077217.1 -1.036107287 1.398289198 1.58E-05 0.002401764 -4.799971919 
ENSDARG00000052288 zmp:0000000634 -1.330947602 -0.219842759 1.64E-05 0.002470597 -4.784320635 
ENSDARG00000052057 pcolceb -0.604547676 2.224035147 1.66E-05 0.002470941 -4.780906373 
ENSDARG00000052437 mia -0.693337732 2.122799642 1.74E-05 0.002555561 -4.760494573 
ENSDARG00000114670 ube2c -1.026576353 0.2743903 1.75E-05 0.002555561 -4.758002832 
ENSDARG00000102050 MCOLN3 -0.920846017 0.748878872 1.75E-05 0.002555561 -4.756374231 
ENSDARG00000021086 znf367 -0.770521938 0.556173729 1.91E-05 0.00277151 -4.717890884 
ENSDARG00000029058 rbbp4 -0.558348587 3.508495036 1.99E-05 0.002819741 -4.700788661 
ENSDARG00000075707 nid2a -0.479884109 4.350436462 1.99E-05 0.002819741 -4.700501036 
ENSDARG00000099355 BX890548.1 0.45130522 3.555172292 2.00E-05 0.002819741 4.699991208 
ENSDARG00000102798 mcm2 -0.66867466 3.600919282 2.01E-05 0.002819741 -4.696808587 
ENSDARG00000026771 tmem41ab -0.666128118 3.530667336 2.02E-05 0.002819741 -4.694488102 
ENSDARG00000087164 crygm2d4 0.48382435 7.829751638 2.06E-05 0.002842833 4.686677563 
ENSDARG00000038156 dusp11 -0.553300866 2.778590783 2.07E-05 0.002842833 -4.684741772 
ENSDARG00000091918 BX548073.1 0.812541603 0.508383523 2.09E-05 0.002852079 4.680262293 
ENSDARG00000104721 si:dkey-203a12.9 -1.009461717 0.646226571 2.14E-05 0.002895781 -4.669609164 
ENSDARG00000062727 cep290 0.43088837 6.052947754 2.15E-05 0.002895781 4.66758394 
ENSDARG00000070239 knl1 -0.801767444 1.318446228 2.23E-05 0.002972651 -4.65211634 
ENSDARG00000037845 col9a3 -0.658972232 6.100689257 2.24E-05 0.002972651 -4.650215325 
ENSDARG00000057074 rpgrb 0.513603171 4.867581488 2.26E-05 0.00298425 4.645303478 
ENSDARG00000030254 cbln9 -0.871377861 1.015030745 2.28E-05 0.00298425 -4.642615194 
ENSDARG00000058533 pole -0.603929278 1.992628356 2.40E-05 0.003130243 -4.618947872 
ENSDARG00000061416 c2cd4a 0.559234714 4.758865837 2.50E-05 0.003208046 4.602541442 
ENSDARG00000038658 cavin4a -0.432620139 5.063362768 2.50E-05 0.003208046 -4.602494649 
ENSDARG00000103744 hacd1 -0.417952662 5.241863198 2.64E-05 0.003373923 -4.577733376 
ENSDARG00000069093 col2a1a -0.61082304 9.257959447 2.68E-05 0.003396925 -4.571934809 
 130 
ENSDARG00000036239 gatm -0.817409366 6.042497757 2.76E-05 0.00345868 -4.558478556 
ENSDARG00000098950 si:dkeyp-92c9.4 -0.913597935 0.157446222 2.76E-05 0.00345868 -4.558470073 
ENSDARG00000034063 unm_sa911 -0.792175134 1.673333752 2.79E-05 0.003472785 -4.553909672 
ENSDARG00000053502 cryaa 0.457328425 6.95995161 2.85E-05 0.003522545 4.544955988 
ENSDARG00000077029 bub1 -0.674879796 1.277637322 2.93E-05 0.00359882 -4.532894968 
ENSDARG00000026759 ldlrb -0.481905048 3.332563054 2.98E-05 0.003637537 -4.525507663 
ENSDARG00000045808 rlbp1b -0.70352991 3.402360079 3.03E-05 0.003673809 -4.518475602 
ENSDARG00000030723 cldn11b 0.414332185 4.000552431 3.12E-05 0.003760725 4.505614721 
ENSDARG00000021404 zgc:110319 0.404499666 4.276119365 3.31E-05 0.003965078 4.479945393 
ENSDARG00000103277 cyp24a1 0.420580436 8.36185793 3.34E-05 0.003979636 4.475681264 
ENSDARG00000038281 natd1 0.426554579 5.256276176 3.38E-05 0.003994797 4.471283722 
ENSDARG00000014041 smarcad1a -0.683564654 1.579195159 3.40E-05 0.003994797 -4.468733499 
ENSDARG00000098591 tubb2b -0.427661245 6.976508032 3.57E-05 0.004173969 -4.446760348 
ENSDARG00000062817 crym -0.80851753 1.487359795 3.59E-05 0.004173969 -4.444446468 
ENSDARG00000040041 mcm4 -0.590566707 3.977590377 3.74E-05 0.00429947 -4.426573573 
ENSDARG00000023587 kcnk5a -0.830636307 1.508119253 3.75E-05 0.00429947 -4.426410572 
ENSDARG00000105511 BX248521.2 0.921371001 1.116761537 3.88E-05 0.004423142 4.411532327 
ENSDARG00000096920 si:zfos-375h5.1 0.459151211 3.354551175 3.91E-05 0.004437406 4.407586902 
ENSDARG00000094077 si:dkey-21e2.16 0.554659101 2.80155962 3.96E-05 0.004470649 4.401813153 
ENSDARG00000010948 kif11 -0.641351805 2.053896762 4.13E-05 0.004635277 -4.383590391 
ENSDARG00000026629 gmds -0.408708627 4.373027833 4.21E-05 0.004695769 -4.375456182 
ENSDARG00000100954 wars -0.544076214 2.328006465 4.34E-05 0.004811284 -4.362413118 
ENSDARG00000071083 si:dkeyp-34c12.1 0.599143599 2.865601086 4.48E-05 0.004935496 4.348868666 
ENSDARG00000103754 aspm -0.594377687 2.718018205 4.58E-05 0.005023664 -4.338718289 
ENSDARG00000004748 zgc:100868 -0.524062321 5.482403449 4.63E-05 0.005047765 -4.334193048 
ENSDARG00000093323 si:ch211-114l13.1 0.628793996 2.25132992 4.88E-05 0.005272815 4.311541766 
ENSDARG00000068431 si:ch211-195h23.3 1.469329276 4.461700867 4.89E-05 0.005272815 4.31039711 
ENSDARG00000055753 suv39h1b -0.799687991 0.251437576 4.94E-05 0.005276249 -4.306408584 
ENSDARG00000052348 smarca5 -0.415370117 4.608576662 4.95E-05 0.005276249 -4.305315526 
ENSDARG00000055314 mcmbp -0.433850967 3.612137046 5.00E-05 0.005300081 -4.300978612 
ENSDARG00000073699 col9a1a -0.443331149 6.062570951 5.03E-05 0.005301124 -4.298526385 
ENSDARG00000092033 si:dkey-239h2.3 0.404465442 6.004973016 5.46E-05 0.005720189 4.263130053 
ENSDARG00000097825 BX465227.1 0.434870817 3.215065311 5.68E-05 0.005892225 4.245844891 
ENSDARG00000041295 lim2.5 0.462360561 4.792372145 5.72E-05 0.005892225 4.242645521 
ENSDARG00000101670 kntc1 -0.638677789 1.858140436 5.73E-05 0.005892225 -4.242140101 
ENSDARG00000079347 zgc:194659 0.582281571 5.341517537 5.75E-05 0.005892225 4.240428608 
ENSDARG00000096988 CR589944.1 0.977171665 1.909412314 5.77E-05 0.005892225 4.238679264 
ENSDARG00000110961 zgc:110045 0.575023831 3.510295679 5.89E-05 0.005911272 4.230205235 
ENSDARG00000029406 h2afx -0.751857654 1.040403266 5.91E-05 0.005911272 -4.228456946 
ENSDARG00000014179 pfkma -0.415850527 5.937842326 5.92E-05 0.005911272 -4.227388574 
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ENSDARG00000079245 si:dkey-73p2.2 -0.990247659 2.868716424 5.96E-05 0.005911272 -4.224478313 
ENSDARG00000037402 lim2.3 0.373060962 5.144101081 5.98E-05 0.005911272 4.223492093 
ENSDARG00000042876 abracl -0.499141376 2.994246545 6.01E-05 0.005911272 -4.220858565 
ENSDARG00000063195 pxk 0.375150905 6.027453402 6.05E-05 0.005911272 4.218527802 
ENSDARG00000011094 ccna2 -0.747639605 1.451212255 6.06E-05 0.005911272 -4.217779277 
ENSDARG00000002986 gda -0.510740933 4.174478014 6.06E-05 0.005911272 -4.217178153 
ENSDARG00000091260 mylk4a -0.445329476 4.814196135 6.17E-05 0.00597961 -4.210009332 
ENSDARG00000093494 si:ch211-217k17.9 -0.55064334 3.785132109 6.24E-05 0.006014323 -4.20496645 
ENSDARG00000077403 col8a1a -0.692800371 2.36446439 6.26E-05 0.006014323 -4.203174075 
ENSDARG00000044685 nr0b2a 0.715383776 4.781100335 6.45E-05 0.006159909 4.190641812 
ENSDARG00000057683 mcm6 -0.766793 3.161765769 6.54E-05 0.006218099 -4.1844244 
ENSDARG00000095147 krt96 0.683397345 5.212867833 6.72E-05 0.006358072 4.172632896 
ENSDARG00000053068 cyp8b1 -0.642855268 3.19002589 6.95E-05 0.006547502 -4.157769333 
ENSDARG00000004232 dlb -0.521416038 2.483284408 7.04E-05 0.006594415 -4.15256553 
ENSDARG00000062702 ankmy1 0.788949229 0.697934556 7.62E-05 0.007087448 4.118195776 
ENSDARG00000036832 cyt1l -0.461112249 8.226281012 7.64E-05 0.007087448 -4.117075994 
ENSDARG00000051880 kcnj11 -0.617937174 1.986641382 8.29E-05 0.007652435 -4.081693215 
ENSDARG00000008982 casq2 -0.393529917 5.079445292 8.52E-05 0.007832735 -4.069399752 
ENSDARG00000076830 si:dkey-65b12.6 -0.788841214 2.531839128 8.56E-05 0.007832735 -4.067462891 
ENSDARG00000051879 abcc8 0.387248666 5.109168371 8.77E-05 0.007966141 4.057246933 
ENSDARG00000011072 ddx11 -0.694392704 0.69733658 8.79E-05 0.007966141 -4.056050399 
ENSDARG00000095048 si:dkey-250k15.7 0.574092494 2.015510223 8.91E-05 0.00804196 4.049911799 
ENSDARG00000090232 clpb 0.41586575 5.393156067 9.13E-05 0.008200855 4.039399282 
ENSDARG00000099873 zgc:163083 -0.716395363 1.083635739 9.23E-05 0.008246957 -4.034958705 
ENSDARG00000093402 si:dkey-286j17.4 -1.094567707 2.222106568 9.27E-05 0.008248745 -4.032867782 
ENSDARG00000038066 kpna2 -0.636640614 2.02478688 9.50E-05 0.008417618 -4.022078852 
ENSDARG00000062943 taco1 -0.622466487 2.268344237 9.85E-05 0.008681344 -4.006702511 
ENSDARG00000042285 atp8b3 -0.521477384 2.264896863 9.98E-05 0.008759846 -4.000823454 
ENSDARG00000054746 uggt1 -0.461280339 3.760335472 0.00010353 0.009045524 -3.984925475 
ENSDARG00000087994 si:ch211-114c17.1 0.610780904 2.59634886 0.00010598 0.0092178 3.974780053 
ENSDARG00000078425 oat -0.579462651 5.409791643 0.00010836 0.009350453 -3.965123832 
ENSDARG00000035018 thy1 -0.50665046 2.6239244 0.00010847 0.009350453 -3.964697022 
ENSDARG00000005462 kif4 -0.593412791 2.055927611 0.0001119 0.009603498 -3.951174296 
ENSDARG00000100915 si:ch211-255f4.7 0.42801666 3.737811127 0.00011529 0.009835525 3.938204603 









Rank statistics uses sign(log2FC) * (-log10PValue). 
Only genes with a FDR less than 0.01 are shown. 
"FC" indicates fold change. 
"CPM" indicates counts per million. 
Positive values under "log2FC" indicate increased expression in the mutant. 
Negative values under "log2FC" indicate decreased expression in the mutant. 
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4.3.2 Supplementary data 2: qPCR validation of RNA-seq data 
 
Supplementary data 2: qPCR validation of RNA-seq data 
 
To support the accuracy and reliability of RNA-seq data, we performed relative standard curve 
quantitative PCRs (qPCRs) on four of the most statistically significantly DE genes with a 
relatively large fold-change in expression. Also, qPCRs were performed on three of the 
significantly changed genes identified in GO iron ion transport to confirm these results. The 




Relative standard curve quantitative PCR 
1000 ng of the total RNA from each sample remaining after RNA-seq was used to synthesise 
20 μL of first-strand cDNA by reverse transcription (SuperScript III kit, Invitrogen, Camarillo, 
California, USA). Standard curves were generated using a dilution series having 40 ng, 20 ng, 
10 ng and 5 ng of wild type cDNA per reaction. Each 25 μL qPCR reaction contained 20 ng of 
cDNA, 0.2 μM of each PCR primer and Power SYBR green master mix PCR solution (Applied 
Biosystems, Thermo Fisher Scientific Inc., Waltham, MA, USA). The qPCR was performed 
on an ABI 7000 Sequence Detection System (Applied Biosystems) using a 96-well plate. The 
amplification consisted of a holding stage and a cycling stage. The holding stage was performed 
at 50°C for 2 mins and then 95°C for 10 mins, and the cycling stage had 40 cycles of 95°C for 
15 s and 60°C for 1 min. Each reaction was conducted in triplicate. The quantities of amplified 
product in each reaction were determined from the standard curve. The mean value of three 
technical replicates was used to represent the quantity. The quantities of transcripts of the genes 
of interest were then calibrated to the quantities of transcripts of the house-keeping gene rpl13 
for relative quantification, enabling quantitative comparison between samples.  
 
The gene expression measured by RNA-seq analysis was plotted as log2CPM (see the left half 
of the following figures in Results), while the qPCR results were plotted as quantities relative 
to rpl13 (see the right half of the following figures in Results) with P-values calculated using 





Validation of statistically significantly DE genes 
QPCRs were performed on transcripts of the genes CABZ01034698.2, mdh1ab, si:ch211-
11p18.6 and si_ch211-213a13.2. The relative quantifications of CABZ01034698.2, mdh1ab 
and si:ch211-11p18.6 indicated significant differences (P-value < 0.05) between wild type and 
heterozygous mutant larvae with the same regulation direction as observed in RNA-seq. 
However, the relative quantification of si_ch211-213a13.2 was different from the RNA-seq 
result, probably due to mis-mapping or misidentification of reads in the RNA-seq analysis. 
Therefore, three of four statistically significantly DE genes identified in RNA-seq were 













Validation of the genes identified in the GO iron ion transport 
The same qPCR approach as above was applied to the genes tfa, tfr1b and fthl31 identified in 
the GO iron ion transport. Only the difference in relative expression level of fthl31 validated 
the RNA-seq result at the statistical significance threshold chosen (P-value < 0.05) in a paired 
t-test. However, although the differences in relative expression levels for tfa and tfr1b did not 
show statistical significance, the relative expression level in each sample generally 
corresponded with the relative log2CPM level in RNA-seq analysis, indicating that the qPCR 
results supported the reliability of the RNA-seq results. Also, detection of statistically 
significantly DE genes by RNA-seq included all the detected genes of the transcriptome in 
estimating variance, while qPCR only examined variation in the gene of interest across samples 












Both the RNA-seq plots and the qPCR plots display obvious variability in gene expression 
within clutches of larvae of the same genotype. For example, although the expression levels of 
fthl31 in wild-type clutches H and I were similar to the expression levels in mutant clutches B 
and D, when analyzed in pairs, the expression levels of fthl31 in the mutants were obviously 
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higher than in the wild-type clutches. In this sense, our paired-mating strategy (Figure 3 of the 




4.3.3 Supplementary data 3: KEGG pathway diagrams 
  
Supplementary data 3: KEGG pathway diagrams 
 
Ten significantly-changed KEGG pathways were identified by GSEA. The KEGG 
diagrams of DNA replication, cell cycle, ECM receptor interaction and oxidative 
phosphorylation are shown in the main paper. The diagrams of the other 6 significantly 
changed KEGG pathways are listed below. Intensity of colour in diagrams represents 
























Chapter 5. Assessing short term spatial working memory 
in heterozygous psen1Q96_K97del zebrafish adults of different 
ages 
5.1 Introduction 
Transcriptome analysis of 7 pdf whole heterozygous psen1Q96_K97del mutant larval 
zebrafish showed changes due to the mutation inconsistent with those identified in 
6-month heterozygous mutant brains, although changes in similar cellular pathways 
were predicted, including oxidative phosphorylation, mitochondrial function, 
lysosomal acidification and iron ion transport. It is likely that some gene expression 
changes seen in 6-month-old mutant brains required time to develop and so are not 
seen in larvae (e.g. iron regulatory element-containing transcript abundance 
changes). Also, a greater number of tissue types is found in whole larvae than in 
adult brains. In addition, gene expression levels showed obvious variability 
between larval clutches of the same genotype as, indeed, was seen for gene 
expression in brains in Chapter 2 and this can make it difficult to identify a 
selection of gene expression changes to represent the pathological genetic state of 
EOfAD. Therefore, it did not appear viable to use mutant zebrafish larvae for drug 
screening through the assessment of gene expression states.  
Cognitive impairment is a major clinical symptom of AD. Zebrafish larvae also 
show behavioural responses to drugs similar to adult zebrafish and other vertebrates 
[1]. Zebrafish larvae show an obvious locomotor response to photic stimuli. They 
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move to a source of light when illumination is reduced, and become transiently 
hyperactive in complete darkness before adopting a resting state [2]. Also, the 
influence of lighting on larvae’s locomotion was studied by MacPhail et al., 2009 
[3]. Locomotion was tested in an initial 10-min period of darkness followed by 
either a 40-min period of illumination or darkness. Locomotion in darkness 
(including the initial darkness) initially increased to a maximum at 4 minutes and 
then decreased to a stable low level after 20 minutes, while locomotion during light 
was initially low and gradually increased to a stable, high level after 20 minutes. 
However, when exposed to the stimulation of alternating light and dark periods of 
around 10 minutes each, zebrafish larvae showed obvious changes in locomotor 
activity where they were stably inactive in light but extremely active in darkness. 
These features have been increasingly employed in high-throughput screening for 
neuroactive drugs [4]. To observe whether the behaviour of heterozygous 
psen1Q96_K97del mutant larvae might be useful in drug screening, their response to 
simulation by repeating intervals of 3-min light and 1-min dark, was assessed by 
Morgan Newman (unpublished data). However, no significant differences in 
activity patterns between wild type and mutant larvae were observed. This is not 
surprising as AD is an age-dependent disease, and so cognitive impairment is 
unlikely to occur at very early ages.  
As heterozygous psen1Q96_K97del mutant zebrafish larvae did not show differences 
in behaviour compared to wild type larvae, we sought to observe behavioural 
changes in older, adult zebrafish. As a model of human disease, psen1Q96_K97del 
mutant zebrafish are expected to show equivalent behavioural changes, such as 
decline in memory. As impairments in short-term spatial working memory have 
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been observed in AD patients with moderate dementia using the Corsi block-
trapping test [5], the assessment of an animal model’s short-term spatial working 
memory might reveal progressive decline in cognition. The Free-movement pattern 
(FMP) Y-maze test designed by Cleal et al., 2020 [6] investigates animals’ search 
strategies by recording direction choices (left, L, or right, R) during an hour of free 
exploration. Impacts on working memory can be assessed by quantifying 
differences in “alternation tetragrams” (LRLR and RLRL), which are the dominant 
search strategy used in vertebrates (see details in section 1.8). Therefore, as part of 
an initial attempt to investigate behavioural differences in adult mutant zebrafish 
compared to their wild type siblings, the FMP Y-maze was employed to assess 
working memory by quantification of alternation tetragrams. 
An assessment of alternation tetragrams using the FMP Y-maze was previously 
performed by Jiayu Ruan (an M.Sc. candidate in the ADGL) on heterozygous 
psen1Q96_K97del mutant zebrafish and their wild type siblings at 6, 12, and 24 months 
of age. The 6- and 24-month-old mutant zebrafish did not show any statistically 
significant differences in alternation tetragrams while a slight decrease in 
alternation tetragrams was identified in 12-month-old mutant zebrafish, indicating 
possible impairments of spatial working memory (Figure 5.1, [7]).  
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Figure 5.1. The normalized percentage of alternation tetragrams in zebrafish of A) 
6 months of age, B) 12 months of age and C) 24 months of age (The figures were 
taken from the thesis of Jiayu Ruan [7]). The mean percentages of alternation 
tetragrams are normalized to that of 6-month-old zebrafish. The number in brackets 
indicates the zebrafish numbers used in tests. WT, wild type; MU, mutant.  
However, the limited sample size and the high variability between samples of the 
same genotype in these tests undermined our confidence in the validity of the 
cognitive difference at 12 months. Therefore, for the work described in this chapter, 
we re-performed the assessment of alternation tetragram behaviour in heterozygous 
psen1Q96_K97del mutant adult zebrafish of 6 months, 12 months as well as 24 months 
of age respectively compared to their wild type siblings to investigate changes in 
short-term spatial working memory during adult aging. No statistically significant 
differences in alternation behaviour were identified at any age.  
The sample sizes used in FMP Y-tests exceeded the required n=14/per group, which 
was calculated using effect size [d] =1.2, power=0.8, alpha=0.05 [6, 8]. Therefore, 
the sample sizes should have been sufficiently large to detect differences with 
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statistical significance. The failure to identify differences in alternation behaviour 
at any age may mean that any difference observed previously was artefactual. 
Alternatively, the failure to detect any difference between genotypes may have been 
due to other factors such as increased variability of behaviour e.g. due to 
environmental stressors that were not accounted for. Also, the movement patterns 
of zebrafish might not reflect the search strategy on which the test is based when 
there are long intervals between two Y-maze arm entries due to low activity. In 
addition, some zebrafish seemed to move randomly during the free exploration 
rather than following an alternation search strategy, no matter what genotype they 
were. Therefore, the assessment of short term spatial working memory using the 
FMP Y-maze test probably did not work well and requires further optimizations. It 
might be worth using a training paradigm to detect changes in cognition, such as 
learning ability or long term memory, although such studies are more technically 




5.2.1 Assessment of spatial working memory in 6-month-old heterozygous 
psen1Q96_K97del mutant zebrafish 
A FMP Y-maze test, assessing short-term spatial working memory, was firstly 
performed on the 6-month-old heterozygous psen1Q96_K97del mutant zebrafish and 
their wild type siblings. The zebrafish movement patterns were recorded and then 
analysed as tetragrams, with the tetragrams RLRL and LRLR regarded as 
alternations, which is the main search strategy used by zebrafish [6]. The total 
counts of each tetragram in a 1-hour period of free exploration are plotted in Figure 
5.2A. The alternation tetragrams LRLR and RLRL occurred more frequently for 
both wild type and mutant zebrafish compared to other tetragrams. The percentage 
of alternation tetragrams LRLR and RLRL relative to all tetragrams were plotted in 
six 10-minute bins across the 1-hour period of free exploration (Figure 5.2B). None 
of the bins showed significant differences in the percentage of alternation 
tetragrams between mutant and wild type zebrafish. Also, the percentage of 
alternation tetragrams showed a very large spread between zebrafish of the same 
genotype, indicating there was large variability of individuals in alternation 
behaviour. The overall probabilities of alternations during the 1-hour test was 
plotted in Figure 5.2C, and no significant differences in alternations could be 
observed, which is similar to previous results from analyses by Jiayu Ruan (Figure 
5.1A, [7]). As 6-month-old mutant zebrafish might be too young to show 
impairments in working memory, the FMP Y-maze test was then performed on 
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Figure 5.2. Assessment of alternation tetragrams in 6-month-old heterozygous 
psen1Q96_K97del mutant zebrafish. A) The counts of each tetragram. B) The 
percentage of alternation tetragrams LRLR and RLRL relative to all tetragrams, 
analysed in 10-min bins. C) the overall predicted probability of alternations during 
the 1-hour test. “•” indicates females, “▴” indicates males.  
 
5.2.2 Assessment of spatial working memory in 12-month-old heterozygous 
psen1Q96_K97del mutant zebrafish 
As no differences in alternations could be identified in 6-month-old heterozygous 
psen1Q96_K97del mutant zebrafish, the FMP Y-maze test was then performed on older 
12-month-old mutant zebrafish. In a previous test heterozygous mutant individuals 
had shown a significant decrease in alternations at this age (Figure 5.1B, [7]). Note 
that, due to a malfunction of the lighting timer system in the room where the 
zebrafish were maintained, room lighting was continuously on for several months 
before and during the test period and this may have affected the circadian behaviour 
of the fish and put them under a degree of stress [9].  
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The counts of each tetragram from this study are plotted in Figure 5.3A. The 
alternation tetragrams LRLR and RLRL showed a tendency to be more frequent 
than other tetragrams in both wild type and mutant zebrafish. However, the 
percentage of alternation tetragrams in each 10-min bin (Figure 5.3B) and the 
predicted overall probabilities of alternations (Figure 5.3C) did not show any 
differences between wild type and mutant zebrafish, which is not consistent with 






Figure 5.3. Assessment of alternation tetragrams in 12-month-old heterozygous 
psen1Q96_K97del mutant zebrafish. A) The counts of each tetragram. B) The 
percentage of alternation tetragrams LRLR and RLRL relative to all tetragrams, 
analysed in 10-min bins. C) the overall predicted probability of alternations during 
the 1-hour test. “•” indicates females, “▴” indicates males. 
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5.2.3 Assessment of spatial working memory in 24-month-old heterozygous 
psen1Q96_K97del mutant zebrafish 
Lastly, the FMP Y-maze test was performed on 24-month-old heterozygous 
psen1Q96_K97del mutant zebrafish and their wild type siblings. Similar to the results 
seen in 6-month-old and 12-month-old zebrafish, the alternation tetragrams LRLR 
and RLRL showed a tendency to be more frequent in both wild type and mutant 
zebrafish (Figure 5.4A), while the percentage of alternation tetragrams in each 10-
min bin (Figure 5.4B) and the predicted overall probabilities of alternations 






Figure 5.4. Assessment of alternation tetragrams in 24-month-old heterozygous 
psen1Q96_K97del mutant zebrafish. A) The counts of each tetragram. B) The 
percentage of alternation tetragrams LRLR and RLRL relative to all tetragrams, 
analysed in 10-min bins. C) the overall predicted probability of alternations during 




Animals carrying EOfAD-like mutations, as models of human EOfAD, are 
expected to show similar effects to those seen in human patients. The major clinical 
symptom of AD is progressive impairments in cognition. As zebrafish larvae 
represent a powerful model for drug screening, and also show behavioural 
responses to neuropharmacological treatment similar to adult zebrafish [1], the 
ADGL initially sought to compare the response of heterozygous psen1Q96_K97del 
mutant zebrafish larvae and their wild type siblings to the stimulation of alternating 
light and dark intervals. No differences in swimming patterns could be identified 
(unpublished data, study performed by Morgan Newman). As impairments in short-
term spatial working memory are observed in AD patients with moderate dementia 
[5], and the FMP Y-maze provides a simple, rapid and advanced method for the 
assessment of spatial working memory in zebrafish adults [6], we employed the 
FMP Y-maze to determine whether impairments in spatial working memory could 
be observed in our EOfAD-like zebrafish adults. Previous FMP Y-maze tests done 
by Jiayu Yuan [7] found a slight decrease in FMP Y-maze alternation search 
strategy, (which are positively correlated with working memory), for 12-month-old 
heterozygous psen1Q96_K97del mutant zebrafish compared to their wild type siblings, 
while no changes in alternation search strategy were observed with 6-month-old 
and 24-month-old mutant zebrafish. To ensure the reproducibility of these results, 
the work described in this chapter repeated the FMP Y-maze tests using 
independent zebrafish families. However, no differences in alternations were 
observed between heterozygous psen1Q96_K97del mutant zebrafish and their wild type 
sibling of all three ages, 6 months, 12 months and 24 months. A power calculation 
 158 
using effect size [d] =1.2, power=0.8, alpha=0.05 showed that n=14 was required 
for each sample group [6, 8]. Therefore, the sample sizes used in our behavior tests 
exceeded that requirement and should have been sufficiently large to detect 
differences with statistical significance. 
The failure to identify differences in alternation search strategy may be due to a 
number of factors. There was great variability in movement patterns between 
zebrafish individuals. Although all zebrafish were allowed the same 1-hour period 
of free exploration in the FMP Y-maze with (as far as we know) no differences in 
external influences, zebrafish individuals showed great differences in activity. The 
most active zebrafish could produce approximately 1000 tetragrams, while the most 
inactive fish could only produce approximately 100. Although the alternation 
tetragrams were analysed as percentages of all tetragram types, the relatively 
inactive zebrafish showed long intervals between two consecutive arm entries so 
that their behaviour might not appropriately represent working memory. Moreover, 
a number of zebrafish individuals of either mutant or wild type genotype, showed 
movement behaviour not favouring alternation tetragrams (i.e. all tetragrams had 
similar frequency). It seemed that not all zebrafish performed the alternation search 
strategy in the FMP Y-maze tests, and their movement patterns were more likely to 
be random during the full exploration. As a relatively new method for assessment 
of animals’ spatial working memory, the FMP Y-maze test probably requires more 
experimental data to improve interpretation of its output and to overcome the 
problems of low animal activity and outliner samples, to achieve better 
discrimination between cognitively impaired and normal individuals. Also, the 
assessment of the changes in cognition in AD should not be limited to working 
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memory (the FMP Y-maze test). Other behavioural tests involving training can 
assess long term memory and learning abilities. Although more technically 
complex, these can be employed in future studies if they detect more easily 




Zebrafish families for short term spatial working memory tests 
Three zebrafish families were used for short term spatial working memory tests at 
6 months (31 zebrafish, 16 wild type and 15 mutant), 12 months (32 zebrafish, 17 
wild type and 15 mutant) and 24 months (40 zebrafish, 19 wild type and 21 mutant) 
of age respectively. Each family was generated from a parental heterozygous 
psen1Q96_K97del mutant zebrafish crossed with a wild type zebrafish, resulting in 
approximately half wild type and half mutant genotypes among the progeny. Each 
zebrafish family was raised in the same tank to minimize variable impacts of the 
environment between individuals. 
 
Short term spatial working memory test using Y-maze 
Two zebrafish individuals were collected and isolated for 30 mins before the tests. 
The tests were performed using the Zantiks AD system (Zantiks Ltd., Cambridge, 
UK) having a Y-maze with three identical arms oriented at an angle of 120° relative 
to each other and filled with 1L of aquarium water. A zebrafish to be tested was 
placed in the Y-maze and its movement was recorded for 1 hour. Testing was 
performed between 10:00 am and 3:00 pm to reduce circadian influences. Data was 
outputted as a time series of arm entries and exits, which were then analysed into 
16 overlapping tetragrams. Two tetragrams, LRLR and RLRL, represented 
alternations. Tested zebrafish individuals were then genotyped by PCR with sex 
recorded. To test whether alternation frequency was affected in psen1Q96_K97del 
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mutants, we fitted the data to a generalised linear mixed model (GLMM) using 
Template Model Builder (glmmTMB) [10] specifying a betabinomial variance 
function. The fixed effects were genotype, 10-min interval bins and time (the start 
time of the FMP Y-maze test), and the random factors were fish identity, day 
(zebrafish families were tested over a continuous series of days) and interaction of 
time and day. Tests of significance of the fixed effects were performed by Anova 
using Type II Wald Chi-square tests [11].  
 
Genomic DNA extraction 
Zebrafish were anesthetized using tricaine solution (168μg/mL), and a small tail 
biopsy (a “tail clip”) was then taken from the zebrafish using a surgical blade. 50μL 
of 1.7mg/μL Proteinase K (Sigma-Aldrich, Missouri, USA) in 1xTE buffer was 
used to degrade proteins and release genomic DNA from zebrafish tail clips through 
incubation at 55°C for 3 hours, followed by enzyme inactivation at 95°C for 15 
minutes. Genomic DNAs were then stored at -20°C for the following genotyping 
PCRs.  
 
PCR for genotype determination 
PCRs were performed in 25 μL reactions containing genomic DNA, 0.2 mM of 
each deoxyribonucleotide triphosphate (dNTP, each at a final concentration of 0.2 
mM), 0.4 μM of each PCR primer, and 2.5 unit of GoTaq® DNA polymerase 
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(Promega, Madison, Wisconsin, USA). PCR cycling was performed with 35 cycles 
of a denaturation temperature of 95°C for 30 s, then an appropriate (primer-
dependent) annealing temperature for 30 s and then an extension temperature of 
72°C for 45 s. PCR products were electrophoresed through a 1.5% agarose gel in 
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5.6 Appendix: Primer information for genotyping 
Primers specific to psen1 wild type allele and psen1Q96_K97del mutant allele 
respectively. 
 


















Chapter 6: Generating aspartate codon-substitution and 
Acne Inversa-like mutations in zebrafish psen1 gene 
6.1 Introduction 
EOfAD is autosomal and dominantly inherited [1], and over 200 EOfAD-causative 
mutations have been identified in the major locus, PSEN1 [2]. The PSEN1 protein 
mainly participates in APP cleavage and amyloid- production through its -
secretase activity. However, the involvement of -secretase in EOfAD pathology 
remains controversial, as the effects of EOfAD-causative mutations on -secretase 
activity are variable (see Section 1.4.3). Moreover, EOfAD-causative mutations in 
the PSEN1 gene obey a “fAD reading frame preservation rule” such that they do 
not truncate the open reading frame and maintain production of a mutant transcript 
that encodes a “full-length” protein [3]. Coding sequence-truncating mutations in 
PSEN1 genes do not cause EOfAD but may cause other diseases. A familial form 
of the skin disease Acne Inversa (Hidradenitis Suppurativa) without EOfAD is 
caused by a dominant, frameshift mutation in human PSEN1, P242LfsX11, which 
leads to a premature termination codon and produces mutant transcripts encoding a 
truncated protein [4]. These kinds of non-EOfAD-causative mutations may lead to 
loss of PSEN1 protein function and probably have some similar functional effects 
to some EOfAD-causative mutations, such as reduction of -secretase activity. 
However, these effects will not be sufficient for EOfAD pathology. Current 
transcriptome studies of EOfAD mainly focus on transgenic animal models (see the 
review by Newman et al., 2017 [5]) and the ADGL has now published or submitted 
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for publication a number of papers describing knock-in models of EOfAD-like 
mutations [6-12]. However, many of the changes identified may be irrelevant to 
AD. Therefore, the generation and analysis of non-EOfAD-like mutations in the 
EOfAD genes may help define molecular changes that do not directly induce 
EOfAD pathology (at least by themselves) and can be excluded from set of EOfAD-
specific transcriptional effects.  
Since -secretase activity is an important function of PSEN1, it is important to 
analyse the effects of its loss on brain transcriptomes in comparison to EOfAD-like 
mutations but while maintaining the ability to produce a full-length holoprotein. A 
study of PSEN1 -secretase activity conducted by Wolfe et al., 1999 [13] 
demonstrated that two transmembrane aspartate residues in PSEN1 are critical to 
the -secretase enzyme’s catalytic site, and mutating either aspartate to alanine 
inhibits -secretase activity. Therefore, substitution of either aspartate leads to loss 
of -secretase activity but with, presumably, less effect on other protein properties. 
The generation of a knock-in aspartate codon-substitution mutation model in 
zebrafish would be useful in transcriptome comparisons with EOfAD-like models 
to investigate whether or not loss of -secretase activity itself induces EOfAD-like 
transcriptome effects. 
In the work described in this chapter, I aimed to generate both an Acne Inversa-like 
mutation and an aspartate codon-substitution mutation in the zebrafish model, 
which would help to define the molecular changes caused by truncation of PSEN1 
protein and by loss of -secretase activity. The CRISPR/Cas system (introduced in 
section 1.6) was used for the mutation generation with template DNA included to 
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enable homology-directed repair (HDR). However, due to the low efficiency of 
HDR in zebrafish (partially due to the rapid development of zebrafish embryos), 
the desired HDR-induced mutations were not achieved. Instead, two mutations of 
interest were identified near human the Acne Inversa-equivalent mutation site in 
the zebrafish psen1 gene. Psen1W233fs substitutes three nucleotides with another four, 
resulting in at +1 shift in the reading frame. This frameshift mutation is assumed to 
produce mutant transcripts encoding a truncated protein similar to the human Acne 
Inversa mutation which can be used in future comparative transcriptome studies. 
Another mutation, psen1W233I_T234L, is a substitution of 6 nucleotides but preserves 
the reading frame. The mutant transcript of this mutation encodes a full-length 
protein with a substitution of two amino acids at a membrane transition site, which 
will likely affect protein structure and hydrophobicity. Therefore, this mutation is 
similar to many EOfAD-causative mutations in human PSEN1, and may be used as 




6.2.1 Attempted generation of an aspartate codon-substitution 
mutation in psen1 
The PSEN1 protein possesses two catalytic aspartate residues, both of which are 
critical for its -secretase activity [13]. A mutation substituting one of these 
aspartate codons with a codon for alanine is desirable for the study of the 
involvement of -secretase activity in AD pathology, as it would cause loss of -
secretase activity possibly with minimal impact on other properties of the protein 
and it would preserve the open reading frame similar to EOfAD-causative 
mutations in human PSEN1. Through transcriptome comparison with our EOfAD-
like models, this aspartate codon-substitution model may inform us whether a lack 
of -secretase activity itself can induce similar brain transcriptome changes. As the 
upstream catalytic site aspartate codon is located on an exon-exon boundary, 
mutating this site may affect transcript splicing. Therefore, we attempted to mutate 
the second catalytic site aspartate codon to codon for alanine. To facilitate the 
generation of HDR-induced mutations (the substitution of aspartate with alanine) 
in zebrafish, template oligo DNA was designed [14] and co-injected with the 





Figure 6.1. The design of sgRNA and oligo DNA template for mutation generation 
in psen1 gene. The exon sequence is shown in red, and the oligo DNA sequence is 
underlined. The CRISPR target sequence is highlighted in green and its PAM site 
is highlighted in yellow. The downstream catalytic site aspartate codon and the 
correlated alanine site in the oligo DNA are highlighted in blue.  
 
Ten embryos from each injection session (where ~65 embryos were injected in total) 
were collected for testing using the T7 endonuclease I assay that cleaves double-
stranded DNA at mismatch sites, to detect the efficiency of mutagenesis by the 
CRISPR/Cas12a system alone. The results of T7 endonuclease I assay are shown 
in Figure 6.2. There were no differences between Lane 2 wild type embryos and 
Lane 3 injected embryos 1, suggesting that the first injection did not work well. 
In contrast, two clear cleavage bands of expected sizes were identified in Lane 4 
injected embryos 2, indicating a good CRISPR/Cas12a cleavage efficiency. The 
remaining embryos of this injected clutch were raised until 6 months of age for 
mutation screening.  
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Figure 6.2. T7 endonuclease I assay on injected embryos. The region containing 
the mutation site was first amplified by PCR and was expected to produce a product 
of ~451 bp in size. After the T7 endonuclease I assay, two cleavage bands were 
expected to be produced for DNA from injected embryos having sizes of ~171 bp 
and ~280 bp. Possibly due to polymorphisms in intron sequence included in the 
PCR-amplified region, there were irrelevant bands produced from cleavage by T7 
endonuclease I.  
 
A small tail biopsy was taken from each 6-month-old injected G0 zebrafish 
individual for genotyping by PCRs with either wild type (aspartate-specific primer 
pair) or alanine-specific primer pairs. The genotyping PCR results are shown in 
Figure 6.3. In the tests using the wild type primer pair, all individual samples 
showed a strong, clear band at the expected product size of 181 bp, while in the 
tests using the mutant (alanine-specific) primer pair, only fish 2, 7 and 9 showed a 
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band at approximately 181 bp with different intensities, indicating that these three 
G0 fish possibly possessed the desired Alanine mutation. Fish 1 showed two strong, 
clear bands at larger sizes, and thus probably contained a complex DNA 
rearrangement that included insertion of the DNA template sequence.  
 
Figure 6.3. Genotyping injected zebrafish individuals at 6 months of age using both 
wild type (aspartate-specific) and alanine-specific primer pairs. The expected size 
of the PCR products for both wild type- and mutation-detection (alanine codon 
detection) primer pairs is 181 bp. 
The G0 fish 2, 7 and 9 were subsequently outbred with a wild type zebrafish to 
generate F1 progeny. The F1 progeny were then genotyped at 6 months of age using 
both the wild type- and alanine codon-detection primer pairs, but none of them 
showed a positive signal for alanine codon-detection (results not shown). However, 
PCRs amplifying a region spanning location of the desired mutation were 
performed on F1 progeny (Figure 6.4), and F1 fish 2 and 7 from G0 fish 2 showed 
two strong, clear bands. The higher band indicated the normal genomic sequence, 
which occurred in all samples, while the lower band was novel and so was excised 
from the gel and purified for sequencing characterisation. Sequencing showed that 
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this PCR fragment was smaller than that from wild type fish due to a 134 bp deletion 
spanning approximately half of exon 10 (89 bp) and downstream intronic sequence 
(45 bp).  
 
Figure 6.4. PCR amplification spanning the aspartate codon region in the F1 
progeny of G0 fish 2. The size of the wild type genomic sequence is 451 bp. 
The F1 fish 2 and 7 heterozygous for the 134 bp deletion were mated with each 
other to generate homozygous F2 progeny, in order to investigate the effects of the 
deletion on transcript formation. The F2 progeny were genotyped at 6 months of 
age, and cDNAs for PCRs were derived from one each of a wild type, heterozygous 
and homozygous mutant brains. PCRs were performed on the cDNAs amplifying a 
region spanning exon 8 to exon 11 (Figure 6.5), and the lower band/smaller 
fragment amplified from the homozygous mutant sample was purified from the gel 
and sequenced. The mutant transcripts lack exon 10 (119 bp), resulting in fusion of 
exon 9 sequence to exon 11 sequence and causing a shift in the reading frame 
followed downstream by a premature termination codon.  
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Figure 6.5. PCR amplification of a region of cDNA derived from psen1 transcripts 
spanning exon 8 to exon 11 in a wild type, a heterozygous, and a homozygous 
mutant F2 progeny. The expected size of this region in normal transcripts is 489 bp 
(higher band), while in mutant transcripts lacking exon 10 it is 370 bp (lower band). 
 
The 134 bp deleted region includes the aspartate codon, which we had aimed to 
substitute with an alanine codon. Therefore, this mutation almost certainly causes 
loss of -secretase activity. However, the change in the reading frame caused by 
loss of exon 10 sequence from transcripts mean that, if these transcripts are 
translated, they will produce a truncated protein. This mutation is, therefore, unlike 
EOfAD-causative mutations that follow the “fAD reading frame preservation rule” 
[3]. Nevertheless, the mutation may still find use in identifying any differential 
effects of truncation of the psen1 coding sequence at different positions, e.g. in 
comparison with the psen1K97fs mutation that truncates the coding sequence in exon 
4 or the psen1W233fs mutation described later that truncates the coding sequence in 
exon 7. Interestingly, we did appear to identify the desired aspartate codon-
substitution mutation in DNA from the tail of the injected G0 fish number 7 (see 
Figure 6.3), but none of its progeny carried this mutation. This supports that HDR 
did occur in this zebrafish but not in cells that were included in the germline. Our 
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results support that the reported low efficiency of HDR in zebrafish [15]. Therefore, 
it is possibly inefficient to screen the injected G0 fish for designed HDR-induced 
mutations as these might not enter the germline. Instead, injected G0 fish could be 
crossed with wild type fish to produce F1 progeny to be subsequently genotyped by 
mutation-specific PCR reactions. 
 
6.2.2 Generation of a familial Acne Inversa-like mutation in psen1 
EOfAD-causative mutations in PSEN1 gene follow a “fAD reading frame 
preservation rule” [3]. A dominant frameshift mutation in the human PSEN1 gene, 
P242LfsX11, does not cause EOfAD but leads to a skin disease Acne Inversa 
(Hidradenitis Suppurativa) [4]. This mutation causes production of mutant 
transcripts encoding a truncated protein, which would lack any -secretase activity 
(as it would lack both catalytic aspartate residues). The transcriptome changes 
caused by this mutation do not induce EOfAD pathology but may be included 
among changes identified in EOfAD mutation-like models, e.g. if the latter also 
cause reduction in -secretase activity. The identification of these changes would 
refine our understanding of what transcriptome changes are essential for EOfAD. 
Therefore, I attempted to generate a model of the Acne Inversa mutation in the 
zebrafish psen1 gene through simultaneous injection of CRISPR/Cas9 and a 
plasmid DNA template to direct HDR. The plasmid DNA template may be more 
stable than an oligonucleotide template and give a higher efficiency of HDR [16]. 
The plasmid DNA template was designed to mimic the sequence of human Acne 




Figure 6.6. A region of the plasmid DNA template (around the desired mutation, 
the entire sequence is shown in section 6.5.1). The mutation site is highlighted in 
yellow. The CRISPR target site is highlighted in green. Substituted nucleotides are 
shown in blue. The nucleotides substituted in addition to those at the P codon were 
included to allow specific binding of a PCR primer to the mutated region and to 
give a stop codon at a similar position to that occurring with the P242LfsX11 
mutation of the human PSEN1 gene. 
To increase the efficiency of HDR in zebrafish embryos, 20 μM of the NHEJ 
inhibitor SCR7 was added into the zebrafish embryo culture medium (as suggested 
by Zhang et al., 2018 [16]). Ten embryos from each batch of injected embryos were 
pooled and PCR was used to detect any desired HDR events (Figure 6.7). 
Compared to wild type embryos, after gel electrophoresis of the PCR products, a 
weak band of the expected size occurred in each batch of injections, supporting that 
HDR-induced mutation occurred at some level in the embryos. However, the low 
levels of the desired PCR amplification products indicated that the HDR might be 
at a low frequency. 
 176 
 
Figure 6.7. Genotyping the injected G0 embryos using PCR primer pairs detecting 
either the wild type or Acne Inversa mutation-like sequences. The expected size of 
the region amplified from wild type genomic DNA is 499 bp, and the expected size 
of the region amplified from the desired mutant sequence is 502 bp.  
As discussed above following the attempted aspartate coding mutagenesis, tail 
biopsies from 6-month-old G0 zebrafish were not genotyped with the Acne Inversa-
like mutation-detecting PCR primer pair. Instead, a T7 endonuclease I assay was 
used to screen for G0 fish carrying any mutation at the targeted mutagenesis site. 
This identified cleavage products of the expected sizes (Figure 6.8). Although 
electrophoresis revealed unexpected cleavage products in several samples 
(possibility due to the presence of polymorphisms in the fish DNAs), cleavage 




Figure 6.8. T7 endonuclease I assays on DNA amplified from 6-month-old G0 
zebrafish individuals. The expected size of the PCR amplification product is 623 
bp, while the product sizes after T7 endonuclease I cleavage are expected to be 126 
bp and 461 bp.  
The five G0 zebrafish carrying mutations at the target site were outcrossed with 
wild type fish to produce F1 progeny. The F1 progeny were genotyped using the 
mutation-detecting PCR primer pair, but no diagnostic PCR amplification products 
were observed, indicating that none of the F1 progeny carried the desired HDR-
induced mutation (Results not shown). Therefore, T7 endonuclease I assays were 
performed on 6-month-old F1 progeny to screen for carriers of mutations differing 
from that originally desired. The mutation target region were then sequenced from 
fish identified as possessing such mutations. The following Table 6.1 lists the 
mutations subsequently identified, including four in-frame mutations and two 
frameshift mutations.  
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Table 6.1. List of mutations identified in F1 progeny. The mutated nucleotides are 
labeled in red with codons indicated below using the one-letter amino acid code. 
The four in-frame mutations maintain the open reading frame and would produce 
mutant transcripts encoding “full-length” proteins so do EOfAD-causative 
mutations following the “fAD reading frame preservation rule”. These mutations 
are located at membrane transition sites (as the third lumenal loop of the Psen1 
protein is very short), and thus should cause the changes in protein structure and 
hydrophobicity. Among these four in-frame mutations, the 6 bp indel mutation, 
psen1W233I_T234L, is the simplest structurally as it only changes two codons, one of 
which is equivalent to a codon in human PSEN1 affected by an EOfAD mutation. 
Therefore, this psen1W233I_T234L mutation has potential use as an additional EOfAD 
mutation-like model for the investigation of EOfAD-specific effects using zebrafish.  
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The two frame-shifting mutations would result in the production of mutant 
transcripts encoding truncated proteins. The mutant transcript of the indel mutation, 
psen1W233fs, would have an earlier premature termination codon than the 7 bp 
deletion mutation and so would encode a smaller protein more similar to that from 
the transcripts of the human familial Acne Inversa mutant allele P242LfsX11. The 
data from sequencing of the psen1W233fs mutation is shown in Figure 6.9.  
 
 
Figure 6.9. Sequence spanning the psen1W233fs indel mutation. Two nucleotides TG 
in the wild type sequence are substituted with three nucleotides GAT, causing a 
frame-shift. 
 
Future work will exploit the psen1W233fs mutation as a model of P242LfsX11 in 
transcriptome comparisons with wild type and EOfAD-like mutations. As patients 
with the P242LfsX11 mutation do not suffer EOfAD, these transcriptome 
comparisons can identify molecular changes due to mutation of psen1 that are not 
by themselves, sufficient to drive EOfAD. 
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6.3 Discussion 
6.3.1 The difficulties in generating HDR-induced mutations in 
zebrafish models 
The zebrafish mutation models intended to be generated in this work were to be 
used to study human EOfAD. Ideally, they would be as similar as possible to the 
original mutations in human PSEN1. Therefore, I attempted to generate them 
through template-guided HDR. However, HDR can be difficult to achieve in 
zebrafish. Normally the frequency of HDR-induced mutations in zebrafish is far 
less than the frequency of non-homology end joining (NHEJ)-induced mutations. 
To increase the likelihood of achieving HDR to create a model of the familial Acne 
Inversa mutation, I utilised a strategy suggested by Zhang et al. in 2018 [16] in 
which the DNA template is carried within a plasmid vector and the NHEJ inhibitor 
SCR7 is added to the embryo culture medium. However, this gave little 
improvement in HDR efficiency as the desired mutation, although detectable by 
PCR in injected G0 embryos, could not be found in F1 progeny. Instead, all the 
subsequently isolated mutations proved to be products of NHEJ.  
It remains quite difficult to generate mutations by HDR in zebrafish, and 
improvements to the efficiency of this process should be investigated. The 
generation of mutations by HDR is essential for the investigation of molecular 
changes due to particular genetic states, and greater success in HDR-induced 
mutagenesis in zebrafish would promote the application of this model in the study 
of human disease. 
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6.3.2 The generation of EOfAD transcriptome profiles using 
multiple EOfAD-like models 
Due to the low success rate of generating mutations by HDR in zebrafish, it can be 
difficult to introduce exact equivalent human EOfAD-causative mutations into the 
corresponding zebrafish genes. Fortunately, for the EOfAD in the PRESENILIN 
genes, mutations generated through NHEJ which follow “fAD reading frame 
preservation rule” and cause slight changes in protein structure and hydrophilicity 
like the many human EOfAD-causative mutations, can be used as EOfAD-like 
models. The psen1Q96_K97del mutation is an example. This mutation maintains the 
open reading frame but causes structural and hydrophilicity changes in the first 
lumenal loop of the translated protein similar to EOfAD mutations such as 
PSEN1L113_I114insT [17] and PSEN1P117L [18], which distort the first luminal loop of 
human PSEN1. However, not all the molecular changes induced by the 
psen1Q96_K97del mutation are necessarily involved in driving development of AD 
pathology. For example, the effects of different EOfAD-causative mutations on -
secretase activity appear to be variable [19, 20]. Within one EOfAD-like model, it 
is hard to define whether or not a particular transcriptome signature element is 
involved in AD pathology. Therefore, more EOfAD-like mutation models must be 
generated to identify transcriptome signature elements which are specifically 
universal to EOfAD. Here, I have generated a 6 bp mutation, psen1W233I_T234L, 
substituting two amino acids in the encoded protein. While this mutation is not 
precisely equivalent to any known human EOfAD mutation in PSEN1, it obeys the 
“fAD reading preservation rule” of EOfAD mutations in PSEN1 and PSEN2 (and 
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APP). The position of this mutation at the lumenal loop 3, transmembrane domain 
6 transition site likely changes the structure and hydrophobicity of the encoded 
protein, similar to the human EOfAD-causative mutations, PSEN1T245P [21], 
PSEN1A246E [22] and PSEN1A246P [23], near the psen1W233I_T234L-equivalent position 
in the human PSEN1 protein. Therefore, the psen1W233I_T234L mutation has the 
potential to be used as another EOfAD-like model to aid in refining EOfAD 
transcriptome signatures. 
 
6.3.3 Use of the Acne Inversa-like mutation model in refinement of 
the EOfAD transcriptome signature 
Human familial Acne Inversa is an autosomal, dominantly inherited skin disease 
caused by a frameshift mutation in human PSEN1, P242LfsX11, which does not 
cause EOfAD [4]. This mutation leads to the production of mutant transcripts 
encoding truncated proteins and so does not obey the “fAD reading frame 
preservation rule”. Analysis of this mutation, or mutations like it, can, by exclusion, 
help us to refine our understanding of which elements of the EOfAD signature are 
critical for EOfAD. (Of course, it is possible that two elements operating in 
combination are critical for EOfAD so we cannot automatically exclude from the 
signature any element which is present in both the familial Acne Inversa and all 
EOfAD mutation-like brain transcriptomes.) 
Although a human Acne Inversa-equivalent mutation in zebrafish was not achieved 
through HDR, two frameshift mutations were identified near the Acne Inversa 
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mutation-equivalent site. Both of these mutations are predicted to cause premature 
termination of the coding sequence. However, the 3 bp indel mutation, psen1W233fs, 
has an earlier premature termination codon more similar to that seen in human Acne 
Inversa mutant transcripts. Therefore, the psen1W233fs mutation will be used as an 
Acne Inversa mutation-like model in further studies. 
The psen1W233fs mutation is currently being exploited in a “3-way” comparative 
transcriptome analysis performed by Karissa Barthelson. A zebrafish heterozygous 
for psen1W233fs was crossed with a zebrafish heterozygous for the EOfAD-like 
mutation psen1T428del (that is an exact equivalent of the human EOfAD mutation 
PSEN1T440del [24]) to produce a family/tank of siblings with either wild type, or 
heterozygous, or transheterozygous genotypes (Figure 6.10). Raising zebrafish 
siblings in the same tank reduces environmental noise in the subsequent 
transcriptome data obtained and a comparative brain transcriptome analysis will be 
performed on the wild type, heterozygous psen1W233fs mutant, and heterozygous 
psen1T428del mutant genotypes. Hopefully, this analysis will reveal cellular functions 
affected uniquely by the EOfAD mutation-equivalent psen1T428del allele and not the 
familial Acne Inversa mutation-like psen1W233fs allele. The brain transcriptome of 
the heterozygous psen1T428del mutants can also be compared to that already defined 
for the EOfAD mutation-like heterozygous psen1Q96_K97del mutants to identify 
transcriptome changes in common. Also of interest, the transcriptome effects of the 
Acne Inversa mutation-like psen1W233fs allele will be compared with the known 
brain transcriptome changes caused by heterozygosity for the psenK97fs frameshift 
allele. It is curious that only one familial Acne Inversa mutation has been identified 
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so far in human PSEN1, raising the possibility that the position of the frameshift in 
the coding sequence is critical to the disease. 
  
Figure 6.10. The mating strategy of a “3-way” comparative transcriptome analysis. 
The family of siblings consists of 4 genotypes but only wild type, heterozygous 
psen1W233fs mutants and heterozygous psen1T428del mutants are used in transcriptome 





The template DNA oligonucleotide to generate an Aspartate codon-substitution 
mutation by HDR was synthesized by Sigma-Aldrich (Missouri, USA), while the 
template DNA plasmid to generate the familial Acne Inversa-like mutation was 
synthesized by Biomatik (Cambridge, Ontario, Canada). The designed sgRNA 
(CRISPR RNA, crRNA), trans-activating crRNA (tracrRNA) and Cas proteins 
were purchased from Integrated DNA Technologies (IDT, Coralville, USA).  
The injection mixture for attempted induction of the Aspartate codon-substitution 
mutation consisted of 21 μM crRNA, 21 μM Cas12a protein and 1.6 μM oligo DNA 
template (no tracrRNA was required), while the injection mixture for attempted 
induction of the Acne Inversa-like mutation contained 20 μM crRNA, 20 μM 
tracrRNA, 12.8 μM Cas9 protein and 107 ng plasmid DNA template. The injection 
mixtures were incubated at 37°C for 10 minutes before injection. 5-10 nL of 
injection mixture was injected into zebrafish embryos at the one cell stage. Embryos 
injected with the CRISPR/Cas12a system were incubated at 34°C, while embryos 
injected with the CRISPR/Cas9 system were incubated at 28°C. Ten embryos from 
each injected clutch were collected after 24 hours to test whether the CRISPR/Cas 
system had worked, and the remaining embryos were raised to 6 months of age, 




The injected G0 embryos were raised to reach sexual maturity (approximately 6 
months of age). Each G0 zebrafish with mutations detected in a tail biopsy (using 
either the T7 endonuclease I assay or specific PCRs) was outcrossed with a wild 
type zebrafish to produce F1 progeny.  
Mutations in F1 progeny are normally stable and heritable. The F1 progeny were 
then raised to 6 months of age for mutation detection and sequencing. Any F1 
individual potentially bearing the mutation of interest was outcrossed with a wild 
type fish to produce F2 progeny. The F2 individuals heterozygous for the mutation 
were used for further experiments (such as “3-way” transcriptome analysis), and 
were also incrossed to generate homozygous individuals that were then used to 
establish a line of fish for propagation of the mutation. 
 
Genomic DNA extraction 
Zebrafish were anesthetized using tricaine solution (168μg/mL), and a small tail 
biopsy (a “tail clip”) was then taken from the zebrafish using a surgical blade.  
50μL of 1.7mg/μL Proteinase K (Sigma-Aldrich, Missouri, USA) in 1xTE buffer 
was used to degrade proteins and release genomic DNA from pools of ten zebrafish 
embryos or from tail clips of individual adult fish after incubation at 55°C for 3 
hours, followed by enzyme inactivation at 95°C for 15 minutes. This genomic DNA 
was then stored at -20°C for the following genotyping PCRs.  
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PCR for genotype determination 
PCRs were performed in 25 μL reactions containing genomic DNA, 0.2 mM of 
each deoxyribonucleotide triphosphate (dNTP, each at a final concentration of 0.2 
mM), 0.4 μM of each PCR primer, and 2.5 unit of GoTaq® DNA polymerase 
(Promega, Madison, Wisconsin, USA). PCR cycling was performed with 35 cycles 
of a denaturation temperature of 95°C for 30 s, then an appropriate (primer-
dependent) annealing temperature for 30 s and then an extension temperature of 
72°C for 45 s. PCR products were electrophoresed through a 1.5% agarose gel in 
1×TAE buffer for separation and identification.  
 
T7 endonuclease I assay  
The T7 endonuclease I assay [25] was used to detect mutant DNA strands among 
wild type PCR products. T7 endonuclease I recognises sites of base mismatches in 
double-stranded DNA and cleaves at these sites. Samples with the expected 
cleavage sizes in T7 endonuclease I assays can be regarded as having mutations at 
the targeted site, although irrelevant cleavage bands may occur e.g. due to the 
existence of sequence polymorphisms. PCR products found to include mutation by 
the T7 endonuclease I assay were subsequently sent to Australian Genome 
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6.6.1 SgRNAs and DNA templates for CRISPR/Cas systems 



































SgRNA sequences are indicated in red, PAM sites are highlighted in blue, and 














Primer for aspartate codon-substitution mutation 
psen1 
5’-TGACGGGACGTGAAAATAAA-3’ 





Common forward primer 
5’-CCAGCATACTGTAAAAGATGAAAT-3’ 
Wild type (aspartate) reverse 
primer 
5’-CCAGCATACTGTAAAAGATGAAGG-3’ Alanine-specific reverse primer 
Primer for Acne Inversa-like mutation 
psen1 
5’-CGTGGCGATGGATTACTTCA-3’ 





Wild type forward primer  
5’-AAGTATCTCCTGAATGGACTGCGT-3’ 
Acne Inversa-specific forward 
primer 





Alzheimer’s disease (AD) is a major health issues worldwide, and its incidence 
shows an increasing trend [1]. The study of AD pathology and the investigation of 
possible treatments have been ongoing for decades [2]. Multiple hypotheses have 
been proposed based on different features seen in disease progression. Each 
hypothesis has its limitations and cannot comprehensively explain the cause(s) and 
pathology of the disease. As the early-onset familial form AD (EOfAD) shows 
dominant inheritance [3], EOfAD-causative mutations can be introduced into 
animal models to explore the molecular basis of the disease in vivo. Rodents, as 
genetically manipulable mammals, are the most common animal models used in 
AD studies. However, the failure in clinical trials of AD therapies which had 
succeeded in preclinical trials using rodent models [4], and the inconsistency in 
brain transcriptome profiles between different transgenic mouse models of AD and 
between transgenic mouse models and human patients [5] has illuminated the 
limitations of rodent models in AD research, indicating that they do not reflect 
comprehensively the disease state of human patients. On the other hand, rodent 
models have a relatively short lifespan, and do not naturally develop NFTs in their 
brains [6], suggesting rodent models might not replicate the pathology seen in 
human AD patients. Their short lifespan is another limitation of rodent models, as 
it has been argued that humans’ long post-reproductive life span and longevity 
might contribute to the onset of AD and its pathological signs, such as the 
development of NFTs in brains [6]. Therefore, it is desirable to use other animal 
models that may reveal different aspects of the molecular interactions and cellular 
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functions related to the human EOfAD genes, PSEN1, PSEN2 and APP. The 
application of diverse animal models in AD studies may achieve a more thorough 
understanding of AD pathology in human patients. The Alzheimer’s Disease 
Genetic Laboratory (ADGL) uses zebrafish to model the molecular effects of AD 
mutations. Although zebrafish models also have the same limitation of a relatively 
short lifespan as rodent models, the unique characteristics of EOfAD genes 
identified in zebrafish (reviewed in Newman et al., 2014 [7]) reveal different 
aspects of the functions of these genes. Also, zebrafish embryos are easily 
accessible for genetic manipulation, and zebrafish have the capability to produce 
large families of siblings. These advantages are ideal for experimental proposes.  
Two EOfAD-like mutations have been generated in the zebrafish psen1 gene, 
psen1K97fs and psen1Q96_K97del. Previous work in the ADGL investigated molecular 
changes induced by EOfAD-like mutations through brain transcriptome analysis. 
Brain transcriptome analysis of young adult (6 months of age) and aged adult (24 
months of age) zebrafish heterozygous for the psen1K97fs mutation showed a 
transcription “inversion” with age (the differential expression of a number of genes 
compared to wild type was in opposite directions at two ages) [8]. This is 
reminiscent of the transcriptional inversion seen in humans in a postmortem 
transcriptome comparison of MCI, AD and age-matched normal brains [9]. 
However, the changes occurring in the regulation of genes during AD progression 
remain unknown. This means that we do not know whether this apparent gene 
expression inversion is due to a slow and irreversible accumulation of cellular 
damage or to a rapid shift into a pathological state (which might be reversible). 
Therefore, a month-by-month study was designed to monitor changes in 
 196 
transcriptome state during aging from 6 months to 24 months, taking advantage of 
the zebrafish’s ability to produce large families of siblings to provide sufficient 
experimental samples. However, the early qPCR results from this study failed to 
validate the changes in gene expression observed in the transcriptome analyses 
upon which it was based, so that DE genes identified in the transcriptome analyses 
could not be used to monitor age-dependent changes in brain transcriptome state. 
Although this inconsistency ultimately led to the study being abandoned, it showed 
us the huge variability in brain gene expression that exists even between the fish of 
the same genotype, and also that an appropriate sample size is critical for a 
transcriptome analysis to reveal changes in cellular function. A power calculation 
subsequently performed by Stephen Pederson using the strategy from Zhao et al., 
2018 [10] found that n=6 could provide a power of ~70% for detection of fold-
change > 2 at a false discovery rate (FDR) of 0.05 across the vast majority of 
expressed transcripts in zebrafish brain transcriptomes. (The previous brain 
transcriptome analyses from psen1K97fs/+ and psen1Q96_K97del/+ fish relative to their 
wild type siblings had used n=3 and n=4 respectively.) The n=6 sample size was 
subsequently used in the ADGL’s transcriptome analyses including my analysis of 
7 day post fertilization (dpf) heterozygous psen1Q96_K97del mutant larvae.  
Our EOfAD-like mutation, psen1K97fs, mimics the human PSEN2K115fs mutation 
which was thought to be the only AD-causative frameshift mutation in the 
PRESENILIN genes. However, the identification of an alternative transcript 
splicing isoform from human PSEN2 that restores the reading frame in PSEN2K115fs 
transcripts [11] indicates that the PSEN2K115fs mutation, like other EOfAD 
mutations, obeys the “fAD reading frame preservation rule”. This challenged the 
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validity of the psen1K97fs mutation as a realistic model of human PSEN2K115fs. 
Subsequent attempts were made to detect such alternatively spliced transcripts in 
heterogynous psen1K97fs mutant brains using RT-PCR to amplify regions spanning 
the mutation site and neighbouring exons, but no alternatively spliced isoforms 
were identified. Based on this, we redefined the psen1K97fs mutation, and the brain 
transcriptome changes it causes, as non-EOfAD-like. However, this mutation can 
still prove valuable for modelling the function of the PS2V isoform of PSEN2 that 
shows increased expression in late onset AD brains.  
Zebrafish larvae represent a powerful tool for high-throughput screening of 
chemicals and drug candidates. Wagner et al., 2015 [1] showed that the most 
effective drugs in an animal model of dyslipidemia were those able to revert disease 
transcriptome signatures back to normal. To translate this idea to our EOfAD-like 
model psen1Q96_K97del to find AD-preventative drugs would require identification in 
larvae of a number of differentially expressed (DE) genes, which could be 
monitored to represent the presumably pathological transcriptome state [12]. 
Therefore, we performed transcriptome analysis on clutches of 7 dpf heterozygous 
mutant larvae. This led to the prediction of affected cellular pathways similar to 
those seen in mutant brains, but there was negligible concordance between the 
genes identified as DE in the larvae and in the mutant brains. Also, the huge 
variability in gene expression between clutches of larvae of the same genotype 
made it difficult to define a set of reproducibly DE genes to represent a pathological 
transcriptome state and that could be used in high-throughput chemical library 
screening. Morgan Newman subsequently performed behavioural testing of 
heterozygous psen1Q96_K97del mutant larvae through assessment of their response to 
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simulation by repeating intervals of 3-min light and 1-min dark. However, she did 
not observe significant differences in activity patterns. Therefore, it does not appear 
viable to use larvae with EOfAD-like mutations for drug screening through 
assessment of either gene expression states or behaviour. This is understandable as 
EOfAD is an adult onset neurodegenerative disease of brain, and so transcriptome 
analysis of whole larvae might fail to observe changes due to insufficient age or the 
dilution of transcriptome changes in CNS with those occurring in non-neural tissues. 
Moreover, AD is an age-dependent disease, and so, at early ages, any pathological 
transcriptome or behavioural changes are expected to be subtle. 
The transcriptome analysis of 7 dpf heterozygous mutant larvae found these 
unsuitable for chemical library screening but did identify several larva-specific 
effects of the psen1Q96_K97del mutation, particularly an effect on regulation of the 
genes encoding the minichromosome maintenance (MCM) proteins. The 
eukaryotic MCM complex functions as a DNA helicase essential for DNA 
replication and cell division. An involvement of EOfAD mutant PSEN1 in cell 
sensitivity to DNA damage has been reported in several studies [13, 14]. This 
observation supports a DNA replication stress hypothesis of AD by Yurov et al. 
[15] proposing that DNA replication stress due to incomplete DNA replication or 
improper repair results in DNA damage and genomic instability. However, the 
effects on DNA replication and cell cycle were only observed in the whole 7 dpf 
growing mutant larvae and not in transcriptome analyses of 6-month-old and 24-
month-old mutant brains (where relatively very little cell replication occurs). 
Therefore, the relevance for the mature CNS of PSEN1 mutation effects on DNA 
replication and the cell cycle require further investigation. Nevertheless, zebrafish 
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carrying the psen1Q96_K97del mutation may be an advantageous model in which to 
investigate such effects further.  
In addition to brain molecular changes, changes in behaviour are another essential 
focus when using animal models in the study of human neurological disease, as 
relevant animal models are expected to show similar symptoms to those occurring 
in humans. Progressive cognitive impairment is the major clinical symptom in 
human AD patients. Impairment of short-term spatial working memory have been 
observed in AD patients with moderate dementia [16] and the short-term spatial 
working memory of animals can be easily assessed using the free movement pattern 
(FMP) Y-maze. Therefore, the FMP Y-maze test was employed as our first attempt 
to assess changes in the behaviour of mutant zebrafish at different ages. However, 
no statistically significant differences were observed between heterozygous 
psen1Q96_K97del mutant fish and their wild type siblings at any of three ages, 6 months, 
12 months and 24 months. Not all zebrafish of either mutant or wild type genotype 
showed an obvious search strategy in their behaviour, and some fish showed 
extremely low activity during the tests. Therefore, our studies found either that the 
current FMP Y-maze test might not be ideal for assessment of short-term spatial 
working memory in zebrafish, or that it requires further optimization. Future 
experimentation should investigate other behavioural tests involving training, 
which can assess long-term memory and learning abilities and may achieve a better 
discrimination between cognitively impaired and normal individuals. For example, 
the learning abilities of zebrafish can be assessed using the method described by 
Aoki et al., 2017 [17]. Zebrafish adults were treated with a 2-hour training session 
in a Y-maze using a specific colour paired with electric shock at one arm, and the 
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fish’s efficiency of choosing the correct arm after training was used to represent 
their learning ability. As electric shock is a strong stimulation, zebrafish 
subsequently do not move randomly as observed in FMP Y-maze tests, and this 
may allow better discrimination between cognitively impaired and normal 
individuals.  
In addition to studies using our existing EOfAD-like mutants, the generation of 
other EOfAD-like or EOfAD-relevant mutations is required for the refinement of a 
brain transcriptome signature of EOfAD. We failed to generate the desired aspartate 
codon-substitution and Acne Inversa-like mutations using HDR due to the low 
efficiency of HDR in zebrafish. Nevertheless, two probably informative mutations 
were identified near the human Acne Inversa mutation-equivalent site. The 6 bp 
indel in-frame mutation, psen1W233I_T234L, can represent another EOfAD-like 
mutation and should help to refine the transcriptome signature that is specifically 
common to EOfAD mutations. Another 3 bp indel mutation, psen1W233fs, causes a 
frameshift close to the site equivalent to the human Acne Inversa mutation and can 
be used, by exclusion, to refine our understanding of which transcriptome elements 
are critical for EOfAD. This frameshift mutation is currently being exploited by 
Karissa Barthelson in a “3-way” comparative transcriptome analysis expected to 
reveal brain cellular functions affected uniquely by the EOfAD mutation-equivalent 
psen1T428del allele and not the familial Acne Inversa mutation-like psen1W233fs allele. 
Also, the psen1W233fs frameshift mutation can be used in comparison with our other 
frameshift mutations, such as psen1K97fs, to investigate differential effects of 
truncating the psen1 coding sequence at different positions. This is an important 
issue since previous research by the ADGL has demonstrated differential dominant 
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effects of forced expression of truncated forms of Psen1 protein including 
truncations similar to those produced by the human PSEN2K115Efs [18] and 
PSEN1P242Lfs [19] alleles. 
Overall, the research presented in this thesis has focused on identifying the effects 
of EOfAD-like mutations in the zebrafish model. The studies span analysis of both 
transcriptome and behaviour for a heterozygous EOfAD-like mutation model 
psen1Q96_K97del, as well as the generation of additional mutations in the psen1 gene. 
The research has been valuable in illuminating the great variability in gene 
expression that occurs in individual bran transcriptomes and in tests of spatial 
working memory using the FMP Y-maze. Future work should investigate 
behavioural tests involving training to assess impairments in cognition. Also, 
transcriptome analysis of the EOfAD-like mutation psen1W233I_T234L, and the Acne 
Inversa-like mutation psen1W233fs, may provide greater insight into the critical 
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